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In this project I cloned, sequenced, and analyzed the genome of baboon 
cytomegalovirus (BaCMV) strain OCOM4-37.  Genomic analysis is an important aspect 
of basic science that allows us to examine the coding sequence of an organism, and 
predict the protein coding regions and possible protein function.  In addition, we can 
compare the genomes of different organisms, in this case primate cytomegaloviruses, and 
determine how closely related they are to one another and what characteristics they share.  
Analysis of other cytomegalovirus (CMV) species shows that these viruses evolve along 
the same lines as their primate hosts.  In other words, the more related two primate 
species are to one another, the more related are the viruses they carry.  After isolation, 
cloning and sequencing the coding sequence of the BaCMV OCOM4-37 genome, 
comparisons were made with other CMV genomes.  These analyses showed that the 
OCOM4-37 strain is most closely related to CMVs isolated from primates most closely 
related to baboons.   
After sufficient growth was observed (demonstrated by cytopathic effects), 
BaCMV was isolated from infected cells and the viral DNA purified.  The DNA was cut 
with restriction enzymes and cloned into Escherichia coli using plasmid and bacterial 
artificial chromosome (BAC) vectors to create gene libraries.  These libraries were 
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screened to identify unique clones that were then sequenced.  Sequences generated from 
these clones were assembled using software designed for this purpose, and in this way 
large contiguous DNA sequences were generated.  Sequence analysis was performed 
using the online database provided by the National Center for Biotechnology Information 
(NCBI) using the Basic Local Alignment Search Tool (BLAST) to identify other primate 
CMV sequences that were closely related to the BaCMV sequence.  Sequence identified 
as homologous with human cytomegalovirus (HCMV) strain AD169 was used to 
construct a genomic map for BaCMV OCOM4-37.  Sequences of other primate CMVs 
(such as clinical strains of HCMV or rhesus CMV) also showed similarities with BaCMV 
that were not shared with HCMV AD169.  In its entirety, this research has confirmed that 
BaCMV is a member of the CMV family and that it is most closely related to the drill 
monkey CMV.  When compared to herpesviruses whose entire genomes have been 
sequenced, BaCMV is most similar to rhesus CMV (RhCMV). 
Since herpes simplex virus type 1 (HSV-1) is the most-intensely studied 
herpesvirus, the following review focuses primarily on this virus as the prototype for all 
herpesviruses.  Where applicable, HCMV is also described since it is more closely related 





REVIEW OF LITERATURE 
 
I. THE HERPESVIRIDAE 
Herpesviruses are large, double-stranded DNA viruses that are classified in the 
family Herpesviridae.  This family encompasses a wide range of viruses that are 
ubiquitous in the animal kingdom, and is divided into alpha (α), beta (β), and gamma (γ) 
sub-families.  Recently, the family Herpesviridae has been split into three families: 
Herpesviridae, Alloherpesviridae, and Malacoherpesviridae (Davison et al. 2009).  The 
mammalian, bird and reptile herpesviruses were retained in the new Herpesviridae 
family.  Within the α-herpesvirus subfamily are the genera Simplexvirus and 
Varicellovirus.  These viruses are grouped together based on their wide host range, short 
reproductive cycle, rapid spread in cell culture, efficient destruction of infected cells, and 
ability to establish latent infection in sensory ganglia (Roizman 1996).  The β-herpesvirus 
subfamily includes the genus Cytomegalovirus.  Viruses in this sub-family typically have 
a restricted host range, grow slowly in cell culture, and establish latency in monocytes 
(Pignatelli et al. 2006; Taylor-Wiedeman et al. 1991), smooth muscle, and/or endothelial 
cells (Jarvis and Nelson 2006).  Cells infected with these viruses often enlarge, hence the 
name cytomegalovirus (literally, large-cell virus).  The two genera of the γ-herpesviruses 
are the Lymphocryptovirus and Rhadinovirus.  Characteristics of viruses in this subfamily 
include replication in lymphoblastoid cells in
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vitro, specificity for either T or B lymphocytes in vivo, and often latency in lymphoid 
tissue (Roizman 1996).   
II. VIRUS STRUCTURE 
Compared to most other viruses, the herpesviruses are large and have complex 
genomes.  All herpesviruses have four basic structural components: 1) a core consisting 
of a single, double-stranded DNA molecule, 2) a capsid, which is an icosahedral structure 
composed of protein subunits, 3) a tegument which is an amorphous region located 
between the envelope and capsid, and 4) an envelope that contains virus-specific 
glycoprotein spikes (Roizman 1996).  The CMVs have the largest genomes of all 
herpesviruses. 
A. The Genome 
While herpesviruses are comparatively large, the size of the genome varies from 
120 to 230 kilobase pairs (kbp) within the family.  In intact virions, the single linear 
dsDNA molecule is packaged in the shape of a torus, i.e. doughnut-shape (Furlong et al. 
1972) while DNA extracted from a virus takes on a linear conformation.  After infection 
in cell culture, however, the linear DNA enters the host cell nucleus and rapidly 
circularizes (Poffenberger and Roizman 1985).  Depending on the size of the genome, 
between 60 and 120 genes may be present.  These genes are usually classified as being 
essential if they are necessary for growth in cell culture, or nonessential if they are 
expendable.  However, genes categorized as nonessential for in vitro replication are often 
required for survival of the virus in vivo (like immune system suppressor genes or genes 
that enhance cell-to-cell spread).  In herpesviruses, genes may be coterminal, overlapping 
and/or coded on opposite strands.  A linear map of the HSV-1 genome depicts 
 5 
covalently-bonded unique long (UL) and short (US) sequences which represent most of 
the coding sequence of the genome (Figure 1A). 
 
The L and S sequences are both flanked by direct or inverted repeat sequences 
which are either located within the genome at the L/S junction (internal) or at the genome 
ends (terminal) (Wadsworth et al. 1975).  Because the L and S sequences invert at 
repetitive sequence junctions during replication, four isomers exist for herpesviruses as 
shown in Figure 1B (Hayward et al. 1975).  Additionally, the number of repeats within 
junctions varies between individual herpesviruses and may account for size differences 
between closely-related species.  Often, the ratio of guanine and cytosine to adenine and 
thymine is used to determine the relatedness between organisms.  For herpesvirus 
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genomes, the G+C ratio ranges from 32-75% (Roizman 1996).  Within the repetitive 
regions are sequences that are involved in DNA packaging called pac1 and pac2 (Figure 
2).  These sequence motifs are conserved in herpesviruses and located within the terminal 
repeat sequences of the genome (Deiss et al. 1986).  The pac1 motif is composed of an 
A-rich region flanked by poly-C runs while pac2 consists of a CGCGGCG near an A-rich 
region (McVoy et al. 1998). 
AAAAAA            CGCGGCG               
34-39                70-76
CCCCCCCC  AAAACACA  CCCCCCGGGGG
152210-152216
pac2 pac1
DR     L           DR     R           
Figure 2.   and  Sequences in HSVI.  Boxes represent long and short direct repeats 
(DR) terminal sequences of the 152261 bp genome.  Expanded detail shows location and 





B. The Capsid 
The viral capsid is a proteinaceous icosahedral shell that provides protection for 
the genome.  In herpesviruses, the capsid consists of 150 hexameric and 12 pentameric 
protein subunits called capsomers, and ranges in size from 100-110 nm diameter (Wildy 
and Watson 1962).  Three categories of capsids have been identified and are designated 
as type A, B or C.  Type A capsids have neither DNA nor an envelope, type B capsids 
contain DNA but are unenveloped, while type C capsids have both DNA and an envelope 
(Gibson and Roizman 1972; 1974).  Some examples of these capsid types are shown in 
Figure 3.  Through electron microscopy, capsid types have been subdivided into eight 
different forms that probably represent various stages of assembly (Roizman 1974).  
However, type A capsids are not intermediate forms of B or C capsids, but rather are 
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disfunctional capsids (Sherman and Bachenheimer 1988).  Each of these capsid types 
varies in the composition of their viral protein (VP) subunits, their content, and their 
molecular weight (Homa and Brown 1997).  While A capsids are entirely non- 
functional, B capsids are capable of producing mature virions (Perdue et al. 1976) and C 
capsids are most similar to mature virions (Homa and Brown 1997).  The outer capsid 
shell capsomer hexons and pentons are composed of the major capsid protein, VP5.  In 
HSV-1, these capsomers are linked together by a tripartite complex of two VP23 (UL18) 
and one VP19C (UL38) minor capsid proteins (Newcomb et al. 1993). 
Figure 3.  Transmission electron micrograph of herpes simplex virus.  Some nucleocapsids 
are empty, as shown by penetration of electron-dense stain.  Letters indicate capsid type (see 
text for detail).  (This micrograph comes from the Centers for Disease Control and Preven-
tion’s Public Health Image Library (PHIL),  identification number #281 Dr. Erskine 
Palmer, 1981).
.   
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Similar capsid types are present in BaCMV OCOM4-37 as well (Figure 4).  
Figure 4.  Transmission Electron Micrograph of BaCMV Strain OCOM4-37.  Letters indi-
cate capsid type.  Bar at lower left represents 100 nm.
 
C. The Tegument 
The tegument in herpesviruses is a collection of proteins that are located between 
the capsid and viral envelope.  The herpesvirus tegument makes up about one-third of the 
volume of the virion (Desai et al. 2001) and is roughly analogous to the matrix of other 
viruses.  However the herpesvirus tegument is more complex, structured, and contains a 
number of functional proteins.  For some time, the tegument was considered to be an 
unstructured proteinaceous region.  More recently cryoelectron microscopic analyses 
have shown that the innermost layer of the tegument (composed of the UL36 gene 
product in HCMV) appears to have icosahedral symmetry similar to that of the capsid 
(Zhou et al. 1999) suggesting that this protein physically interacts with the major capsid 
protein (McNabb and Courtney 1992).  This is an example of a tegument protein that 
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links structural components of the capsid with viral glycoproteins to maintain the 
integrity of the virion.  Another HCMV protein, UL37, has been shown to interact with 
UL36 and is proposed to be the second layer of the tegument (Klupp et al. 2002).  
Various other tegument proteins have been identified in herpesviruses to date and a 
number of these have been characterized (Mettenleiter 2002; Zhou et al. 1999).  Some 
known functions of tegument proteins include unpackaging and transport of capsids to 
the nuclear pore (product of HCMV UL47 and HSV-1 ICP1-2), (Batterson et al. 1983; 
Bechtel and Shenk 2002; Knipe et al. 1981), suppression of host cell protein synthesis  
(product of HSV-1 UL41) (Everly et al. 2002), transactivation of other viral genes 
(product of HCMV UL32) (Liu and Stinski 1992), virion production genes (Meyer et al. 
1997), egress from the nucleus (products of HSV-1 UL31 and UL34) (Fuchs et al. 2002; 
Reynolds et al. 2001), and immunomodulation genes (Child et al. 2004; Trgovcich et al. 
2006).  An example of immunomodulation is seen where HCMV pp71 (UL 82) causes 
disruption of MHCI cell surface expression to prevent antigen presentation (Trgovcich et 
al. 2006).  In addition to this, pp71 plays a role as a transactivator of IE genes in much the 
same way as the HSV-1 ICP0 protein  (Preston and Nicholl, 2005).  Tegument protein 
homologues of HCMV conserved in most herpesviruses are UL31, UL34, UL36, and 
UL37.  Table 1 shows functions of some HSV-1 tegument proteins (for HCMV tegument 
proteins see Table 10). 
D. The Envelope 
There has been much speculation regarding acquisition of the herpesvirus 
envelope since they undergo envelopment twice.  Therefore, the origin of the herpesvirus 
envelope has been proposed by two different mechanisms.  One model (referred to as the 
re-envelopment pathway), begins with assembled nucleocapsids that bud through the 
 10 
inner nuclear membrane (Vlazny et al. 1982).  At this point, the envelope acquired from 
the inner membrane fuses with the outer membrane to release the nucleocapsids into the 






UL7  Interacts with adenine nucleotide translocator 2; 
nonessential in vitro 
(Tanaka et al. 2008) 
UL11  Virion egress and secondary envelopment  (Baines and Roizman 1992; 
Loomis et al. 2001) 
UL14  Interacts with UL11; associated with nuclear 
targeting of capsids 
(Yamauchi et al. 2008) 
UL16  Interacts with UL11 (Yeh et al. 2008) 
UL36 VP1/2 Release of DNA from capsids during entry (Desai et al. 2008) 
UL37  Interacts with UL36; required for virus maturation (Desai et al. 2001) 
UL41 vhs Inhibits host cell protein synthesis (Smiley 2004) 
UL46 VP11/12 Modulates transactivating tegument protein VP16 (Liu et al. 2005) 
UL47 VP13/14 Modulates transactivating tegument protein VP16; 
RNA-binding protein 
(Donnelly et al. 2007) 
UL48 VP16 Transactivates immediate early genes (Ellison et al. 2005) 
UL51  Unknown; nonessential in vitro (Daikoku et al. 1998) 
Table 1.  Herpes Simplex Virus 1 Tegument Proteins and Their Functions 
at the trans-Golgi face.   
Another model, the luminal pathway, proposes that virions acquire a double 
envelope as they pass through the inner and outer nuclear membranes.  They then travel 
from the inner nuclear space directly to the Golgi apparatus or within the lumen of the 
endoplasmic reticulum (ER) (Enquist et al. 1998).  In either case, viral glycoproteins 
undergo modification within the Golgi apparatus and mature virions are released from the 
cell via typical secretory pathways.  Based on recent studies using immunogold electron 
microscopy to determine the distribution of gD targeted to the ER, the re-envelopment 
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Protein name Function References 
UL4  Contains signal peptide; nonessential 
in cell culture 
(Chen and Stinski, 2002) 
UL16  Inhibits NK cell cytotoxicity; 
involved in immune regulation 
(Vales-Gomez and Reyburn 
2006; Wilkinson et al. 2008) 
UL18 MHC homologue Inhibits NK cell cytotoxicity; 
involved in immune regulation 
(Prod'homme et al. 2007; 
Vales-Gomez et al. 2005) 
UL55 Glycoprotein B (gB) Involved in cell entry; mediates cell-
to-cell spread 
(Jarvis et al. 2004) 
UL75 Glycoprotein H (gH) Involved in cell entry; mediates cell-
to-cell spread 
(Jarvis et al. 2004; 
McWatters et al. 2002) 
UL110 Glycoprotein M (gM) Integral membrane protein that 
complexes with gN; nonessential in 
cell culture 
(Mach et al. 2000; Mach et 
al. 2005) 
UL115 Glycoprotein L (gL) Contains a signal peptide and is 
involved in cell entry; mediates cell-
to-cell spread 
(Kaye et al. 1992) 
US10  Delays trafficking of MHC-I; 
involved in immune regulation 
(Furman et al. 2002) 
US11  Causes selective degradation of 
MHC-I; involved in immune 
regulation    
(Oresic and Tortorella, 2008) 
Table 2. Cytomegalovirus Envelope Glycoproteins 
III. LIFE CYCLE 
The HCMV replication cycle is similar to that of most herpesviruses.  The most 
basic virus replication cycle consists of attachment, penetration, biosynthesis, assembly, 
and egress.  Herpesviruses have large genomes compared to other viruses, and as might 
be expected from this, their life cycles are more complex. 
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A. Attachment 
1.  Viral Envelope Glycoproteins 
Because viruses are non-motile, the attachment process is random and depends on 
Brownian movement of the virus particles for contact with a host cell.  In addition, 
attachment is energy independent and may involve several steps involving multiple viral 
and cellular proteins.  Once attachment occurs, penetration quickly ensues as these are 
closely-integrated processes. 
An important consideration when investigating viral attachment mechanisms is 
host cell polarity.  In vivo, epithelial cells possess both an apical (or outer) surface and a 
basal laminal (or interior) surface, and are therefore described as polarized.  Each of these 
surfaces has different cell-surface receptors that may enhance or inhibit viral attachment 
depending on whether or not they can bind a particular viral glycoprotein.  Given this 
fact, an important consideration with in vitro experimental conditions is the use of non-
polarized mammalian cell lines whose receptors may be randomly distributed on the cell 
surface.  Therefore, experimental models may not precisely reflect viral attachment 
processes in vivo, but can certainly provide valuable information regarding the types of 
cellular receptors and viral proteins involved.   
Experiments with HSV-1 and nonpolarized cells have shown that glycoprotein C 
(gC) and, to a lesser degree, glycoprotein B (gB) are involved in the initial stages of 
attachment to cell-surface heparan sulfate (Shieh et al. 1992; WuDunn and Spear 1989).  
In a subsequent step, glycoprotein D (gD) interacts with a cellular coreceptor (described 
below), and finally fusion occurs between the viral envelope and the cellular membrane.  
In addition to the role gB and gD play in fusion with the host cell membrane, they have 
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also been linked to HSV-1 tropism for the central nervous system (Izumi and Stevens 
1990).   
Likewise, attachment of HCMV requires initial binding of heparan sulfate 
proteoglycans (HSPG) on the host-cell surface to glycoprotein gC-II and/or gB to 
enhance stable attachment of the virion to cell-surface receptors (Compton et al. 1993).  
While gC-II has been identified as the major HCMV heparan-binding protein (Kari and 
Gehrz 1992), gB-mediated binding has been demonstrated in HSPG-deficient CHO 
(Chinese hamster ovary) and fibroblast cells where gB binding was diminished, but not 
entirely eliminated (Boyle and Compton 1998; Norkin, 1995).  The fact that some gB 
binding occurred in these experiments seems to indicate that there must be alternative 
receptors for gB in addition to heparan sulfate.  Indeed evidence exists (in HSV) for a 
specific gB entry receptor (Bender et al. 2005).  Similarly in HCMV, the gB protein 
interacts and binds with cellular annexin II which could explain why gB also binds to 
cells lacking HSPG (Pietropaolo and Compton 1997).  These data indicate that there may 
be additional receptors, and other glycoproteins (like gH) that play a role in the 
attachment/penetration process.  What is known, however, is that gB is essential for viral 
entry and cell-to-cell spread based on its function as a ligand and fusion protein (Navarro 
et al. 1993; Singh and Compton 2000) and that it is one of the most conserved proteins in 
all herpesviruses.  This, of course, would indicate how important gB is to the entire 
herpesvirus family. 
Structurally, HCMV glycoprotein B has a surface exposed (SU) component 
represented by a 116 kDa subunit and a transmembrane region (TM) domain consisting 
of a 55 kDa subunit.  Four possible hydrophobic (transmembrane) regions have been 
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predicted based on the amino acid (aa) sequence of the open reading frame (ORF).  One 
is in the 116 kDa subunit and the remaining is in the 55 kDa subunit.  The first of these 
domains, located between aa 1-24 at the N-terminus, acts as a cleavable signal sequence 
(Britt and Mach 1996).  The second hydrophobic domain is between aa 714-747.  gB 
deletion mutants for this domain are not secreted and are incompletely processed.  This 
indicates some function for this region in gB secretion, folding and/or processing 
(Reschke et al. 1995).  The most hydrophobic region is found between aa 751-771 and 
serves as a membrane anchoring sequence.  The function of a fourth hydrophobic region 
between aa 784-792 remains undefined.  There is also a series of 12 cysteine residues that 
are conserved in the gB sequence of CMVs (Chou, 1992; Rapp et al. 1992; Schleiss 
1994; Spaete et al. 1988), and a heparan-binding site exists within the C-terminal 
fragment of a soluble form of gB (aa 492-692) (Carlson et al. 1997). 
There are three antibody-binding sites on HCMV gB (Meyer et al. 1992), and two 
of these induce virus-neutralizing antibodies (Kniess et al. 1991; Wagner et al. 1992).  
One antigenic domain (AD-1) is located toward the C-terminal end between aa 560-640 
and is immunodominant to the other domains (Wagner et al. 1992).  AD-2 spans a region 
at the N-terminus between aa 50-86 and contains two separate binding sites: one at aa 50-
54 (site I) and the other at aa 67-86 (site II) (Kniess et al. 1991).  Site II of AD-2 is the 
only other region known to induce virus-neutralizing antibodies (Meyer et al. 1990).  The 
third antigenic domain, AD-3, is also at the C-terminus and spans aa 798-805 (Silvestri et 
al. 1991).  These three domains are shown in Figure 5.  Interestingly, via aa 1-750, gB 
has been shown to directly induce the interferon pathway through interaction with an 
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unknown cell surface receptor (Boehme et al. 2004).  This indicates a role for gB in 
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Figure 5.  Linear Representation of HCMV A 169 Strain gB (U 55) Gene.  (A) Shows the signal 
sequence (aa 1-26), the cleavage site (aa 460) and the transmembrane domain made up of three
hydrophobic regions.  Cleavage of the 906 aa precursor at aa 460 creates the surface (SU) and
transmembrane (TM) sections.  (B) Proposed fusion domains of gB based on homology with glyco- 
proteins from other viruses that have fuseogenic domains.  (C) Antibody-binding sites are represented 
as rectangles in the AD-1 and AD-2 sections.  Ellipses represent conformation-dependent antibody 
binding sites.  (Adapted from Britt and Mach, 1996).
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2.  Host Cell Receptor 
The host cell receptor is a cell-surface molecule that undoubtedly performs some 
cellular function, but which also interacts with the virus to permit attachment.  These 
receptors are sometimes referred to as viral receptors.  Attachment to the host cell 
receptor is critical to initiate infection, so it is common for multiple host cell surface 
proteins to serve as receptors for a given viral species.  There are three distinct families of 
cellular molecules that act as viral receptors for HSV-1 attachment.  One, a member of 
the tumor necrosis factor (TNF) family designated herpesvirus entry protein A (HveA) is 
found primarily in lymphoid tissue and plays a limited role as a receptor (Warner et al. 
1998).  Another group of receptors are members of the immunoglobulin family and act as 
adhesion molecules in a variety of tissues including skin, brain, and spinal ganglia 
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(Cocchi et al. 1998).  These molecules were formerly designated HveB and HveC but 
have been renamed nectins (from the Latin, to connect) based on their cellular function 
(Takahashi et al. 1999).  3-O-sulfated heparan sulfate (which HSV-1 binds to) is the sole 
representative of a third viral receptor family (Liu et al. 2002; Shukla et al. 1999).  These 
three cell surface receptors are referred to as co-receptors because binding of two or more 
receptors enhances viral entry.  In HCMV, a cell-surface HSPG has been identified as the 
receptor.  This has been demonstrated in HPSG-deficient human fibroblasts and CHO 
cells as the virus does not infect these cells (Compton et al. 1993; Neyts et al. 1992).  
Additional evidence for HSPG as a receptor is that sulfated polysaccharides compete with 
HCMV in vitro to inhibit infection of fibroblast cells (Neyts et al. 1992). 
B. Virus Entry 
Attachment and penetration are closely linked events that involve a number of 
viral glycoproteins.  In α-herpesviruses, glycoproteins gB and gD, and the gH-gL 
heterodimer are required for penetration (Spear et al. 2000).  In CMVs, which are  
β-herpesviruses, only gB and the gH-gL complex are required for viral entry (Boyle and 
Compton, 1998).  For the α-herpesviruses, gD has been shown to bind either the 
herpesvirus entry mediator (HVEM) receptor (Montgomery et al. 1996) or HveC (i.e. 
nectin-1) (Campadelli-Fiume et al. 2000), and after this primary interaction gB and gH-
gL generate fusion with the host cell membrane.  As previously discussed, heparan 
sulfate is usually bound by gC prior to stable attachment of gD.  While heparan sulfate 
receptors are not necessarily required for fusion to occur, HSV-1 entry diminishes in their 
absence (Pertel et al. 2001).   
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1. Virus Uncoating and Transport 
After fusion, the herpesvirus capsid is released into the cytoplasm and must be 
transported to nuclear pores where uncoating takes place.  Cellular transport mechanisms 
are used to move herpesvirus components to various compartments within the cell and 
this requires nuclear localization signals (NLS).  The NLS represents an aa motif that can 
be recognized by cellular binding proteins.  Capsid transport occurs via microtubular 
networks existing within the cell.  This has been demonstrated by electron microscopy 
which shows capsids bound to microtubules in neurons (Penfold et al. 1994), and also 
through antibody labeling which revealed attachment of dynein, the microtubule-
dependent motor, to capsids (Sodeik et al. 1997).  
Some tegument proteins such as virion host shutoff protein (vhs) and US11 are 
released into the cytoplasm after fusion of the viral envelope and a host cell membrane.  
Other tegument proteins either remain associated with the capsid or are transported 
independently to the nucleus (O'Hare 1993; Yang et al. 2002).  An example of a CMV 
tegument protein that is immediately transported to the nucleus is phosphoprotein 65 
(pp65), which is encoded by the UL83 gene.  Not surprisingly, the primary structure of 
pp65 has a bipartite NLS as shown through experiments using deletion mutants 
(Schmolke et al. 1995a).  The pp65 protein may play a role in transcription activation 
since it has been shown to compromise the activity of at least one viral-associated protein 
kinase (Schmolke et al. 1995b).  As microtubule transport of the capsid ensues, it is 
believed that various tegument proteins dissociate and are carried to areas of the cell in 
which they function. 
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Once the capsid reaches the nucleus, it binds to the nuclear pore complex (NPC) 
which is a protein-lined aqueous channel that exists in the double-membraned nuclear 
envelope (Whittaker and Helenius 1998).  Immediately after binding the NPC, the viral 
genome is ejected into the nucleus leaving the empty capsid behind (Ojala et al. 2000; 
Sodeik et al. 1997).  It has also been suggested that the VP1-3 tegument protein may play 
a role in nuclear localization and/or DNA release at the NPC.  This is because the protein 
sequence of HSV-1 VP1-3 contains four, weak bipartite NLS and a number of arginine-
rich regions.  By comparison, the human immunodeficiency virus type I genome contains 
regions that are high in arginine which are also involved in nuclear targeting (Truant and 
Cullen 1999).  The VP1-3 sequence is also believed to function in DNA extrusion since 
VP1-3 mutant HSV-1 strains are unable to release DNA at the NPC at nonpermissive 
temperatures (Ojala et al. 2000).  In addition to this, the VP1-3 protein is tightly bound to 
the capsid (Spear and Roizman 1972), and since the capsid penton is believed to be the 
site of DNA release (Newcomb and Brown 1994), interaction between the capsid and 
VP1-3 to facilitate this process is plausible.  Once viral DNA is released into the 
nucleoplasm, immediate-early (IE) gene transcription begins. 
C. Biosynthesis 
1. Genome Transcription  
The biosynthetic strategy used by herpesviruses involves sequential events in 
which different transcription units are transcribed at different times.  Because these 
events occur as a cascade, the transcribed genes are categorized as immediate early (IE), 
early (E), or late genes (L).  L genes are further subdivided into the leaky late (γ1) and 
true late (γ2) categories.  This cascading regulatory system allows for efficient temporal 
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control of enzyme synthesis, DNA synthesis, and structural (late) protein production.  
These transcriptional events occur as a defined sequence designed to inhibit cellular gene 
expression in favor of virus replication.  One critical step involves the destabilization of 
host cell mRNA by the vhs protein which enters the cell as a component of the infectious 
virion (Everly et al. 2002).  Following this, transcription of IE genes begins and the IE 
proteins activate the E genes.  Transcription of E genes is not dependent on DNA 
synthesis, whereas L gene transcription is (Conley et al. 1981).  But once the E transcripts 
are produced, they promote viral DNA replication.  Finally, DNA synthesis stimulates 
transcription of the early-late (γ1 ) or true-late  (γ2) genes which code for the structural 
proteins of the virus.   
For each class of genes, host cell RNA polymerase II is used for transcription 
(Costanzo et al. 1977), and transcription is initiated at promoter regions in the 5’ non-
coding region of the gene.  However, the arrangement of promoter and regulatory 
sequences for each gene class is somewhat different.  For all classes, the TATA box, to 
which transcription factors bind to facilitate binding of RNA polymerase, is located 20-
35 bp upstream from the initiation codon.  For most classes, binding sites for one or more 
cellular transcription factors are also found upstream of the TATA box.  An exception to 
this is seen in the γ2 gene subclass which lacks a transcription factor binding site, but has 
an initiator and activator element downstream of the TATA box (Guzowski and Wagner 
1993).   
In HSV-1, the IE genes code for proteins designated as ICP0, ICP4, ICP22, 
ICP27, ICP47 (infected cell polypeptides), and Us1.5.  With the exception of ICP47, 
these are regulatory proteins that are involved in regulation of viral gene transcription.  
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The functions of ICP47 appear to be retention of MHCI class proteins in the ER 
(Hagmann et al. 1995; York et al. 1994) and inhibition of antigen presentation to CD8+ T 
cells (Fruh et al. 1995; Hill et al. 1995).  These activities contribute to evasion of the 
host’s immune system (see Latency and Persistence section).  Nevertheless, synthesis of 
all these IE proteins requires the transcriptional activating protein VP-16 (UL48) 
(Triezenberg et al. 1988) which is brought into the host cell as part of the tegument.  To 
function as a transcriptional activator, VP-16 must somehow enter the nucleus where 
transcription occurs.  There is evidence that translocation of VP-16 into the nucleus is 
promoted through some interaction with cellular protein HCF (host cell factor) within the 
cytoplasm (LaBoissiere and O'Hare 2000).  Once in the nucleus, VP-16 binds to host cell 
protein octomer 1 (Oct-1) to enhance activity of cellular transcriptional proteins already 
bound to viral DNA (Stern and Herr 1991).  Subsequently, ICP4 becomes the major 
transactivating protein for the E and L genes (Carrozza and DeLuca, 1996; DeLuca et al. 
1985).  ICP4 is also able to repress its own transcription (DeLuca and Schaffer 1985; 
O'Hare and Hayward 1985).  It has been demonstrated that IPC4 activates transcription 
by interacting with transcription factor IID (TFIID) which requires interaction with TBP-
associated factor (TAF250) mediated by the C-terminal region of ICP4 (Carrozza and 
DeLuca, 1996).  ICP4 has a number of functional domains including a DNA-binding 
region, a nuclear localization region, and two transactivating regions (DeLuca and 
Schaffer 1988; Shepard et al. 1989).  ICP27, contains an RNA-binding sequence, a 
leucine-rich nuclear export signal, and an export control sequence, and so is able to 
shuttle between the cytoplasm and nucleus of the cell (Soliman and Silverstein 2000).  In 
its role as a shuttle protein, ICP27 is able to facilitate the export of viral RNA transcripts.  
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ICP27 binds RNAs via an arginine-glycine region referred to as an RGG box (Sandri-
Goldin 1998).  These transcripts must contain the same 5’ cap and 3’ poly A tail that 
cellular transcripts possess in order to allow export from the nucleus.  ICP27 also plays a 
role in inhibiting host cell protein synthesis by redistributing splicing factors that modify 
cellular RNA transcripts (Phelan et al. 1993; Sandri-Goldin et al. 1995).  In HCMV, 
UL69 is the homologue of ICP27, but it cannot substitute for ICP27 in HSV-1-infected 
cells due to some functional differences (Winkler et al. 1994; Winkler and Stamminger 
1996). 
Viral mRNA is translated by cellular systems under the influence of specific 
regulatory signals.  Since the IE transcripts initiate both E and L gene transcription, 
control mechanisms exist to ensure temporal regulation of expression.  One means of 
doing this is to shutdown IE and E gene expression at appropriate times.  There are two 
processes currently known to promote this.  First, ICP4 can bind to repressor elements in 
its own promoter to repress its own transcription (Faber and Wilcox 1986; Kristie and 
Roizman 1984).  Since ICP4 is essential for transcription of IE and E genes, this would 
decrease expression of these genes.  Second, the major DNA-binding protein ICP8, 
which is involved in replication, (Bayliss et al. 1975; Chen and Knipe 1996; Gao and 
Knipe 1991) represses L gene expression from the parental viral genome (Chen and 
Knipe 1996; Godowski and Knipe 1983; 1985; 1986) but enhances L gene expression 
from progeny genomes (Gao and Knipe 1991).   
2. DNA Replication  
When HSV DNA is released from capsids into the nucleus, it quickly changes from linear 
to a circular form (Uprichard and Knipe 1996).  Actual replication occurs in unique 
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structures described as replication compartments (Quinlan et al. 1984).  These 
compartments form near nuclear domain 10 (ND10) sites, which are cellular structures 
with which viral DNA and viral replication proteins associate (Ishov and Maul 1996; 
Quinlan et al. 1984).  To begin DNA synthesis, the HSV-1 origin binding protein (OBP) 
may bind to one of the three origins of replication (ori) in the genome.  There is one site 
(oriL) located between the viral replication proteins ICP8 (UL29) and DNA polymerase 
(UL30) genes (Weller et al. 1985), and two copies of the oriS site in the repeat sequences 
flanking the US region (Frenkel et al. 1975).  Only one of the three sites is required to 
begin viral DNA replication (Igarashi et al. 1993; Polvino-Bodnar et al. 1987).  In 
HCMV, these lytic-phase DNA replicator (oriLyt) sequences are found near the middle 
of a structurally-complex area of the UL region (Anders et al. 1992; Masse et al. 1992).  
Initially, replication begins in both directions on the circular DNA molecule resulting in 
bidirectional replication.  Shortly thereafter, replication probably continues by rolling-
circle replication which produces head-to-tail concatemeric DNA (Jacob et al. 1979).  
Genetic and biochemical techniques have identified seven viral proteins (UL5, UL8, 
UL9, UL29, UL30, UL42, and UL52: see Table 3) involved in HSV-1 DNA replication 
(Challberg, 1986).  In addition to these virally-encoded proteins, DNA synthesis also 
depends on cellular factors such as topoisomerase and DNA ligase.   
a) Replication Proteins 
(1) Origin Binding Protein 
The OBP encoded by UL9 consists of 851 aa and is involved in theta replication of DNA 
(i.e. circular DNA molecules).  This protein has two functional domains, ATP-binding 




Protein name Function Reference 
UL5 Helicase-primase 
component 
Helicase, primase, and ATPase activity (Dracheva et al. 1995) 
UL8 Helicase-primase 
component 
Enhances nuclear localization (Barnard et al. 1997) 
UL9 Origin –binding protein Unwinds double-stranded DNA (Fierer and Challberg, 
1992) 
UL29 Single-stranded binding 
protein 
Allows origin unwinding and progression 
of the replication fork 
(Boehmer and Lehman, 
1993) 
UL30 DNA polymerase 
holoenzyme 
Acts as the catalytic subunit (Purifoy et al. 1977) 
UL42 DNA polymerase 
holoenzyme 
Acts as a processivity factor (Gottlieb et al. 1990) 
UL52 Helicase-primase 
component 
Helicase, primase, and ATPase activity (Klinedinst and 
Challberg 1994) 
Table 3. Viral Proteins Involved in HSV-1 DNA Replication 
binds to an origin of replication as a dimer at the conserved sequence  
5’–CGTTCGCACTT-3’ (Elias and Lehman 1988; Koff and Tegtmeyer 1988).  Once the 
OBP unwinds the double-stranded DNA, it recruits single-stranded DNA binding protein 
(ICP8), and together these two proteins recruit the remaining five viral proteins to 
complete the replication complex. 
(2) Single-Stranded DNA Binding Protein 
The single-stranded DNA binding protein (SSB) is encoded by UL29 and 
produces a protein of 1196 aa.  It was originally called the major-binding protein (Bayliss 
et al. 1975).  As its name implies, ICP8 binds more efficiently to ssDNA than to dsDNA 
(Lee and Knipe 1985; Ruyechan 1983).  This protein is essential for viral DNA synthesis 
and optimal expression of late genes.  While ICP8 is able to destabilize the DNA helix to 
allow origin unwinding and replication fork progression (Boehmer and Lehman, 1993), it 
has also been shown to stimulate both the rate and degree of helicase activity for UL9 
(Boehmer et al. 1993).  Additionally, this protein has been shown to promote renaturation 
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of complementary single-stranded DNA which could account for the frequent 
recombination events that occur in HSV-1-infected cells (Dutch and Lehman, 1993).  
Since ICP8 is large and interacts with many other replication proteins, it may function as 
scaffolding protein to assemble the HSV DNA replication complex (de Bruyn Kops and 
Knipe, 1988).  ICP8 also plays a role in recruitment of replication proteins to small 
prereplication sites before viral DNA replicates (Bush et al. 1991; Liptak et al. 1996).  
Once DNA replication starts, ICP8 is required for formation of large, globular viral 
replication compartments in infected cell nuclei (de Bruyn Kops and Knipe, 1988).  
Evidence of these functions is demonstrated by immunocytochemical and biochemical 
analysis of ICP8 which shows binding to other HSV proteins or DNA causes 
conformational and localization-associated antigenic changes to occur in the ICP8 protein 
(Uprichard and Knipe 2003). 
(3) DNA Helicase-Primase Complex 
The DNA Helicase-Primase complex is a heterodimer consisting of the UL5, 
UL8, and UL52 proteins (Crute et al. 1988).  UL5 contains 882 aa and two conserved 
sequences which are essential for DNA replication: the ATP-binding and helicase motifs 
(Zhu and Weller 1992).  There are six conserved sequence motifs in UL5 that are found 
in all members of the DNA and RNA helicase superfamily (Figure 6).   
The product of UL52 contains 1058 aa, has a divalent metal-binding motif common to 
other DNA primases, and is required for cleavage and packaging of viral DNA (Borst et 
al. 2008).  Like UL5, it is also required for DNA replication.  Together, UL5 and UL52 
form what is referred to as the core enzyme sub-complex which conducts helicase, 
primase, and ATPase activities.  The last protein of the helicase-primase complex (UL8) 
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is 750 amino acid residues and functions to enhance nuclear localization and also 
stimulates core enzymatic activities. 
(4) DNA Polymerase Holoenzyme 
The fact that HSV-1 encodes its own DNA polymerase was not definitively 
established until genetic experiments mapped the gene to the HSV-1 genome in the late 
1970s (Purifoy et al. 1977).  Further support for this finding was provided later when the 
sequence of the HSV UL30 protein was compared to that of mammalian DNA 
polymerase α and found to have several shared regions of sequence similarity (Gibbs et 
al. 1988).  The HSV DNA polymerase holoenzyme is a heterodimer composed of a 1235 
aa catalytic subunit, UL30,  and a 488 aa accessory factor, UL42 (Purifoy and Powell 
1976).  The interaction between the two is required for viral DNA replication.  The UL30 
subunit (Pol) has both polymerase and intrinsic 3’-5’ exonuclease activity that allows 
proofreading as the enzyme replicates DNA.  The UL42 subunit is a double-stranded 
DNA binding protein that acts to increase processivity of UL30 (Gallo et al. 1989; 
Gottlieb et al. 1990).  Because HSV-1 DNA polymerase has broader substrate specificity 
than cellular DNA polymerase, it has been a good target for drug therapy.  Another 
recently-investigated target for drug therapy involves inhibition of the interaction 
between UL30 and UL42 to prevent DNA replication (Pilger et al. 2004).  The HCMV 
homologues of HSV-1 DNA polymerase are the UL54 polymerase (Heilbronn et al. 
1987) and the UL44 accessory protein (Ertl and Powell 1992).  The DNA polymerase is 
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SEQUENCE I II III IV V VI 
 
UL5   94 ITGNAGSGKSTCVQ 136 VIVIDEAGLLG 26 LVCVGSPTQTAS 44 NNKRCVEHE 442 AMTITR SQGL SLDKVAICF  8 SAYVAMSRT 
uvrD  26 VLAGAGSGKTRVLV 174 NILVDEFQNTN 16 VMIVGDDDQSIY 26 QNYRSTSNI 267 LMTLHS AKGL EFPQVFIVG 23 LAYVGVYRA 
rep  19 VLAGAGSGKTRVIT 175 YLLVDEYQDTN 16 FTVVGDDDQSIY 26 QNYRSSGRI 271 LMTLHA SKGL EFPYVYMVG 22 LAYVGITRA 
recB  20 IEASAGTGKTFTIA 345 VAMIDEFQDTD 18 LLLIGDPKQAIY 24 TNWRSAPGM 286 IVTIHK SKGL EYPLVWLPF 44 LLYVALTRS 
recD 164 ISGGPGTGKTTTVA  82 VLVVDEASMID 16 VIFLGDRDQLAS 24 QLSRLTGTH 198 AMTVHK SOGS EFDHAALIT 11 LVYTAVTRA 
PIF 255 YTGSAGTGKSILLR  46 ALVVDEISMLD 25 LIFCGDFFQLPP 29 KVFRQRGDV 219 MQTIHQNSAGKRRLPLVRFKA 33 QAYVALSRA 
 
 
Figure 6.  Conservation of the UL5 Protein.  The UL5 protein is represented by a shadowed box, and the six conserved 
motifs are represented by dark bars.  The amino acid sequences of the six conserved motifs from six proteins (UL5, Rep, 
Uvr, RecB, RecD, and PIF) are shown.  UvrD, rep, recB, and recD are Escherichia coli proteins and PIF is yeast helicase.  
Shaded aa are identical.  The numbers between the aa sequences refer to the number of the residues separating each motif 
(Zhu and Weller 1992). 
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(5) Other Viral Replication/Modification Proteins  
In addition to viral proteins essential for replication in vitro, a number of other 
proteins are non-essential in cell-culture, but probably are essential in non-dividing cells 
like neurons.  This may be because several of these proteins are important in metabolism 
of nucleotides, which are less abundant in resting cells, so these viruses have adapted to 
produce their own enzymes to enhance viral DNA replication. 
One of these enzymes, thymidine kinase (TK) encoded by the UL23 gene, is 
involved in phosphorylation of pyrimidine and purine nucleosides.  Like HSV-1 DNA 
polymerase, TK has a broad substrate specificity so serves as a target for antiviral drugs 
such as the nucleoside analog acyclovir (Fyfe et al. 1978).  TK recognizes acyclovir as a 
nucleoside and adds phosphate groups to the molecule.  This molecule then is 
incorporated into the growing DNA chain and leads to chain termination since it lacks an 
attachment site for the next nucleotide.  HSV TK is a homodimeric complex of the UL23 
gene product that most likely produces nucleoside triphosphate precursors for DNA 
synthesis and is reportedly necessary for HSV reactivation from latency (Chen et al. 
2004).  Additionally, efficacy of the antiviral drug acyclovir requires phosphorylation by 
TK, and drug-resistance may develop due to mutations in the viral TK gene (Coen, 
1994).  CMVs do not produce TK but instead, another protein kinase (the UL97 gene 
product) serves the same function and acts to phosphorylate acyclovir (Talarico et al. 
1999).   
Two other proteins encoded by herpesviruses are the DNA repair enzyme uracil-
DNA glycosylase (UNG/UL2) (Caradonna et al. 1987) and deoxyuridine triphosphatase 
(dUTPase/UL50) (Preston and Fisher, 1984).  UNG is an enzyme that acts to remove 
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uracil from DNA when it is accidentally integrated during replication or when it occurs 
after cytosine deamination (Lindahl and Nyberg 1974) or incorporation of deoxyuridine 
monophosphate (dUMP) into DNA (Caradonna et al. 1987).  Like many other HSV 
replication or modification proteins, UNG is required for DNA synthesis in non-dividing 
cells (Chen et al. 2002).  dUTPase proteins are found in all eukaryotes, bacteria, and a 
number of DNA viruses, and helps maintain low levels of uracil in the cell to decrease its 
misincorporation into DNA.  Phylogenetic analysis of herpesvirus mammalian dUTPase 
genes indicates that the viral gene probably originated through capture of a host gene.  
This produced a herpesvirus dUTPase which has a larger size than most dUTPases, but 
stills functions as a monomer (McGeehan et al. 2001). 
A third enzyme, ribonucleotide reductase (RR, UL39, ICP6), reduces the ribose in 
ribonucleotides to deoxyribose (Bacchetti et al. 1986; Dutia 1983).  It is a complex of 
UL39 [the small subunit (RR2) having peak expression 6 to 8 h post-infection (PI)], and 
UL40 [the large subunit (RR1) having onset of synthesis at 2 h PI] (Frame et al. 1985; 
Honess and Roizman 1974).  Studies have shown that the large subunit is required for 
viral replication in non-dividing cells in vitro in both HSV-1 (Goldstein and Weller 1988) 
and HSV-2 (Smith et al. 1992).  In addition to its function as a ribonucleotide reductase, 
the large (RR1) subunit demonstrates intrinsic serine-threonine kinase activity (Cooper et 
al. 1995) which has been linked to IE gene expression and viral growth, at least in HSV-2 
(Smith et al. 1998).  HCMV UL45 is a homologue of HSV ribonucleotide reductase, but 
is dispensable for growth in human fibroblasts and endothelial cells (Hahn et al. 2002). 
Finally, alkaline nuclease (UL12) is a phosphoprotein required for efficient virus 
reproduction.  It functions as both an endonuclease and exonuclease to facilitate DNA 
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maturation and encapsidation.  It also appears to interact with ICP8 collaboratively to 
affect strand exchange between linear double-stranded DNA and circular single-stranded 
DNA (Reuven et al. 2003, Thomas et al. 1992)  This suggests that ICP8 and alkaline 
nuclease catalyze homologous recombination in a similar fashion as a recombinase 
(Bortner et al. 1993; Gourves et al. 2000).  
D. Assembly and Packaging 
Assembly of herpesviruses occurs in the host cell nucleus following DNA 
replication.  Capsid proteins, however, are synthesized in the cytoplasm of the cell.  This 
necessitates translocation of capsid proteins into the nucleus where they form mature 
capsids.  Capsid assembly proteins (UL80 proteins) possess NLS sequences which 
facilitate translocation of the major capsid protein into the nucleus (Nguyen et al. 2008).  
Once capsid proteins are in the nucleus, they are capable of self assembly.  Self-assembly 
has been demonstrated in vitro using purified viral protein subunits (Newcomb et al. 
1999).  Once capsids are assembled, concatemeric viral DNA is cleaved at precise 
distances from the pac1 and pac2 sites (Deiss et al. 1986) and concurrently packaged into 
capsids (Ladin et al. 1982).  Within the direct repeat (DR1) is a recognition signal which 
allows capsid binding, and at a second location a DNA cleavage site ensures packaging 
of the entire genome (Varmuza and Smiley 1985).  Also, eight viral proteins (HSV-1 
UL6, UL15, UL25, UL28, UL32, UL33, UL36, and UL37) function in genome 
packaging, and each has a specific function.  During encapsidation, twelve UL6 protein 
molecules are incorporated into the capsid by interaction with the UL26.5 capsid protein 
to make up the portal complex through which DNA passes (Newcomb et al. 2003).  Two 
other genes, UL15 and UL28, code for a viral terminase, the enzyme that drives DNA 
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into the capsid (White et al. 2003).  The UL25 protein is believed to be an anchoring 
protein that stabilizes capsids to prevent loss of DNA that has already been packaged 
(Newcomb et al. 2006; Ogasawara et al. 2001).  Functions of the other proteins (UL32, 
UL33, UL36, and UL37) are less well understood.   
E. Egress 
After viral transcription, replication, capsid production, and DNA packaging are 
complete, viral nucleocapsids must leave the nucleus and undergo further processing 
before leaving the cell.  Prior to egress, the tegument is added, envelopment occurs, viral 
glycoproteins are processed in the ER and Golgi, and then mature virions are transported 
to the plasma membrane.  The first step in the envelopment process involves the UL31 
and UL34 proteins, which are needed for acquisition of an envelope from the inner 
nuclear membrane (Reynolds et al. 2001).  These two proteins form a complex that is 
involved in primary envelopment of capsids by budding through the inner membrane, 
probably by partially dismantling the nuclear lamina (Scott and O'Hare 2001).  In HSV-1, 
an additional protein (encoded by the US3 gene) functions as a protein kinase and 
appears to act as a modulator of the UL34 gene product which targets it to the nuclear 
membrane (Purves et al. 1992).  A second capsid protein, UL37, facilitates exit of capsids 
from the nucleus and may also play a role in re-envelopment at the Golgi (Desai et al. 
2001).  At the outer nuclear membrane, de-envelopment occurs and the capsid is released 
into the cytoplasm.  This is where tegumentation is completed before the virion buds into 
trans-Golgi vesicles containing processed viral glycoproteins (Mettenleiter 2002).  In 
HCMV, these vesicles contain viral gB, trans-Golgi network 46 protein (a Golgi marker), 
mannosidase II (a Golgi resident enzyme), and the Rib 3 secretory vacuole marker 
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(Homman-Loudiyi et al. 2003).  The HCMV tegument protein, pp150, is also crucial for 
virion egress and may play a role in tegumentation and envelopment as well (AuCoin et 
al. 2006).   
1. Glycoprotein Processing 
Glycoprotein processing is another critical event that must occur prior to release 
of progeny virions.  An example of such processing is illustrated by gB.  As previously 
mentioned, gB is a highly-conserved glycosylated envelope protein common to all 
herpesviruses.  It is the major envelope glycoprotein of the virion, is found in the 
membranes of infected host cells (Farrar and Oram, 1984), is recognized by neutralizing 
antibodies (Britt 1984; Nowak et al. 1984b; Rasmussen et al. 1985), and is highly 
immunogenic in humans (Britt, 1984).  Functionally, gB promotes virion penetration into 
cells, cell-to-cell transmission, fusion of infected cells, and is the primary target for the 
cell-mediated immune response (Britt et al. 1990; Navarro et al. 1993; Utz et al. 1989). 
The HCMV gB transmembrane protein is expressed early in the infectious cycle 
(Smuda et al. 1997) and consists of 906 aa encoded by the UL55 gene (Chee et al. 1990; 
Cranage et al. 1986).  gB is translated as a 105 kDa precursor protein which undergoes 
processing in the ER and Golgi to yield a mature 150 kDa glycoprotein (Britt and Auger, 
1986; Britt and Vugler, 1989).  High mannose carbohydrates are added in the rough ER.  
As the precursor protein is transported through the Golgi apparatus, the carbohydrates are 
further processed, and the 150 kDa gB is then cleaved into 116 kDa and 55 kDa subunits.  
Cleavage occurs by a cellular furan protease which recognizes the consensus sequence 
RXK/RR (Britt and Vugler, 1989; Vey et al. 1995).  Proteolytic cleavage of gB has been 
shown to occur in the passaged HCMV AD169 strain as well as the clinical HCMV 
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Towne strain (Spaete et al. 1988).  Although gB cleavage is considered essential for the 
HCMV life cycle in vivo, cleavage is dispensable for growth in cell culture (Strive et al. 
2002).  Once cleavage has occurred, the gB subunits remain linked together by disulfide 
bonds.  
In both the RER and Golgi apparatus, the gB molecule undergoes prolonged 
folding, extensive disulfide bond formation and rearrangements (Billstrom and Britt, 
1995).  Finally, additional trimming or modifications may occur in the rough ER or Golgi 
as well as addition of carbohydrates (Huber and Compton 1999).  The cleaved gB 
molecules associate to form the gp55-116 complex on the viral envelope and surface of 
infected cells (Spaete et al. 1990; Spaete et al. 1988). 
F. Latency and Persistence 
For viral persistence or latency to develop, herpesviruses must somehow evade 
host immune system surveillance.  Typically in persistent infections, small numbers of 
virus progeny remain in tissues from which they are not quickly cleared.  This occurs in 
immunologically “privileged” tissues where low levels of virus are constantly produced 
and shed.  In HCMV infections, virus can be shed in immunocompetent individuals for 
years.  In latent infections, which are typical of herpesviruses, the virus lies dormant in a 
non-replicating state in certain tissues until reactivated.   
CMVs may remain latent in peripheral blood lymphocytes, bone marrow pre-
cursor cells, and monocytes-macrophages (Hahn et al. 1998; Kondo et al. 1994).  In 
monocytes and macrophages, the mechanism for latency has been linked to suppression 
of the major IE promoter/regulatory (MIEP) region of the genome (Sinclair and Sissons 
1996).  In HSV-1 and HSV-2, latency is established in nerve cells and this confers the 
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added benefit of allowing them to be easily transported around the body via neuronal 
fibers.  For HSV-1, the replication initiator protein, UL9, which is bound by neural F-box 
protein (NFB42) is believed to be responsible for neuronal latency (Eom et al. 2004).  
However, the primary site of infection and viral replication for HSV-1 and HSV-2 is 
mucosal or epidermal cells, and the early signs of infection are lesions which are full of 
virus.  Once the initial symptoms subside, the virus remains latent in non-dividing 
neurons of sensory or autonomic ganglia.  During this time, the viral genome remains 
intact and there is little or no production of viral proteins.  In this state, immune detection 
of the infected cell is blocked by various viral evasion mechanisms.  Reactiv-ation of 
herpesviruses usually occurs due to some type of stress imposed on the host such as 
ultraviolet light, illness, etc., and results in reentry of the virus into the lytic replication 
cycle.  This pattern of latency-reactivation is recurrent in herpesvirus infections and is 
grouped into three operational events: establishment, maintenance, and reactivation.  
Establishment of HSV-1 latency begins with acute infection in mucosal epithelia 
followed by entry of the virus into a sensory neuron.  Because HSV-1 infection often 
involves the oral, optic or nasal mucosa, the trigeminal ganglia (TG) are a primary site 
for latency (Baringer and Swoveland, 1973).   
In the latent state, two observed conditions likely have an effect on viral gene 
expression: 1) the viral genome becomes a circular episome (Rock and Fraser 1985) and 
2) the viral genome associates with cellular histones to develop a chromatin-like 
appearance (Deshmane and Fraser, 1989).  Another likely mechanism involves regulation 
of IE promoters in sensory neurons.  Evidence of such regulation is apparent where the 
ICP4 promoter is functional in Schwann cells but not in sensory neurons of the TG (Taus 
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and Mitchell 2001).  This indicates that neuron-specific factors differentially regulate IE 
promoters.  In addition to this, certain factors may prevent formation of the VP16 
transcriptional activating complex in sensory neurons.  One such factor could be a 
decrease in host cell factor (HCF) since it is required to induce IE promoter activity.  
Such a decrease in HCF may be attributed to the activities of cellular transcription factors 
that bind HCF (Lu and Misra 2000a; Lu and Misra 2000b).  Sensory neurons are also 
known to produce transcription factor Brn-3.0, which can bind to non-coding regions of 
the HSV-1 genome, (Turner et al. 1997) and other proteins that may play a role in 
expressing IE genes (Hagmann et al. 1995).   
As previously mentioned, there is minimal expression of viral mRNA during 
latency and during this time no structural proteins are produced.  Instead, transcription of 
a special set of RNAs referred to as LAT (latency-associated transcripts) occurs.  LAT 
are restricted primarily to the nucleus, and these RNAs map to the long terminal repeat 
region of the genome (Stevens et al. 1987).  Unlike promoters for other HSV-1 genes, the 
LAT promoter is activated within sensory neurons.  This promoter consists of a strong 
promoter region (LAP1) and a weaker promoter region (LAP-2) (Chen et al. 1995; Goins 
et al. 1994).  There are numerous binding sites for cellular transcription factors within the 
LAT promoter including two cyclic AMP (cAMP) responsive element (CRE)-binding 
sites and three Sp1 sites (Figure 7).  The CRE site nearest the TATA box has been shown 
to influence LAT expression in neurons and is also involved in reactivation from latency 
(Bloom et al. 1997), (Goins et al. 1994; Leib et al. 1991; Rader et al. 1993).  The LAP-2 




























Figure 7. Representation of LAP1 and LAP2 Regulatory Regions and Associated Cis-acting 
Elements. LAP is the latency-active promoter, Sp1 and E2F are transcription factor con-
sensus sequences, USF is an upstream transcription factor, CRE is a cyclic AMP response 
element, INR is an insulin-like growth factor receptor, CAAT and TATA are transcriptional 
factor binding sites.  Adapted from Goins, et al. 1994. 
LAP1 LAP2
 
of LAP-1 in latent infection (Lokensgard et al. 1997; Lokensgard et al. 1994).  LAT itself 
does not encode for a protein, but is instead an RNA molecule that functions to regulate 
latency (Stevens et al. 1987).  This has been demonstrated in transiently transfected cells 
where LAT is able to decrease the promoter-transactivating ability of ICP0 (Farrell et al. 
1991).  While most studies have shown that LAT plays an important role in establishment 
of latency, it does not appear to be essential (Sawtell and Thompson 1992; Thompson 
and Sawtell 1997).  However, spontaneous reactivation of HSV-1 from latency is 
drastically impaired in LAT-negative mutants (Perng et al. 1999; Perng et al. 1994).  
Another reported function of LAT is inhibiting apoptosis in transiently transfected cells 
(Ahmed et al. 2002).  Apoptosis (one type of programmed cell death) is observed in 
virus-infected cell culture (Teodoro and Branton 1997) and presumably helps prevent 
viral spread in vivo.  While LAT does not appear to be necessary for reactivation, virally-
encoded TK does seem to be (Coen et al. 1989; Watkins et al. 1998).  Another viral 
enzyme that is probably important in reactivation is RR.  This enzyme provides protein 
kinase (PK) activity which must be present for IE gene expression during reactivation 
(Smith et al. 1998).  Given these factors, the mechanism of reactivation is not completely 
understood, but it is clear that viral or cellular activating proteins must somehow 
“overcome” latency-associated down-regulation for productive viral replication to occur. 
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IV. THE CYTOMEGALOVIRUSES 
Like other herpesviruses, the CMVs are enveloped, double-stranded DNA viruses.  
They possess the largest genomes of all members in the herpesvirus family.  The HCMV 
genome consists of 230 kilobase pairs (kbps), while other CMVs such as guinea pig 
CMV, are somewhat larger at 240 kbps.  The HCMV genome has been extensively 
studied and serves as the prototype for the primate CMVs.  As seen in HSV-1, four 
isomers of the HCMV genome exist due to inversion of the long and short genome 
components.  Other primate CMV genomes however, appear to exist as only one isomer. 
A. Pathogenecity 
Of all viruses in the family Herpesviridae, HCMV is one of the most prevalent in 
humans.  Approximately 50-90% of all individuals in developed countries will 
serologically test positive for HCMV, and seroprevalence increases with age (Staras et al. 
2006).  Since the virus is often latent in kidney tubules, mammary glands or salivary 
glands of infected individuals, it is often acquired in infancy or childhood from infected 
adults or children (Homa and Brown 1997).  The latter is especially true in day-care 
centers where infected children in close contact with uninfected children efficiently 
spread the virus.  In individuals with normal, healthy immune systems, HCMV infection 
is usually subclinical.  However, individuals who are immunocompromised may be 
severely affected by the virus (Hill et al. 1995).  AIDS patients suffer numerous CMV-
related diseases.  Organ transplant recipients, who use immunosuppressive drugs to avoid 
tissue rejection, are at risk of developing symptoms from reactivation of their own latent 
HCMV and are also at risk of acquiring HCMV from the transplanted donor organ.  In 
addition to causing disease in immune deficient individuals, HCMV is also capable of 
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crossing the placenta and infecting a fetus in utero.  This often leads to stillbirth, 
miscarriage, or severe congenital complications (Hayward et al. 1975; Ishov and Maul 
1996; Michaels et al. 2003). 
The prototype HCMV laboratory strain AD169 has a relatively large genome of 
230 kbp.  By 1989, the entire genome of AD169 had been mapped and sequenced (Chee 
et al. 1990).  The map reveals unique sequences (where most genes are located) and 
repetitive sequences that contain very few genes.  The genome map is divided into 
regions designated the terminal repeat long (TRL), unique long (UL), internal repeat long 
(IRL), internal repeat short (IRS), unique short (US), and terminal repeat short (TRS) 
similar to that shown in Figure 1 for HSVI.  As seen in HSV-1, there are four different 
isomers of the genome that represent inversions of either the UL or US regions of the 
genome (Figure 1).  Additionally, this particular strain contains over 200 potential ORFs 
(Chee et al. 1990).  Protein products for many of these ORFs have been identified and 
expressed in vitro to discover the structure and function of the encoded proteins.  
However much of the genome is still being evaluated to determine the functions of other 
proteins.   
The genes expressed by the virus are categorized as immediate early (IE) early 
(E) or late (L).  In general, IE genes produce functional proteins and enzymes that 
suppress cellular activities and stimulate E gene expression.  E genes are associated with 
viral DNA synthesis and nucleic acid metabolism, and L genes primarily produce 
structural proteins.  This appears to be a sequential process involving transcriptional 
regulation in which IE and E genes must be expressed to allow L gene expression.   
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V. RESEARCH OBJECTIVES 
The goals of this research project were to sequence the unique regions of the 
BaCMV genome, identify important genes, and to compare these genes with homologous 
genes of related CMVs.  When this project began, the only completely sequenced and 
published CMV genome was that of HCMV strain AD169 (accession #X17403).  During 
the course of this research, the chimpanzee (CCMV) and rhesus monkey (RhCMV) 
cytomegalovirus genomes were sequenced and published as well (AF480884; 
AY186194).  The BaCMV sequence provides an additional model system for research on 
CMVs.  Also, comparison of BaCMV strain OCOM4-37 sequence data with closely-
related primate CMV genomes will provide new information regarding similarities and 
differences between these viruses.  Sequencing, in and of itself, is a valuable component 
of basic science, but it is also useful because it provides a “roadmap” to identify genes 
and hence speed up research.  Consequently, the BaCMV OCOM4-37 sequence has been 
used to develop a diagnostic PCR assay (Ross et al. 2005) and to identify genes for 
expression of recombinant proteins for diagnostic purposes. 
Because the HCMV, CCMV, and RhCMV genomes have been completely 
sequenced and published, they were compared to the BaCMV sequence.  The BaCMV 
genome was expected to show greatest homology with CMV genomes of most closely-
related primates since this has been observed for other herpesviruses.  Additionally, by 
aligning conserved gene sequences from primate and other animal CMVs with 
homologous BaCMV sequences, we were able to show phylogenetic relationships that 
cluster herpesviruses into groups depending on the subfamily in which they belong.  It is 
common for CMV strains passaged in the laboratory to lose genes that are critical for 
 39 
infection in an animal host, but are not essential for growth in cell culture.  Therefore, a 
difference in gene number was expected between clinical isolates and laboratory strains.  
HCMV strain AD169 is a laboratory strain that has previously been shown to lack genes 






I. CHEMICAL REAGENTS AND MATERIALS 








Chloroform, [ethylenediamine] tetracetic acid (EDTA), EtOH, ether, formamide, H2O  
(HPLC grade), methanol, SDS, PEG, phenol, Tris[hydroxymethyl]-aminomethane (Tris) 
 
Boehringer Mannheim GmbH 
Digoxigenin (DIG) Oligonucleotide Tailing Kit 
 
Fisher 
Boric acid, calcium chloride (CaCl2), disodium phosphate (Na2HPO4), potassium 
phosphate monobasic (KH2PO4), monosodium phosphate (NaH2PO4), sodium 




Delbecco's modified Eagle medium [high glucose 4500 mg/L, with L-glutamine 
catalogue number 320-1965AJ] (DMEM), fetal bovine serum (FBS) 
 
Kodak 
1D Image Analysis Software ver. 3.5 
 
New England Biolabs 
GPS-1 Genome Priming System Kit, 1Kb plus DNA ladder, λDNA/ Hind III fragment 
ladder, Klenow enzyme 
 
Pharmacia 
Dideoxy-, and deoxy-nucleotide triphosphates, Lambda DNA, Pancreatic RNase
 41 
Polaroid 
DS-34 camera and 3000 ISO type 667 film 
 
Qiagen 
GelPilot 1 kb plus ladder 
 
Schleicher & Schuell 
Protran nitrocellulose transfer membrane 
 
Sigma 
Bovine serum albumin (BSA), bromophenol blue (BPB), ethidium bromide (EtBr), 
ampicillin, salmon sperm DNA, proteinase K.   
 
Stratagene 
pBluescript II SK(+) (phagemid vector) 
 
TAKARA Bio Inc. 
LA PCR Kit ver. 2.1 
 
B. Enzymes  
Pharmacia 
DNA polymerase (Klenow fragment),and T4 DNA ligase 
 
Pancreatic RNase 
Pancreatic RNase was boiled to remove DNase activity, and suspended in 10 mM Tris-
HCl pH 7.5, and 15 mM NaCl at a final concentration of 10 mg/mL. 
 
Sigma  
Proteinase K (Sigma P 0390) 20 mg/mL stock solution in sterile dH2O. 
 
Restriction Endonucleases (R.E) 
R.E's were obtained from Boehringer Mannheim, BRL, New England Biolabs, 
Pharmacia, and Promega.  They were used with the supplied buffers at recommended 
concentrations and temperatures. 
 
C. Preparation of Buffers, Solutions and Media 
Cell Culture Media 
If the media was older than 3 months, L-glutamine was added as a supplement to a final 
concentration of 0.1 mM.  Gentamycin 25 mg per mL stock solution was used at a final 
concentration of 25 mg per L. 
 
1X Phosphate-buffered Saline Buffer (1X PBS) 
A solution of 0.8% NaCl, 2% KCl, 1.5% NaH2PO4, 2% KH2PO4 was dissolved in H2O 




A solution of 5X SSC, 50% de-ionized formamide, 0.1% SDS, 1mM EDTA, 25 mM 
NaH2PO4, 1 mg Salmon Sperm DNA was prepared. 
 
20X Standard-Sodium Citrate  (20X SSC) buffer 
A solution of 3 M NaCl, 300 mM Sodium citrate was dissolved in H2O for use as a stock 
solution.  1X and 5X SSC buffers were prepared by dilution of this stock solution. 
 
6X Stop (Agarose Gel Loading Buffer) 
A solution of 2.5%  Bromophenol Blue, 2.5%  xylene cyanol, 30%  glycerol was 
dissolved in H2O. 
 
DIG Wash Solution (2X SSC) 
A solution of 10 ml of 20X SSC, 1.0 ml of 10% SDS was mixed with 89 ml of distilled 
H2O. 
 
DIG Wash Solution (0,1X SSC) 
A solution of 0.5 ml of 20X SSC, 1.0 ml of 10% SDS was mixed with 89 ml of distilled 
H2O. 
 
DIG Buffer 1 
A solution of 0.1 M maleic acid and 0.15 NaCl was dissolved in 98.5 ml distilled H2O 
and pH adjusted to 7.5 with solid NaOH. 
 
DIG Blocking Solution 
A solution of 1.0 g of blocking reagent (Carnation powdered milk) and 100 ml of DIG 
buffer 1 was mixed with stirring at 65 ºC to dissolve. 
 
DIG Buffer 3 
A solution of 0.05 ml of 1 M Tris-HCL pH 9.5, 1.0 ml 5M NaCl and 0.1 ml of 1 M 
MgCl2 was added to 48.85 ml of distilled H2O. 
 
DIG Color-substrate Solution 
A solution of 10 ml of DIG Buffer 3, 45 μl of NBT-solution (vial 9 from DIG kit) and   
35 μl of X-phosphate solution (vial 10 from DIG kit) was mixed. 
 
Resuspension Buffer   
10 mM Tris 7.4 
3 mM MgCl2 
10 mM NaCl 
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Proteinase K digestion solution 
2 ml cell lysate (1 ml water/150mm plate) 
1925 μl water 
40 μl 1M Tris 
40 μl 0.5M EDTA 
200 μl 10% SDS 
25 μl proteinase K (20 mg/ml) 
 
SOB Media (without magnesium) 
20 g tryptone 
5 g yeast extract 
0.584 g NaCl 
0.186 g KCl 
H2O to 1 liter 
pH adjusted to 7.4 with NaOH 
 
SOC Media 
98 ml SOB medium 
1 ml 2 M Mg2+ Stock 
1 ml 2M glucose 
 
2M Mg2+ Stock Solution 
20.33 g MgCl2 -6 H2O 
24.65 g MgSO4 -7 H2O 
H2O to 100 ml 
Autoclave (or filter sterilize) and store at RT 
 
2M Glucose 
36.04 g glucose 
H2O to 100 ml 
Filter sterilized and stored at RT 
 
Wash Buffer for Electroporation 
100 ml glycerol 
900 ml H2O 
 
0.5X TE 
5 mM Tris-HCl 
0.5 mM EDTA (pH 7.5)] 
 
Saturated NaI 
Solid NaI was added to 100 ml 10 mM Tris/5mM EDTA in a dark glass container while 
stirring.  Additional NaI was added until no more would dissolve.  The solution was 
stirred overnight to ensure saturation.  The NaI solution was stored at RT and allowed to 
stand overnight before use.    
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Tris-Borate-EDTA (TBE) Buffer 
A solution of 0.089 M Tris-HCl pH, 0.089 M Boric acid, 0,002 M EDTA was dissolved 
in H2O.  
 
Tris-EDTA (TE) buffer 




A solution of 16 g Bacto Tryptone, 10 g Bacto Yeast Extract, 5 g NaCl was dissolved in 
approximately 900 ml of distilled H2O and pH adjusted to 7.0 with NaOH.  Total volume 
was increased to 1L and the solution was sterilized by autoclaving.  The autoclaved 
media was cooled to room temperature (RT) and then ampicillin was added to  
100 μg/mL. 
 
Agar Plates  
2YT + 100 µg/ml Amp 
1.5 % agar 
 
D. Sources of Materials 
Biorad 
1.5 microfuge tubes 
 
Corning 
2 x 3 well cell culture plates, 96 well cell culture plates, 15 x 60 mm petri dishes, 20 mm 
x 100 mm petri dishes, 750 cm2 cell culture flasks, 1500 cm2 cell culture flasks 
 
Falcon 
15 mL conical centrifuge tubes 
 
Perkin Elmer 
GeneAmp PCR 2400 
 
Promega 
Wizard-Prep suction apparatus model #9993 
 
Qiagen 
Midiprep rack, catalog #19014 
 
Schleicher & Schuell 
Dot Blot apparatus 
 
Whatman 
3mm filter paper, nylon mesh (75 μM) 
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1. Kits 
GPSTM-1 Genome Priming System  
Kit Components: 
Control Target Plasmid (LITMUS 28) 
pGPS1.1 Transprimer Donor 
pGPS2.1 Transprimer Donor 
PrimerN (30-mer) 
PrimerS (30-mer) 
Start Solution (20X)  
TnsABC* Transposase 
GPS™ Buffer Pack (10X) 
 
Promega Wizard PCR Prep  
Kit components 
Wizard® PCR Preps DNA Purification Resin 
Direct Purification Buffer 
Wizard Minicolumns 
Syringe Barrels (3cc) 
 
Qiagen Midi and Maxi Prep 
Kit Components 
QIAGEN tips (midi or maxi) 
QIAfilter Midi or Maxi cartridges 
Caps for QIAfilter 
Buffer P1, Buffer P2 and Buffer P3 
Buffers QBT, QC, QF 
RNase A (ribonuclease) 
 
TaKaRa LA PCR 2.1 
Kit Components 
TaKaRa LA Taq™ (5 units/μl)  
dNTP Mixture (2.5 mM ea.) 
10 × LA PCR Buffer II (25 mM Mg2+ plus) 
10 × LA PCR Buffer II (Mg2+ free) 
MgCl2 (25 mM) 
Control Template (100 ng/μl genomic DNA derived from HL60) 
Control Primer LA3 (10 μM) 
Control Primer LA4 (10 μM) 
λ- Hind III digested MW Marker (100 ng/μl) 
2 × GC Buffers I and II (5 mM Mg2+ plus) 
Control Primers GC1 and GC2 (10 μM) 
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E. Bacterial Strains 
Gibco 
MAX EFFICIENCY DH10B Competent Cells  
E. coli F- mcrA Δ(mrr-hsdRMS-mcrBC) Δ80dlacZ ΔM15 ΔlacX74 deoR recA1 araD139 
Δ (ara, leu) 7697 galU galK rpsL endA1 nupG. 
 
Invitrogen 
DH5αF'IQTM Competent Cells  
E. coli F'φ80dlacZΔM15 Δ(lacZYA-argF)U169 deoR recA1 hdR17 (rk-, mK+) supE44 λ-
thi-1 gyrA96 relA1/F' proAB+ lacIqZΔM15 zzf::Tn5 [KmR ] 
 
TOP10F’ DH5αF'IQTM Competent Cells  
E. coli F´[lacIq Tn10 (TetR)] mcrA Δ(mrr-hsdRMS-mcrBC) Φ80lacZΔM15 ΔlacX74 
recA1 araD139 Δ(ara-leu)7697 galU galK rpsL endA1 nupG 
 
F. Vectors 
BACPAC Resource Center  
Children's Hospital Oakland Research Institute 
Oakland, California, USA. 
pBACe3.6 (bacterial artificial chromosome)   
 
Invitrogen 
pCR2.1-TOPO and pCR-XL-TOPO  
 
pSL301 (Brosius, 1989) 
 




pBluescript II SK + (Alting-Mees and Short, 1989) 
 
II. BACTERIAL CELLS 
A. Propagation and Storage of Bacterial Cells 
Stocks of E. coli were prepared by growing cells to late logarithmic phase in 2YT 
media, in a New Brunswick air incubator at 37 °C with vigorous shaking.  Sterile 
glycerol was added to an approximate final concentration of 25%.  Cells were aliquoted 
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into 1.5 ml microtubes (Biorad) and stored at -80 °C.  DH5αF' cells were obtained from 
Gibco/BRL as a glycerol stock and stored at -80 °C. 
Cells containing a plasmid were grown to logarithmic phase in appropriate 
selective media and stored at -80 °C after addition of glycerol to an approximate final 
concentration of 25%.   
B. Preparation of Frozen Competent E. coli by the Rubidium Chloride Procedure 
This procedure produces cells with a transformation efficiency of ~ 107 
colonies/μg.  The protocol and solutions are described in Sambrook et al. (1989).  
Competence was determined by transformed colonies produced per μg of supercoiled 
plasmid DNA.  These cells were used for most laboratory cloning experiments.  
However, when transforming cells with very small quantities of DNA, commercial super-
competent cells were used (Stratagene 5 x 109 colonies/μg, Invitrogen 1 x 109 
colonies/μg). 
C. Transformation of E. coli Using Frozen Competent Cells Prepared by the 
Rubidium Chloride Procedure 
The basic protocol described in (Sambrook et al. 1989) was used.  DNA samples 
were brought to 50 μl with HPLC H2O and placed on ice.  The frozen, competent cells 
were quickly thawed, 3 μl DMSO added and mixed by inverting the tube.  Then 50 μl of 
competent cells were added to each tube of DNA and mixed by inversion.  After a 30 min 
incubation on ice, the transformation mixtures were heat-shocked by placing the tube at 
42 °C for 90-120 sec.  2YT broth (400 μl) was added and the mixture incubated at 37 °C 
for 30-45 min to allow the antibiotic resistance gene to be expressed.  If β-GAL 
blue/white selection was required, 10 μl 1M IPTG was added to each tube.  To obtain 
individual colonies, 100-200 μl of the transformation mixture was spread using a sterile 
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glass “hockey-stick” onto each agar plate.  The agar plate contained the appropriate level 
of antibiotic and if β-GAL blue/white selection was desired, the plate also included X-
GAL.  The plate was incubated at 37 °C for 12-18 hr until colonies were visible. 
D. Transformation of BACs Using Electroporation 
Transformation of BACs was carried out by electroporation.  The transformation 
efficiency was about 40 to 1,500 transformants from one μl of ligation product, or 20 to 
1000 transformants/ng DNA.  One to 2.5 μl of the BAC ligation material was 
transformed into 20-25 μl of E. coli DH10B competent cells (Gibco BRL, USA) using 
the BRL Cell-Porator system (Gibco BRL) according to the manufacturer’s protocol.  
The parameters for electroporation were as follows: Voltage: 400V, Capacitance: 330 μF, 
Impedance: low ohms, Charge rate: fast, Voltage Booster resistance: 4 Kohms.  The 
electroporated cells were transferred to 15 ml culture tubes with 0.4-1 ml SOC and 
shaken at 220 rpm for 50 min at 37 °C.  The SOC medium was spread on one or two LB 
plates containing 12.5 μg/ml chloramphenicol and incubated at 37 °C for 20-36 hr.  
White colonies were selected and transferred to 96-well microtiter plates containing LB 
freezing media.  The microtiter plates were incubated at 37 °C overnight then stored at 80 
°C. 
III. CELLS AND VIRUSES 
A. Mammalian Cells 
Human foreskin fibroblast (HFF) cells were obtained from Dr. J. Waner, 
Oklahoma University Health Science Center (OUHSC) (Oklahoma City, OK).  Human 
embryonic lung fibroblasts (MRC-5) were purchased from ATCC (Manassas, VA).  The 
Towne strain of HCMV was generously provided by Dr. J. Zaia, City of Hope National 
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Medical Center (Duarte, CA) while RhCMV 68-1 and HCMV AD169 were provided by 
Dr. P. Barry, University of California at Davis (Davis, CA). 
B. Isolation of Baboon CMV 
The BaCMV OCOM4-37 strain was isolated from an oropharyngeal swab of an 
olive baboon (Papio cynocephalus anubis) at the OUHSC colony (Oklahoma City, OK).  
The isolation and characterization has been described in detail elsewhere (Blewett et al. 
2001).  The isolate was plaque purified by two rounds of limiting dilution.  The 
supernatant from positive cultures was added to a subconfluent monolayer of fibroblasts.  
At 4 hr PI the medium was removed and replaced with medium containing 2 % 
methylcellulose.  At 5-7 days PI, isolated plaques were aspirated with a Pasteur pipette 
and inoculated onto fresh sub-confluent fibroblast monolayers.  These infected cell 
cultures were passaged until viral cytopathic effects (cpe) was evident in >75% of the 
monolayer, harvested, and used to grow working virus stocks. 
IV. BASIC TECHNIQUES 
A. Agarose Gel Electrophoresis and Visualization 
Agarose gel concentrations varied between 0.7% and 1.5%, with lower 
concentration gels used for high molecular weight DNA.  Gels were cast in a Biorad 
horizontal gel apparatus.  1X TAE was used in the gel and as a running buffer.  A loading 
solution of 6X Stop was added to samples containing 0.5-2.0 μg of DNA.  Bacteriophage 
Lambda DNA, digested with Bst EII or Hind III, was used as size markers.  DNA was 
loaded into 1 mm wide wells and electrophoresed at 40-80 volts to separate DNA 
fragments.  DNA was stained in a dilute solution of EtBr (0.01 μg/uL) and rinsed with 
deionized H2O.  The DNA was visualized under short-wave ultraviolet (UV) light 
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(Fotodyne-3-3000).  Images were captured using a KODAK 1D Image Analysis Software 
version 3.5. 
B. Oligonucleotide Synthesis 
Oligonucleotide syntheses were performed at the Recombinant DNA/Protein 
Resource Facility at Oklahoma State University, Stillwater, OK. 
V. DNA PURIFICATION AND ANALYSIS 
A. Purification of Herpesvirus DNA 
Ten T100 flasks of MRC-5 cells at 25% confluency were infected with BaCMV 
at an m.o.i. of 0.1 - 0.5 pfu per cell.  These cultures were maintained, trypsinized, and re-
plated until the majority of cells in the culture showed cpe.  Uninfected MRC-5 cells 
were then added to the flasks to produce 100% confluency.  After 36 - 48 hr the flasks 
were subjected to a 37 ºC - 80 ºC freeze/thaw cycle twice, followed by scraping of the 
flasks.  Cell debris was concentrated by centrifugation and the supernatant containing 
cell-free virus was removed and pooled.  The pellet of cell debris was resuspended in 
resuspension buffer and cells gently ruptured with a Dounce homogenizer.  Nuclei were 
collected by centrifugation and the supernatant containing virus saved.  The supernatants 
were then centrifuged at 24,000 rpm at 25 ºC for 60 min in a SW27 rotor to concentrate 
the virus particles.  Virus particles were resuspended in 2 ml of TE, 2 ml of a Proteinase 
K digestion solution added, and the mixture incubated at 37 ºC for at least 2 hr.  Saturated 
NaI (6 ml) and 100 μl of 10 mg/ml EtBr were added (in a dim room), mixed, and 
transferred to a 15 ml heat-seal Beckman ultracentrifuge tube.  After balancing and 
sealing, the tubes were centrifuged at 44,000 rpm for 64 hr.  After removal from the 
centrifuge rotor, the DNA bands were visualized under UV light to identify the wide, top 
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cellular DNA band and the lower, narrow viral DNA band.  Viral DNA was collected 
using a syringe with an 18 gauge needle, and the DNA extracted 5 times with equal 
volumes of chloroform to remove EtBr.  The aqueous solution was transferred to dialysis 
tubing and dialyzed 6 -18 hr against 4 liters 10 M Tris/0.01 mM EDTA at 4 ºC to remove 
the NaI.  The DNA in the resulting solution was precipitated with (NH4)OAc and EtOH, 
collected by centrifugation, dried, resuspended in 200 μl TE buffer, and stored at 4 ºC. 
B. Circular DNA Preparations 
During replication in host cells, herpesvirus genomes circularize.  To enhance the 
likelihood of recovering circular viral DNA, a specific protocol was used to selectively 
extract large circular viral DNA molecules from virus-infected mammalian cells.  The 
procedures are described fully in Hirt (1967) and were adapted as described (Messerle, et 
al. 1997).  To prepare circular BaCMV OCOM4-37 DNA for cloning, human fibroblasts 
were infected and incubated until cpe was general in each of eight T150 flasks.  The 
medium was removed and scraping solution (0.6% SDS, 10 mM EDTA pH 7.5) was 
added at a volume of 5 ml for every 75 cm2 of cells in the flask.  This was incubated at 
RT for 10 – 20 min, the cell monolayer scraped off and transferred to centrifuge bottles.  
A ¼ volume of 5 M NaCl was added to give a 1M NaCl final concentration and the 
bottles were mixed gently inverting the tube 10 times.  Cellular DNA and proteins were 
precipitated by incubating the bottles overnight at 4 ºC in an ice bucket.  After 
centrifugation at 17,000 g for 30 min, the supernatants were transferred to clean bottle, 
gently extracted with phenol:chloroform, and the DNA precipitated with NaOAc and 
ETOH.  After 200 μl of TE was added to the pellet, the DNA was allowed to rehydrate 
overnight in a 4 ºC refrigerator.   
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C. Purification of Plasmid DNA 
Small-scale purification of plasmid DNA was performed using the alkaline-lysis 
procedure (Maniatis et al. 1982).  Pancreatic RNase was added to miniprep DNA at a 
final concentration of 0.1μg/ml to remove contaminating RNA.  Large scale preparation 
of plasmid DNA by alkaline-lysis and Qiagen maxiprep purification was performed 
essentially as described by the manufacturer’s protocol.  Lysozyme was not used in either 
purification procedure.   
D. Recovery of DNA from Agarose Gels 
DNA fragments (1-10 μg) were separated by agarose gel electrophoresis and 
visualized.  Gels were stained in dilute EtBr and visualized briefly under long-wave UV 
to avoid nicking the DNA strands.  The desired band was excised and placed in a 0.5 ml 
microtube with a punctured bottom covered with silicanized glass wool (Heery et al. 
1990).  This tube was nested inside a 1.5 ml microtube, centrifuged at 10,000 g for 10 
min at RT.  The buffer in the 1.5 ml tube containing the DNA was extracted with 
phenol:chloroform, and then precipitated using 7.5M (NH4)OAc and EtOH (Maniatis et 
al. 1982).  The DNA was resuspended in TE and the quality and quantity determined by 
running a sample on an agarose gel and comparing it to a known standard such as lambda 
virus DNA.   
E. Transfer of DNA to Membrane 
Southern blotting was used to transfer DNA from an agarose gel to a Nytran 
membrane (Maniatis et al. 1982, Southern 1975).  DNA was separated by electrophoresis 
on a 0.8% agarose gel, stained and photographed.  DNA fragments were depurinated by 
incubating the gel in 0.25 M HCl treatment for 15 min.  The DNA was then denatured by 
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soaking the gel for 3 x 20 min periods in 0.4 N NaOH.  A sponge was cut to the same 
size of the gel, placed in a glass Pyrex dish, and two pieces of 3 mm filter paper were 
placed on top.  The gel was placed upon the filter paper.  A Nytran membrane was cut to 
the same size as the gel and placed directly onto the gel.  Two similarly-sized sheets of 
3mm filter paper were placed on this membrane.  A 6” stack of paper towels 2 mm 
narrower than the gel was placed on the filter paper and a light weight (250 g ) set on top.  
The dish was filled with 0.4 N NaOH to the top of the sponge.  During 12 - 16 hr, the 
paper towels were removed and replaced, and transfer buffer was replenished as 
necessary.  After transfer, the position of the wells was marked on the Nytran membrane 
and the DNA cross-linked to it by a 30 sec burst of short-wave UV light.  The membrane 
was stored at -20 °C until the hybridization step. 
F. Southern Hybridization 
Filters were incubated at 45 °C for 6 - 8 hr in hybridization bags containing 
prehybridization solution.  Digoxigenin (DIG)-labeled probe preparations (concentrations 
varied between 0.1 μg - 5 μg) were boiled for 2 min, added to the bag and incubation 
continued overnight.  The filters were removed from the bag and washed once for 15 min 
with 5X SSC at RT, three times for 15 min with 2X SSC, 0.1% SDS at RT, three times 
for 15 min at 45 °C and dried.  DIG-labeled probe binding was detected using the 
manufacturer’s protocol and is described in more detail on page 64.  
VI. DNA SEQUENCING AND COMPUTER ANALYSIS TOOLS 
DNA sequencing was performed at the Recombinant DNA/Protein Resource 
Facility at Oklahoma State University, Stillwater, OK.  Sequencing of random fragments 
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from some clones was performed at University of Oklahoma ACGT Facility (Dr. Bruce 
Roe) in Norman, OK. 
DNA sequencing traces were assembled using Seqman (DNAStar, Madison, WI).  
DNA and protein sequences were manipulated and aligned for similarity using EditSeq 
and MegAlign (DNAStar, Madison, WI).  Primer sequences were designed using 
PrimerSelect (DNAStar, Madison, WI.).  MapDraw (DNAStar, Madison, WI.) and ORF 
Finder (http://www.ncbi.nlm.nih.gov) were used to locate potential coding sequences.  
The Basic Local Alignment Search Tool (BLAST) was used to search Genbank for 
similar DNA or protein sequences (Altschul et al. 1990).  CLUSTAL was used for 
aligning DNA and protein sequences for phylogenetic analysis (Higgins and Sharp 1989).  
MEGA and PHYLIP were used to infer phylogeny amongst aligned sequences 
(Felsenstein 1993; Kumar et al. 2001; Tamura et al. 2007).  CorelDraw 8 (Corel 
Corporation, Ottawa, Ontario) was used in the preparation of figures.   
VII. SCREENING FOR TERMINAL CLONES OF THE BaCMV GENOME 
A. Directional Cloning of Terminal Fragments 
1. Viral DNA End-Filling 
NaI purified BaCMV OCOM4-37 DNA was used for directional cloning.  The 5’ 
and 3’ terminal ends of viral DNA were filled in using dNTPs and Klenow fragment of 
DNA polymerase to create blunt ends.  This was accomplished by mixing 5 μl (0.5 μg – 
1.0 μg) of viral DNA with 1 μl of Klenow enzyme (2U/μl), 2 μl Klenow buffer, 0.66 μl 
10 mM dNTPs and water to make a 20 μl total volume.  The mixture was incubated for 
15 min at 25 ºC.  Klenow enzyme was inactivated by heating to 75 ºC for 10 min.   
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2. Vector DNA Preparation 
A plasmid vector had to be prepared that would accept blunt-ended terminal 
fragments of the OCOM4-37 genome.  SmaI is a RE that cuts DNA to create blunt ends 
at the recognition site.  Plasmid cloning vector pSL301 was used because it has a multiple 
cloning site (MCS) containing all unique six bp RE recognition sites including SmaI.  
The pSL301 vector has a single cutting site for BamHI, Hind III, and Not I , so using each 
of these enzymes in combination with SmaI created vectors that would only accept 
fragments from blunted termini (e.g. blunt-BamHI, blunt-Hind III and blunt-Not I ).   
Eight μg of pSL301 was digested with 10 units of SmaI for 2 hr at 25 ºC to create 
blunt ends.  Enzymes were denatured by phenol:chloroform extraction, and the plasmid 
DNA was purified by ethanol precipitation.  After drying and resuspension in TE (pH 
8.0), a sample of the digested DNA was electrophoresed on an agarose gel and visualized 
to ensure the enzyme had digested the vector.  A second series of digests were performed 
to create ends compatible with three different restriction enzymes, BamHI, Hind III or 
Not I .  SmaI digested vector DNA (2 μg) was cut with 10 units of appropriate RE and 
allowed to digest at 37 ºC overnight then extracted, precipitated, washed and dried as 
previously described.  Each vector DNA pellet was resuspended in 30 μl TE.  Four μl of 
vector was run on a 0.8% agarose gel and a single band was visualized at the expected 
DNA size (3.2 kb).   
3. Digestion, Ligation and Transformation of the BaCMV OCOM4-37 Insert DNA 
The Hind III cut vector, religated without insert, produced an excess of vector 
colonies so BamHI and Not I  -digested vectors were used for ligation reactions with 
BaCMV OCOM4-37 digests.  Two tubes of viral DNA (0.3 μg) with filled-in termini 
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were digested for 2 hr at 37 ºC with BamHI or Not I .  This generated terminal genome 
fragments having one blunt, filled end and one sticky end (Figure 8).  Each digest was 
extracted with phenol:chloroform, precipitated and dried.  The air-dried digests of 
BaCMV DNA were resuspended in the following ligation solutions.  One ligation 
reaction (5 μl) was prepared by adding 1 μl of SmaI/BamHI cut pSL301 DNA (0.15 μg), 
0.5 μl of ligation buffer, 1 μl of high concentration ligase (20U/μl) and 2.5 μl of distilled 
H2O.  A second similar ligation was prepared using Not I  instead of BamHI.  Both 
reactions were incubated for 4 hr at 16 ºC.  All 5 μl of each ligation reaction was used in 
transformation of high efficiency commercially-competent Sure Shot TOP10 F’ cells 
using manufacturer’s protocol. 
4. Preparing Miniprep Digests for Terminal Sequence Screening 
After transformation, 7.1 μl of 1M IPTG and 250 μl of pre-warmed SOC media 
were added to each tube.  Each transformation reaction (100 μl) was spread onto 
2YT/AMP/XGAL agar plates and incubated overnight at 37 ºC.  The number of blue 
colonies (representing self-ligated vector) was higher than expected but white colonies 
(containing inserts) were present on each plate.  White colonies were selected for DNA 
purification and grown overnight in 2YT/AMP broth with shaking.  Minipreps were 
performed using the standard protocol and resuspended in 100 μl of TE.  For the digests 
of potential blunt- BamHI clones, plasmid DNA (5 μl) was digested with EcoRI and 
BamHI.  These REs cut the pSL301 multiple cloning at sites 5’ and 3’ of the expected 
insert DNA.  The potential blunt-Not I  clones were digested with EcoRI and Xho I since 
these REs were expected to excise the insert.  The digested DNA samples were 















Figure 8.  Directional Cloning of Terminal Fragments from the BaCMV Genome.  Panel A shows 
pSL301 cut with I and I restriction enzymes to produce a blunt- I linear vector.  Panel B 
shows the BaCMV OCOM4-37 DNA genome with filled-in termini and then cut with I restriction 
enzyme. Panel C shows the successful ligation of a blunt- I BaCMV DNA fragment into the vector.





















B. Circularization of the BaCMV Genome 
The previously-described attempt to obtain clones at each terminus using 
directional cloning generated a clone at the 3’ terminus of the genome but no clone was 
found at the 5’ end.  Therefore a different strategy was undertaken.  This strategy was to 
use circular BaCMV DNA cut with Not I .  Ideally, the Not I  digest would produce a 
fragment containing the ligated DNA from each terminus (Figure 9).  Circular BaCMV 
DNA was obtained from infected cells as described in Methodlogy Section VII-B 
(circular DNA preparation) or by the method below.  
Not I
Not I Not I
Not I
Not I




Figure 9.  Circularization of the BaCMV Genome.  Termini of the viral genome 
are ligated to cirularize the molecule.  I is used to cut the genome into large 
fragments which are then cloned into pBlueScript.  Clones are then screened 





1. Ligation and Circularization Reaction 
Eight μl of BaCMV OCOM4-37 DNA (1.0 μg/μl) was mixed with 1 μl of 10X T4 
DNA ligase buffer and 1 μl of T4 DNA ligase (1.3 U/μl) for a final volume of 10 μl.  The 
mixture was incubated in a PCR thermocycler at 16 ºC for 2 hr then at 65 ºC to denature 
the enzyme. 
C. Cloning Circular BaCMV DNA 
Circular BaCMV DNA digested with Not I  would generate a fragment containing 
the annealed termini.  The other Not I  fragments would be useful genomic clones since 
they are likely large in size.   
1. No t I  Digests of Ligated BaCMV DNA 
Ten μl of the ligation reaction was mixed with 50 units of Not I , 5 μl of React 3 
buffer and 30 μl of distilled H2O and incubated at 37 ºC for 2 hr.  The mixture was then 
phenol:chloroform extracted, precipitated with EtOH, dried, and resuspended in 12 μl of 
TE.   
2. Ligation of Digested BaCMV Circular DNA (Created by Ligation) and pBS/ 
Not I -Cut Vector  
Two μl of pBS/ Not I -cut vector (0.25 μg/μl) was added to 6 μl of Not I -cut DNA 
(0.05 μg/μl), 1 μl of 10X T4 ligase buffer, and 1 μl of T4 ligase (1.3 U/μl) for a final 
volume of 10 μl.  The mixture was incubated at 16 ºC overnight and then used to 
transform TOP 10F’ cells using the standard protocol.  Two hundred μl of the 
transformation reaction was spread on three plates containing 2YT/AMP/XGAL and 
grown at 37 ºC overnight.  Twelve colonies were selected for growth overnight and 
plasmid purification using the standard protocol.  Restriction digests were performed on 
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all white colonies and run on an agarose gel.  All Not I  clones having a vector and an 
insert band were saved for screening with a Not I  end-labeled probe. 
3. Not I  Digestion of BaCMV Circular DNA Prepared from Cell Culture 
Five μl of circular BaCMV DNA prepared from infected cells (approximately 0.8 
μg) was combined with 1 μl of Not I  (10 units), 2 μl of React 3 buffer, and 12 μl of 
distilled H2O and incubated at 37 ºC for 2 hr.  The mixture was then gently 
phenol:chloroform extracted, precipitated with EtOH, dried, and resuspended in 20 μl of 
TE. 
4. Ligation of Not I  Digested BaCMV Circular DNA into the pBACe.3.6 Vector 
There are several reasons why cloning DNA into BACs was advantageous.  First, 
large pieces of DNA exceeding 200 kbp can be cloned and maintained in a BAC.  
Cloning the 5’ terminus of BaCMV proved difficult.  It is possible that the BaCMV 
genome may not have useful RE recognition sites near the 5’ terminus.  In earlier 
projects, attempts were made to clone BaCMV DNA fragments larger than 15 kbp into 
plasmids.  This is a low efficiency cloning strategy and may explain the lack of success.  
This approach used circularized DNA, thereby avoiding the need to manipulate the viral 
genome to “blunt” the ends.  The joined termini would likely be a large piece of DNA, 
thus needing a BAC for efficient cloning.  Another good reason to utilize BAC cloning is 
that DNA which is “difficult” to clone by other means can be maintained in a BAC.  This 
is because there is only one or a very few copies of the BAC in each bacterial cell.  
Therefore we planned to ligate Not I  digested circular BaCMV DNA into the vector 
pBAC e3.6 (Frengen et al. 1999), and electroporate the ligation reaction into 
commercially electrocompetent E. coli. 
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The pBACe3.6 vector contains a pUC origin, so the vector DNA can be easily 
prepared.  This insert is in the MCS and flanked by RE sites.  The vector was digested 
with BamHI or Not I  using standard procedures and the reaction then electrophoresed on 
an 0.8% preparative agarose gel.  This digestion cuts out the pUC insert leaving the 
pBACe3.6 vector linearized with BamHI or Not I  compatible ends.  The linearized vector 
was purified from the gel and dephosphorylated using the manufacturer’s suggested 
procedure.  
Two μl of pBACe.3.6/ Not I -cut vector (0.4 μg/μl) was added to 10 μl of Not I -cut 
DNA (0.4 μg/μl), 1 μl of 10X T4 ligase buffer, 1 μl of T4 ligase (1.3 U/μl) and 5 μl of 
distilled H2O for a final volume of 20 μl.  The mixture was incubated at 16 ºC overnight.  
Ligation reaction was drop dialyzed for 2 hr against 0.5X TE using a membrane with a 
25,000 MW cutoff.  The ligation reaction was electroporated into E. coli DH10B cells as 
described in section II-D.  Over 50 colonies were obtained.  Six colonies were randomly 
selected for growth overnight and BAC DNA purified using the standard BAC miniprep 
protocol.  Restriction digests were performed on all six preparations and run on an 
agarose gel to determine cloning efficiency.  All clones had inserts indicating high 
cloning efficiency.  As many isolated colonies as possible were archived for later 
screening, and are represented as clones in the 3800 series.  
D. Screening Pooled Clones and BAC Clones Using Dot-Blot Method 
Existing BaCMV libraries were screened to find clones from each terminus that 
had not been previously identified.  Clones that were not already sequenced were pooled 
in groups of 9 – 12 for screening.  These grouped clones were used for dot blots to allow 
large numbers of clones (1,000+) to be screened simultaneously.  The probes used for 
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screening were produced from existing clones already mapped to a site adjacent to 
regions of interest.  Two sets of dot blots were prepared.  The first blots contained the 
pooled groups mentioned above.  The second blot contained individual clones that were 
positive from the first blot.   
1. Probe Preparation for Dot-Blot Screening 
A good deal of internal BaCMV genome sequence had been produced, but little 
sequence existed for the termini.  To identify BaCMV clones from either terminus of the 
genome, probes were produced for screening purposes.  One method used to produce 
probes was end-tailing of the genomic DNA using terminal transferase and DIG-labeled 
dUTP.  The other method used was to label stock clones thought to be close to the termini 
with DIG using random hexamers as primers.  
End-tailing reactions were prepared containing 0.2 μg of NaI purified BaCMV 
OCOM4-37 DNA, 8 μl of 5X reaction buffer, 8 μl of CoCl2 solution, 2 μl alkaline-
constant DIG-labeled 0.35 mM dUTP, 2 μl 1.0 mM ATP, and 2 μl terminal transferase 
(100 units) for a total volume of 40 μl.  The mixture was incubated at 37 ºC for 15 min.  
Distilled H2O (60 μl) was added for a final volume of 100 μl and the reaction was 
centrifuged for 60 sec.  Qiagen PB buffer (500 μl) was added to the mixture and the DNA 
was purified by Qiagen miniprep technique (previously described).  The dried DNA was 
resuspended in 50 μl of TE buffer.  Two probes (Not I  and PmeI) were prepared using 25 
μl (0.1 μg) of end-tailed BaCMV DNA, 1 μl of Not I  or PmeI, 3 μl of the appropriate 10X 
RE buffer and 1 μl dH2O, and incubated for 2 hr at 37 ºC.  Both of these REs recognize 
and cut at an 8 bp site producing large DNA fragments.  Large fragments are likely to 
overlap and hybridize with more clones than smaller fragments would.  Ideally, this 
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overlap could allow detection of clones at or near the genomic termini.  Although all the 
fragments in the digestions would bind to BaCMV clone DNA, only the end fragments 
would be DIG-labeled.  Ten μl of each probe was used to screen dot blots and the rest 
was stored at -20 ºC.   
To screen our BaCMV library for clones at the left terminus, two additional 
probes were produced (from stock clones H639 and B165) using random hexamers as 
primers.  Clones H639 and B165 had previously been mapped to the left terminus of the 
BaCMV genome.  To generate the H639 probe, 10 μg of the plasmid clone DNA was 
digested with 3 μl of buffer, 1 μl of Hind III (10 U/μl) and 6 μl of distilled H2O for 1 h.  
The digested DNA was run on an agarose gel overnight and the 5.5 kb BaCMV insert 
band was cut from the gel.  The gel fragment was purified by centrifugation in a 0.5 ml 
test tube containing siliconized glass wool followed by phenol:chloroform extraction, 
ETOH precipitation, drying, and resuspension in 20 μl TE.  Three μl of the H639 DNA 
was diluted to 15 μl using dH2O and then denatured in a boiling water bath for 10 min.  
The test tube was immediately placed on ice and 2 μl DIG-labeled hexanucleotide mix, 2 
μl 10 mM dNTP mixture and 1 μl Klenow enzyme (2 U/μl) was added.  The solution was 
mixed, centrifuged briefly, and incubated for 60 min at 37 ºC.  Two μl of 0.2 M EDTA 
(pH 8.0) was added to stop the reaction.  The labeled DNA was precipitated by adding 
2.5 μl 4M LiCl and 75 μl of -20 ºC EtOH.  The solution was mixed and kept at -70 ºC for 
30 min.  Finally, the mixture was centrifuged for 15 min, washed, dried, and resuspended 
in TE.  The same protocol was used to generate the B165 probe except that the amount of 
DNA was increased to 15 μg, the buffer to 4 μl, BamHI to 3 μl, and H2O to 3 μl in the 
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digest step.  In the DIG-labeling steps, all components were increased 4X except for the 
Klenow enzyme.  All other steps were completed per the manufacturer’s protocol.  
2. Pooling Clones and Preparing Membranes 
All clones used for dot blot screening were from the BaCMV library of clones. 
Most of these clones had been pooled and designated as follows: 
Pool numbers Restriction enzyme used Clone numbers 
S1 – S70 BamHI or Hind III fragments Various (~710 total) 
S71 – S78  EcoRI or XbaI fragments 2320 – 2399  
S79 – S85 Blunt/ Not I  fragments 3031 – 3101  
Table 4.  Pooled Clones Used for Dot Blot Screening 
All clones were pooled in 1.5 ml tubes containing 9 – 11 clones each.  Fifteen μl of each 
clone (0.2 μg/μl) was added to the pool and TE was added to increase the volume to 200 
μl.  Pools S1–S78 were screened with the Not I -cut probe and groups S1 – S85 were 
screened with the PmeI-cut probe.  Positive controls included 20 μl of miniprep DNA 
(0.2 μg/μl) from QN3063 and 5 μl of midiprep (1.0 μg/μl) DNA from H639 (previously 
identified terminal clones).  Negative controls included 20 μl of miniprep DNA (0.2 
μg/μl) from QN3058, 5 μl (1.0 μg/μl) of midiprep H589 (both from internal regions) and 
20 μl (1.0 μg/μl) of the pBlueScript SKII+ vector.  Each of these control samples was 
increased to 200 μl with TE.  After screening pooled clone groups S1 – S85, pooled 
clones that showed high color intensity for both dot blots (Not I  and PmeI probed) were 
selected for individual screening.   
Dot blots for all clone groups, or individual clones, using either probe were 
prepared as follows: 20 μl of each sample was added to 180 μl of TE, and 5 μl of 10 N 
NaOH added to denature the DNA.  This mixture was incubated at 37 ºC for 5 min and 
chilled on ice.  Two hundred μl of chilled 0.125X SSC was added to each tube to a final 
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volume of 400 μl.  Two hundred μl of the DNA solution was loaded into separate wells 
of a dot blot apparatus overlaid with a nylon membrane cut to size.  The corner of the 
membrane was notched to designate orientation.  Two hundred μl of 0.125X SSC was 
added to wells without sample as controls.  All samples were allowed to sit 30 min at RT 
and wells were vacuum-suctioned for 2 min to dry.  The membrane was removed from 
the dot blot apparatus and air-dried at RT for 15 min.  The membrane was placed face 
down on plastic wrap and exposed to UV light for 60 sec to cross-link DNA. 
3. Hybridization and Washes 
The nylon membrane was placed in a tupperware container and prehybridized in a 
20X SSC solution for 1.5 hr at 65 ºC on a rocking platform.  Ten μl (20 % of preparation) 
of the probe and 190 μl of TE were added to a 0.5 ml test tube.  The cap of the tube was 
perforated to allow steam to escape and the probe was boiled for 5 min to denature the 
DNA and immediately placed on ice.  The prehybridization solution was removed from 
the membrane and replaced with hybridization solution.  The hybridization solution was 
heated to 65 ºC and the probe added.  The membrane and probe were incubated at 65 ºC 
overnight with shaking, then removed and rinsed with 100 ml 2X SSC + 0.1% SDS wash 
solution.  Two additional washes were performed at RT with shaking for 15 min using 
100 ml of the same wash solution.  Two more washes were then performed using 100 ml 
of 0.1X SSC + 0.1% SDS at 65 ºC for 15 min, each with shaking. 
4. Colorimetric detection of DIG-labeled probe. 
The membrane was soaked in 10 ml of DIG buffer 1 for 5 min then incubated 
with rocking in 100 ml of blocking solution.  The solution was removed and the 
manufacturer’s suggested volume of anti-DIG antibody (alkaline phosphatase-
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conjugated) diluted in 20 ml of blocking solution was added.  The membrane was 
incubated with rocking for 30 min then drained.  Two washes were performed using 100 
ml of DIG buffer 1 with rocking for 15 min each.  Wash solution was removed after each 
wash, and finally the membrane was soaked in 20 ml of DIG buffer 3 (see p. 42).  This 
soaking step was performed in the dark without rocking and checked periodically for 
color change.  Development was stopped by washing the membrane in a large volume of 
TE.  The developed membrane was placed in the dark to dry then photographed.  After 
drying, 86 clones were selected from pools for individual screening using the same 
hybridization screening.  Twenty-five of the 86 individual clones were digested with the 
appropriate RE to excise the insert and the digested DNAs run on an agarose gel.  After 
eliminating duplicates or aberrant clones, a total of twelve individual clones were sent for 
sequencing (see Results II-C-1). 
Dot blots using the H639 and B165 probes and pooled clones S1-S85 (and later 
individual clones) were performed using the same methods described above.  Two clones 
(E2290 and E2363) were positive in the H639 screening so were chosen for additional 
testing. 
Screening pooled clones with the B165 probe yielded positives from 4 wells.  
Clones from these 4 wells were used to prepare a blot to screen the following individual 
clones: B356 – 365, B614 – 623 and E2286 – 2290.  From this dot blot two clones, B359 
and E2290, were chosen for further analysis. 
5. Screening Not I  Clones Using Southern Blot Method 
The following Not I  clones generated by circularization of the BaCMV genome 
were selected for screening by Southern blot: Not I  clones 3208, 3210, 3211, 3212, 3215, 
 67 
3217, 3218, 3219, 3223, 3231, 3232 and 3234.  Restriction digests were prepared using 3 
μl of plasmid DNA (0.2 μg/μl), 0.5 μl of Not I  (10 U/μl), 1 μl of buffer and 5.5 μl of 
distilled H2O.  Positive control DNA from terminally-located clones B165, H620, N1655 
and QN3063 were also digested for screening.  Each of the 3 digests contained 3 μl of 
DNA (0.5 μg/μl), 1 μl of buffer, 1 μl of the compatible restriction enzyme (10 U/μl) for 
that clone and 5 μl of distilled H2O.  The mixtures were incubated at 37 ºC for 2 hr and 
then run on an agarose gel overnight.  Southern blot was performed.  The blot was 
developed and clones 3208, 3210 – 3212, 3217, 3218, 3223, 3231, 3232 and 3234 were 
identified as positive.  These clones were digested with Hind III and SacI, 
electrophoresed on an agarose gel, and visualized to identify clones that were unique.  
The following five clones appeared to be unique and were sent to the OSU core facility 
for sequencing: 3208, 3211, 3217, 3231 and 3232.  
VIII. SCREENING POOLED CLONES FOR CLONES IN GAP REGIONS USING 
SOUTHERN BLOT 
There were three areas of the genome that the BaCMV library clones did not 
cover.  A different strategy was used to find clones within these gaps.  Two gaps were in 
the US region of the genome and the other was at the UL right terminus.  To identify 
clones containing DNA from these regions, screening by Southern blot was performed 
using probes produced from clones bordering the gaps.  Two libraries were chosen for 
this: the pooled clones (previously used for dot-blot screening) and the BAC clones 3826, 
3828, 3854 and 3870.  The BAC clones were quite large (>12 Kb) so were more likely to 
overlap gap areas than some of the smaller pooled clones.  DIG-labeled probes were 
made from clones adjacent to the gaps and included B110, B315, H596 and H659.   
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A. Probe Preparation for Southern Blots 
Probes from clones B110, B315, H596 and H659 were all produced by PCR using 
primers specific for each clone.  PCR reactions contained the following components: 1 μl 
of plasmid DNA (0.2 μg/μl), 15 μl of 3.3 x L buffer, 5 μl of 25mM MgOAc, 1 μl of 
primer, 2 μl 10mM dNTPs, 1.7 μl DIG-labeled 1mM dUTP, 1.2 μl rTth polymerase 
(2U/μl) and 15.7 μl dH2O.  Each PCR-generated probe was extracted, precipitated and 
washed.  Then 0.5 μl of each probe was dotted on a nylon membrane and tested with anti-
DIG antibodies.  The intensity of color after development demonstrated the degree of 
digoxigenin-labeled dUTP incorporation into the probe.  The B110 probe was darkest and 
the H569 probe showed the least color development.  Labeling of the H569 probe was 
sufficiently poor that it was not used for screening individual clones.  
B. Southern Blot Screening of pBlueScript Clones 
Three separate screenings were performed using the B110, B315 and H659 
probes.  Individual clones were selected for screening based on the degree of color 
intensity seen on previously-screened dot blots of pooled clones.  The following clones 
were digested with compatible restriction enzymes and loaded onto an agarose gel for 
electrophoresis: BamHI clones 347, 349, 350, 351, 386, 419, 420, 422; EcoRI clones 
585, 2293, 2302, 2303, 2311; XbaI clones 2246, 2247, 2262, 2263, 2270, 2273; and Not I  
clone 1709.  The digested DNA was then transferred to a nylon membrane using the 
Southern blot method and each membrane was probed using one of the three probes and 




C. Southern Blot Screening of BACs 
BAC clone screening was performed somewhat differently than for individual 
pBlueScript clones.  First, all BAC clones were screened on a single membrane.  Second, 
all four probes (B110, B315, H569 and H659) were used.  All BAC clones were double-
digested with EcoRI and Not I  and then electrophoresed on an agarose gel.  The DNA 
fragments were transferred to a nylon membrane using the Southern blot method.  The 
membrane was then probed and developed. 
IX. GENERATING BaCMV CLONES OR PCR PRODUCT FOR SEQUENCING 
A. Genome Sequencing by Transposon Priming 
The GPS1.1 transposon mutagenesis system was used for sequencing clones 
having a large DNA insert.  A good sequencing reaction produces 500 – 800 bp of DNA 
sequence.  When newly identified clones were sent for sequencing, primers that bind near 
the vector MCS were used so sequence data from the ends of the clone were generated.  
Therefore most of the clones chosen for transposon mutagenesis already had data 
generated for the ends.  These clones ranged in size from 1 kbp to >15 kbp, so a 
considerable amount of the internal region still needed to be sequenced.  Transposon 
mutagenesis introduces a transposon containing universal priming sites in random 
locations on target DNA (Figure 10).   
In a given reaction containing many copies of a plasmid, transposons insert in 
different locations on each individual plasmid thereby providing sequence priming at 
different points along the length of the clone.  Transposon, target DNA, and transposase 
ratios are adjusted to favor insertion of a single transposon per plasmid.  This technique 
was very effective and was used to provide internal sequence from at least 21 different 
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Figure 10.  The GPS-1 Genome Priming System.  The transposon 
(Transprimer) inserts DNA randomly into the DNA target.  The 
recombinant transposon can then be transferred to bacteria via 
transformation.  Genes for kanamycin and chloramphenical confer 
selection properties.  Primers N and S allow sequencing from either 
strand at the insertion point.  Figure taken from manufacturers 
product insert.
 
plasmid clones of BaCMV OCOM4-37.  The following clones were chosen for GPS1.1 
transposon mutagenesis: BamHI – 97, 110, 112, 119, 129, 131, 150, 161, 201, 241, 301, 
372, 406, 1612 and 3287; Hind III – 602, 619, 631 and 659; Not I  1690; and SmaI/Not I  
3094.   
For all transposon mutagenesis reactions, the concentration of target DNA was 
adjusted to 0.08 μg/ml.  Concentrations were determined by gel electrophoresis of target 
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DNA with Lambda DNA of known concentration.  In each reaction, 2 μl of GPS buffer, 
1μl of GPS1.1 transprimer, 0.08 μg/ml of target DNA and dH2O to bring the volume to 
18 μl were mixed together in a 0.5 ml test tube.  The contents were mixed by pipeting the 
solution a few times.  One μl of transposase enzyme (mixture of TnsA 7μg/ml, TnsB 
10μg/ml, TnsC 20μg/ml) was added and the solution again mixed.  The mixture was 
incubated at 37 ºC for 10 min before 1 μl of start solution was added.  The contents were 
mixed by pipeting and incubated for 1 hr at 37 ºC.  The mixture was heated to 75 ºC for 
10 min to inactivate the enzymes.  The entire reaction (20μl) was transformed into 
commercially-competent TOP10 F’ cells and placed in a shaking water bath for 30 min at 
37 ºC.  Seventy-five μl of the transformed cells were spread on 4 LB KAN/AMP plates 
and incubated overnight at 37 ºC.  Results were variable but most reactions yielded 
enough colonies to pick to provide DNA for sequencing.  Colonies were selected for 
minipreps, the DNA digested, and DNA fragments separated by gel electrophoresis 
Based on the known sequence of the transprimer, useful BamHI clones were 
expected to have four bands while Hind III clones were expected to have three bands.  
Digestion with BamHI produces one 3 kb vector fragment and one 1.4 kb fragment 
containing the transprimer.  The sizes of the remaining two bands are dependent on the 
insertion site of the transprimer.  For Hind III digestion of the Hind III clones, a 3 kb 
vector fragment is also expected.  Again, the sizes of the two remaining bands depend on 
the location of the transprimer insertion site.  An example of RE digests, electrophoresis 
and a gel of clones from a GPS1.1 transprimer reaction is shown in Figure 11.  Clones 
BamHI 4416, 4418, 4428, and Hind III 4434, 4435 show the desired bands.  Initially, 
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clones BamHI 4428, and Hind III 4434, 4435 were sent for sequencing.  The other clones 
were reserved for later sequencing. 
Figure 11.  Transposon Mutagensis of pBS HI 97, pBS HI 150 & 
pBS III 602. Using NEB GPS1.1.  DNA size markers are in lane 1.  Frag-
ment sizes in bp: 100, 200, 300, 400, 500, 650, 850, 1000, 1650, 5000, 6000, 




B. Cloning and Sequencing the UL1 Region Using HCMV Primers SP216 and 
SP217  
None of the preceding approaches yielded sequence from the UL1 region of the 
genome.  Sequencing the coding regions of the genome was a primary goal of this study.  
The UL1 gene in HCMV is the first coding sequence in the genome.  By amplifying and 
sequencing the UL1 region of the BaCMV genome, data adjacent to the terminus would 
be available as a starting point for primer walking into the repetitive terminal sequences 
upstream of the UL1 sequence.  Primer pairs (SP216 and SP217) were designed for the 
UL1 region of the HCMV genome, and these primers were used to attempt amplification 
of the BaCMV UL1 region using PCR.  It was expected that although the primers would 
not bind specifically to the BaCMV UL1 sequence, sufficient homology would exist 
between the two genomes to allow binding at low annealing temperature to produce a 
BaCMV UL1 PCR product.  The PCR product was cloned into pCR2.1-TOPO, 
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transformed into competent cells, DNA purified, and then sent to be sequenced.  Direct 
cloning PCR products into the TOPO vector was possible because the vector DNA has 
been linearized and has topoisomerase attached, which allows the PCR product to be 
cloned more efficiently. 
PCR reactions were prepared as follows: 
 HCMV (+) BaCMV (+) HCMV (-) BaCMV (-) 
DNA 5 (0.25 μg) 5 (0.25 μg) 0 0 
3.3x rTth buffer 15 15 15 15 
100mM SP216 primer 1 1 1 1 
100mM SP217 primer 1 1 1 1 
10mM dNTP 8 8 8 8 
25mM MgOAc 5 5 5 5 
rTth polymerase (0.5U/μl) 2 2 2 2 
dH2O 13 13 13 13 
Table 5.  PCR to Amplify Sequence from the UL1 Region of the BaCMV Genome   
Reactions included positive and negative controls.  (All volumes are in μl). 
 
The HCMV DNA reaction was included as a positive control.  Two negative 
control reactions (labeled HCMV- and BaCMV-) had no input DNA and were included 
to test for DNA contamination.  Each reaction was performed at the following 
temperatures: 99 °C to denature (30 sec), 55 °C to anneal primers (30 sec) and 72 °C for 
extension (1 min).  The thermocycler was set at 30 cycles and the final extension step 
was increased to 20 min.  Five μl of HCMV and BaCMV positive reactions were run on 
an agarose gel and both reactions showed a band at approximately 600 bp as expected 
(Figure 12).  The remaining 45 μl of the BaCMV PCR reaction was electrophoresed, then 
the band of amplification product was cut out of the gel and phenol:chloroform purified.   
A TOPO cloning reaction was performed using 2 μl of DNA, 1 μl of salt solution, 1 μl of 
TOPO vector and 2 μl of distilled H2O.  Two μl of the TOPO cloning reaction was 
transformed into TOP 10F’ cells and then 100 and 200 μl was spread on two separate 
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Figure 12.  UL1 PCR Product.  
Left lane shows the 1 Kb DNAsiz e 
marker.  Two right la nes show
HCMV and BaCMV UL1 PCR 
product .  Each UL1 band
approxi mates 600 bp.
plates of 2YT/AMP media and grown at 37 °C 
overnight.  This yielded numerous colonies; 12 
were selected for miniprep purification and 
designated clones numbers 3597 – 3608.  Clone 
3599 was sent for sequencing (see Results II-C-
2).   
C. Generating DNA for Sequencing Using 
PCR 
Where gaps in sequence were believed to 
exist between sequenced clones, PCR was also 
used to generate DNA for sequencing.  Using this 
method can be problematic since PCR is prone to 
errors.  To minimize this problem, rTth 
(recombinant Thermus thermophilus) DNA 
polymerase was used for DNA amplification since 
Perkin-Elmer states that it has higher fidelity than Taq polymerase.  Primer pairs were 
designed using sequence data adjacent to the gap to generate a PCR product spanning the 
sequence gap.  The PCR product was then cloned into the pCR2.1-TOPO vector or sent 
directly to the OSU sequencing facility along with the primers used to generate the 
sequence.  (Sequencing of PCR product was necessary when TOPO cloning failed).  
Prior to TOPO cloning, the PCR product was purified using the Promega Wizard Prep 
kit.  The manufacturer’s protocol was followed and the DNA was eluted by adding 50 μl 
of TE and centrifuging the minicolumn for 20 sec at 10,000 x g. 
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Most PCR reactions were performed using the standard protocol (described 
elsewhere).  However, some clones that did not yield good product using standard PCR 
showed better results using TaKaRa LA (long and accurate) PCR.  This kit is designed to 
generate PCR products up to 40 kb and can also be used for DNA having a high GC 
content.  It was suspected that the gap regions had been difficult to amplify due to 
possible high GC DNA content in these areas.  G:C base-pair bonds are more stable than 
those of A:T bonds so may be difficult to denature during PCR.  This resistance can 
decrease PCR and/or sequencing efficiency.   
The TaKaRa kit was used to PCR into one gap site that existed between clones 
apBS BamHI 97 and pTOPO5252 to create clone 5548 which was > 5kb.  A forward 
primer (SP286) and reverse primer (SP367) were designed and used for this reaction.  
Two μl of BaCMV OCOM4-37 circular DNA (10ng/ml) was used as template.  The PCR 
reaction also contained 5 μl of 10X LA-PCR buffer, 8 μl of 10 mM dNTPs, 1 μl of      
100 mM SP286, 1 μl of 100 mM SP367, 0.5 μl of TaKaRa LA Taq polymerase (5U/μl) 
and 32.5 μl of distilled water.  The reaction was run for 30 cycles at 98 °C (10 sec), 64 °C 
(60 sec) and 68 °C (15 min).  All 50 μl of the product was run on an agarose gel, the 
DNA band was cut out of the gel, phenol:chloroform purified and cloned into the TOPO 
XL vector.  This vector is designed to accept large inserts (up to 10 kb). 
To generate DNA sequences for the region between clones B110 and H659, 
various primer pairs were designed and used for PCR (Figure 13).  The following sets of 

















Figure 13.  The upper bar represents the 
sequenced HCMV (AD169) genome.  The  boxes represent cloned BaCMV DNA fragments 
and have been placed on the map based on their similarity with HCMV.  Blue =  HI 
clone, Green =  a III clone, and Red is uncloned but sequenced 
PCR fragments. The red and blue arrows show the location of DNA primers.
Bam
HindOrange = RI clone, Eco





forward primer in each reaction while SP467 and SP266 were the reverse primers (see 
Appendix B). 
The PCR product from each reaction was cloned into the pCR2.1-TOPO vector, 
transformed into XL1-Blu cells, plated on 2YT/AMP, and grown overnight.  Clone DNA 
was then purified using the standard miniprep protocol and digested with EcoRI.  The 
digests were run on an agarose gel and those clones having appropriate DNA bands and 
the greatest DNA concentration were sent for sequencing (see Results section II-E). 
PCR primers SP378 and SP471 were used to amplify DNA across the un-
sequenced region that existed within the BAC clone N3851.  These primers generated a 
product having three distinct bands.  The largest was approximately 5.5 kbp, the middle 
band was 1.6 kbp and the smallest one was about 600 bp (Figure 38A).  All three bands 
were excised from on agarose gel and purified.  The large band was TOPO cloned and 
the two smaller ones were stored for future consideration.  Only 8 colonies grew when 
plated on 2YT/AMP media.  All were selected for minipreps but only 7 of the clones 
grew.  These 7 were purified using the standard miniprep protocol and then digested and 
electrophoresed on an agarose gel (Figure 38B).  Clones 7272, 7274 and 7275 were sent 
for sequencing.   
D. Generating Sequence Data Through Primer Walking 
Because the GPS1.1 transposons insert randomly into clone DNA, sequences do 
not always overlap and there are unsequenced regions where gaps exist.  This leaves 
some areas with insufficient coverage.  Additionally, there were some DNA inserts that 
were difficult to sequence, perhaps due to repetitive sequences, high GC content or 
secondary structure.  For these unfinished clones, primer walking was the best strategy to 
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produce new data.  This method had not been used previously because it is both time-
consuming and more expensive.  When sequencing DNA, it is ideal to sequence both 
strands and to have two or more sequence data files (traces) for each strand (Figure 14).   
Figure 14.  Strategy View of  BaCMV  OCOM4-37 Clone B406 Alignment.  Shows alignment 
of several GPS-1 clones, orientation, origination point and areas of overlap.  Solid arrows 
represent forward primer sequence, dashed arrows represent reverse primer sequence.  The box 
at 9133 - 9304  bp (A) shows DNA only sequenced on one strand and the box at 9773 - 10055 bp 




Overlapping sequencing data is used to assemble a consensus sequence and sequencing 
both DNA strands twice helps verify the accuracy of the data.  In primer walking, the 
DNA sequence of a newly-generated sequence strand is used to design a new primer.  
This primer is then used in sequencing to generate more DNA sequence data that extends 
the previous sequence data.  New DNA sequence is used to design yet another primer 
which is then used to further extend the DNA sequence and so on until the entire region 
of interest is sequenced (Figure 15).  For clones that had gaps or that were difficult to 
sequence, new primers were designed (Primer Select, DNAStar, Madison, WI) adjacent  
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to the region to be sequenced.  Purified Qiagen miniprep DNA was used for each 
sequencing reaction and a typical sequencing reaction would provide from 500 – 800 bp 
of new data. 
Figure 15.  Primer Walking of the pBAC N3851 Clone.  Each name under Contig 4909 
corresponds with an individual sequencing reaction.  The names designate the origin of the DNA 
being sequenced and the primer used for sequencing.  
The arrows on the right side of the 
figure show the direction of the primer and length of the resulting sequence.  Primers used in 
primer walking are all directed toward the right end of the alignment.
Exceptions to this naming system represent 







In this investigation, over 217,000 bp of DNA from the OCOM4-37 strain was 
sequenced.  It is projected that there are about 8,000 - 12,000 bp are left to complete the 
BaCMV genome.  The HCMV genome consists of 229, 354 bp and RhCMV contains 
221,459 bp.  Therefore, the projected size of the BaCMV genome is probably somewhere 
between HCMV and RhCMV.  The entire US region of the genome has been cloned and 
sequenced.  However, in the UL component of the genome there are two gaps which have 
proven difficult to sequence (Figure 16).  A clone in the BaCMV library has been 
identified that spans one of these gaps but subcloning DNA and sequencing of this region 
has proven difficult.  This difficulty is probably due to either secondary structure or 
repetitive sequences within this region.  The terminal UL contiguous sequence (left 
contig) is contained within a plasmid clone and contains the terminal repetitive sequence 
(TRL) and ORFs BaUL01 through BaUL25 (partial).   
 TRL




Figure 16.  Gaps in Unique Long Sequence:  The UL sequence is composed of BaUL28 through BaUL122 
(partial).  And the US contig contains the internal repetitive sequence (IR), the terminal repetitive short 




I. PRELIMINARY DATA 
This preliminary data was generated by Dr. Blewett and R. Preston Rogers in 
1997 – 1999.  Initially, a large quantity of BaCMV OCOM4-37 was grown in cell 
culture, and DNA purified on NaI gradients.  This DNA was digested with restriction 
enzymes, fragments separated by agarose gel electrophoresis, and the gel stained and 
photographed to determine the quality of DNA recovered and to choose REs for cloning.  
The preparation contained high molecular weight DNA, as the uncut DNA lane 
showed little degradation (Figure 17).  The REs that cut at 8 bp recognition sites, AscI, 
Not I , PacI and PmeI either did not cut or cut the DNA into a small number of pieces.  
The restriction enzyme DraI (with a 6 bp AT-rich recognition sequence) also cut the 
genome into a small number of pieces.  Since the cloning project was to use 
plasmid/phagemid vectors of the pUC lineage (in which DNA fragments > 15 kbp are 
difficult to clone), REs that digest the genome into smaller pieces were desired.  The 
enzymes BamHI and Hind III digested the majority of the BaCMV genome into 
fragments < 15 kbp (Figure 17).  The enzymes EcoRI (data not shown), SspI and XbaI 
cut the genomic DNA into less useable fragments.  BamHI was chosen for the first 
random library.  
A. Viral DNA Restriction Enzyme Digest 
Genomic BaCMV OCOM4-37 DNA was digested with BamHI, ligated into 
BamHI -cut plasmid vector (pBluescript II SK +), transformed into E. coli TOP10F’ 
cells, and spread on agar plates containing 100 μg/ml ampicillin plus IPTG and X-GAL. 
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Figure 17.  Restriction enzyme digestion of BaCMV OCOM4-37 DNA. Lambdavirus DNA 
was digested with II or III to provide size markers. The numbers on each side of the 









White colonies were used to inoculate 2 ml of 2YT plus Amp and incubated overnight. 
B. BamHI Miniprep Example 
Plasmid DNA was isolated using the miniprep procedure, digested with BamHI, 
electrophoresed and photographed (Figure 18).  After digestion and electrophoresis, all 
clones should have a plasmid DNA band (approximately 2.9 kbp) and a unique viral 
DNA insert band.  Numerous clones containing unique BamHI fragments were identified.  
To differentiate unique clones with similar sized inserts, clones with similar-sized inserts 
were digested with XbaI plus Hind III, electrophoresed on an agarose gel, stained and 
photographed (Figure 19).  
There is one XbaI and a Hind III in the MCS of the pBluescript II SK (+) vector 
(one on each side of the BamHI site).  Therefore, digestion with XbaI plus Hind III will 
cut the insert out of the vector.  If the insert contains sites Xba I and/or Hind III, multiple 
bands will result on the gel thereby allowing duplicate clones to be identified.  Lanes 2-6 
and 9 in figure 18 show examples of multiple clones containing the same BamHI 
fragment.  Clones containing unique DNA inserts were sent to the Core Facility at OSU 
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Figure 18.  Potential BaCMV OCOM4-37 HI DNA Clones. DNA fragments cloned into pBluescript II 
SK+ digested with HI.  Minipreps 95-130 are indicated by number. The pBS lane is vector DNA. 
Lambdavirus DNA was digested with II to provide size markers. The numbers on each side of the gel are 







Figure 19.  Identifying Unique BaCMV OCOM4-37 HI Clones. HI DNA clones were digested with I and III.  Lanes 1 - 45 
are  Minipreps (96, 97, 103, 105, 106, 118, 121) (128, 131, 150_ (101, 123, 179, 194, 197) (95, 122,172) (132, 140, 143, 144, 153) (98, 111, 
113, 129, 149, 154, 161, 171, 181, 199) (97, 102, 119, 120, 136, 139, 151, 159, 189, 193, 195, 201).  Lambdavirus DNA was digested with
EII or III  to provide size markers. The numbers on each side of the gel are the DNA size standards in base pairs.  





































C. BLAST SEARCH 
Digital DNA sequencing data in the form of Abi trace files were received from 
the sequencing facility.  Sequence data was edited by the removal of vector MCS 
sequences at the 5’ end and poor quality chromatogram peaks at the 3’ end.  The resulting 
DNA sequence data was used to search GenBank with BLAST.  A typical BLAST result 
is shown in Figure 20. 
Figure 20.  Typical BLAST Search.  GenBank was searched using the BLASTN program and 
the unique DNA sequence generated when the HI Clone 97 was sequenced using reverse 
primer.  The searches results are truncated for display purposes.  This BaCMV clone is homo-
logous to the unique short region of the HCMV genome.
Bam
 
Homology of the BaCMV clones with HCMV AD169 was used to position BaCMV 
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Figure 21. The upper bar represents the sequenced HCMV (AD169) 
genome. The gB and pp65 genes are shown as arrowheads.  The thin black bars represent the BaCMV (OCOM4-37) 
genome.  The thick black boxes represent the previously sequenced portions of the BaCMV genome.  Th e colored 
boxes represent cloned BaCMV DNA fragments and have been placed on the map based on their sequence similarity 
with HCMV. Blue =  HI clone, Green =  III clone, Orange = RI clone and Yellow = I clone. Bam Hind Eco Xba






D. PCR Amplification and Sequencing Across Clone Junctions 
Once unique BamHI clones that had homology to HCMV or RhCMV had been 
placed on a map, primers were designed to sequence or amplify across BamHI site 
junctions or across gaps between nearest BamHI fragments.  If an overlapping DNA 
fragment from another RE digest was cloned and mapped to that area, the primer was 
used to sequence that template.  In most cases, PCR amplification of viral DNA was 
necessary.  The end sequences from BamHI clones and PrimerSelect software (DNAStar, 
Madison, WI) were used to select appropriate primers sequences.  Purified BaCMV DNA 
was used as the template for PCR.  Amplification products were sent for sequencing or 
were cloned into pCR2.1-TOPO.  Miniprep DNA was prepared from the TOPO clones 
and digested with EcoRI (which cuts on each side of the PCR product insertion site).  
The resulting DNA fragments were separated by gel electrophoresis, stained and 
photographed.  Those clones that had good quality inserts of the expected size were sent 
for sequencing.  The resulting DNA traces were placed in the master assembly after the 
MCS and primer sequence were removed from the 5’ end and poor quality data removed 
from the 3’end. 
Sequencing of non- BamHI clones (Hind III, EcoRI or XbaI clones) or PCR 
amplification products across the ends of BamHI clones confirmed that many clones 
were indeed adjacent as mapped (Figure 22).  In some cases, small fragments, some as 
small as 16 bp, were found between BamHI clones.  As this project continued, all BamHI 







Figure 22  PCR Amplfication of BaCMV OCOM4-37 DNA between clones B110 & B150.  
Part A  Primers SP86 & SP119 were used to amplify viral DNA or a negative control reaction with 
no DNA. The amplification products were separated by gel electrophoresis, stained and 
photographed. Part B. A schematic diagram showing the HI clones, PCR primers and the 


















II. DISSERTATION FINDINGS 
At the time that this project began, approximately 70% of the BaCMV genome 
had been cloned but little sequence data had been produced.  Therefore, the aims of this 
research were 1) to clone the remaining 25 – 35% of the genome, 2) to sequence internal 
regions of clones for which only end sequence data was available, 3) to identify clones 












Figure 23.  Digests of pSL301 Vector and Mam-
malian DNA.  First lane shows the 1 Kb DNA 
size marker.  VB, VH and VN lanes are pSL301
(vector) cut with either HI, III or I. 
 IB, IH and IN lanes are  mammalian (insert) DNA
cut with the same restriction enzymes.






between clones, and 5) to primer walk through clones that were difficult to sequence.  
Once the genome was cloned, sequenced and assembled, the final consensus sequence 
would be analyzed and compared with other herpesvirus genomes.  This involved 
performing BLAST searches on sequences to identify homologues from other 
herpesviruses and then creating independent alignments with other primate virus 
homologues for which published genomes were available.  Several BaCMV homologues 
were grouped into herpesvirus gene families and further analysis revealed distinguishing 
features seen in other herpesviruses.   
The results described below cover several categories: 1) genomic cloning 2) 
screening existing clones 3) generating 
PCR product for sequencing 4) trace 
file assembly, and 5) genome analysis. 
A. Directional Cloning to Capture 
Terminal Fragments 
1. Evaluating Vector and Insert 
DNA by Gel Electrophoresis 
After digesting both the pSL301 
vector DNA and mammalian DNA with 
BamHI, Hind III or Not I  (see 
Methodology VII-A-2), the purified 
vectors and test inserts were run on a 
gel and appeared as seen in Figure 23.   
Vector bands were visible for 
each restriction enzyme digest and the mammalian insert DNA was smeared due to 
numerous cuts (as expected).  The vector DNA bands should be similar sizes but migrate 
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at slightly different rates.  This is likely due to uneven wells, not a difference in vector 
size.  The vectors were ligated with appropriate insert DNA and transformed into 
TOP10F’ cells and the resulting colony numbers are shown in Table 6.  Each vector had 
been dephosphorylated to reduce vector self ligation.  The Hind III plates had too many 
vector only colonies (lacking an insert) indicating the vector was self ligating.  Therefore, 
only the BamHI and Not I  vectors were used for ligation with BaCMV DNA.   
Restriction Enzymes SmaI/BamHI SmaI/Not I  SmaI/Hind III 
Colonies per plate 4 15 89 129 175 115 
Table 6. Colonies Resulting from pSL301 Vector Cloning and Transformation
Most of the potential blunt-Not I  clones had both vector and insert bands (Figure 
24) and are possible termini.  Two that seemed to have the most concentrated DNA 
(QN3058 and QN3063) were sequenced.  Both clones yielded good sequence data and 
mapped to the US terminus of the genome.  Another 24 minipreps were prepared from 
additional colonies but, since they appeared to be duplicates of previous clones, none 
were sequenced.  Clones with small inserts were not sequenced since we were expecting 
end fragments to be large.  All clones made in this experiment, whether apparent 
duplicates or containing a small insert, were later screened by DNA hybridization.  A 
clone made in this experiment (pSL301 QN3094) turned out to be the 3’ terminal 
fragment in later screening experiments. 
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Figure 24.  Miniprep Digests of Clones QN3056 - QN3077.  Clones QN3058 and Q   3060 
(identified by an *) appear to be similar and QN3063 and QN3068 (identified by a +) appear 
to be duplicates.  QN3058 and QN3063 were selected for sequencing because they had more 
concentrated  DNA. 
N
* * + +
pSL301 3056 3077
Minipreps digested with BamHI-EcoRI
 
B. Using Circular BaCMV DNA to Generate Clones Containing the Termini 
Previous screening methods had not identified sequence data from the UL 
terminus so cloning fragments from circularized genome DNA was attempted.  This 
strategy was to circularize the normally linear viral genome and then digest the DNA 
with Not I  to create fragments that could be cloned into plasmid or BAC vectors.  One of 
the Not I  fragments should contain the joined US and UL termini.  The other genomic 
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fragments may also represent uncloned sections of the genome.  Two strategies were used 
to circularize the genome (as described in Methodology).   
Linear, NaI-purified BaCMV DNA was self-ligated to produce circular 
molecules.  This DNA was digested with Not I , purified and ligated into a plasmid vector 
also digested with Not I .  After growing bacteria transformed with plasmid clones 
overnight, the plates looked promising as each plate had more white colonies than blue 
ones.  Unfortunately, this method did not yield data from the UL terminus as hoped.  
None of the clones that were screened by Southern Blot using a Not I  end-labeled probe 
mapped to the termini.  Results for the clones that were sequenced are as follows: 3208 
aligned near B153 at the center of the UL region, 3211 was a duplicate of N1655 and 
aligned in the US region, 3217 and 3232 were duplicates and aligned at the 3’ end of the 
BAC 3851 clone and 3231 aligned to the 3’ end of 3208 in the UL region.  All of the 
clones generated with this method appear to be fragments or concatamers of genomic 
pieces but none were end fragments nor were any clones recovered that contained large 
genomic fragments. 
The second strategy was to purify circular BaCMV DNA.  Herpesvirus genomes 
are in a circular state during viral replication and these molecules were preferentially 
obtained by the Hirt DNA purification method.  Figure 25 shows circular BaCMV DNA 
prepared by this method, digested with BamHI, and then electrophoresed on an agarose 
gel.  These results show the DNA can be digested with BamHI and there is not a lot of 




Figure 25.  Circular BaCMV DNA Preparation.  
A HI digested DNA preparation was separatedBam
by electrophoresis for 2 hrs (left) or overnight (right). 















At this time, the two Not I  terminal fragments were assumed to be large, (>10 kbp each).  
Therefore, after the BaCMV DNA circular DNA was digested with Not I  and purified it 
was cloned into a BAC vector.  This vector, pBACe3.6, had been digested with Not I  and 
purified.  The digested DNAs were then introduced into E. coli DH10B by 
electroporation.   
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BAC clone DNA was purified from isolated colonies, resulting in 58 clones.  
Figure 26 shows a typical gel electrophoresis of a Not I  digestion for some of these 
clones.  The large, ~9 kbp vector fragment can be seen in each lane.  Insert DNA sizes  
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Figure 26  pBACe3.6 BaCMV OCOM4-37 CircDNA Minipreps 3848 - 3865 digested with I  A large size 
DNA marker is on the left, a 1kb+ marker is on the right and the numbers are fragment sizes in kbp. The 
pBACe3.6 vector band is expected to be ~9 kbp.
Not .



























range from > 20 kbp to  < 7 kbp.  Some clones, i.e. 3850, were chimeras containing 
multiple Not I  fragments.  However, most of the clones appeared to contain one large 
Not I  fragment and were considered useful in genomic sequencing.  At this time, it was 
believed the terminal clone would be large, so the only clones that were characterized 
were those that contained a > 9 kbp insert.  Clones 3851 and 3852 were end sequenced, 
and mapped to regions near the 3’ terminus and near the 5’ terminus respectively.   
C. Screening Existing and New BaCMV Clone Libraries by DNA Hybridization 
to Identify US or UL Terminal Fragments 
1. Dot Blot Results 
The purpose of dot blot screening was to find clones in the BaCMV libraries that 
contain DNA located near either terminus of the genome.  Both Not I  and PmeI are rare 
cutters of BaCMV DNA.  These REs were used to create probes by digesting end-tailed 
genomic BaCMV DNA to generate large, labeled end fragments.  The longer probes are 
more likely to overlap terminal fragments and should hybridize to them when screening 
the clone library.  After 8 – 10 min of development, a number of positives were visible on 
both the Not I  and PmeI-probed dot blots and those clone pools with greatest intensity of 
color were selected for individual clone screening.  Both positive and negative control 
results were as expected (Figure 27).  Pooled clones shown in Table 7 were selected for 
individual screening.  Those clones which had already been evaluated as terminal clones 
by other methods were omitted from individual screening as were clones that had 
previously been sequenced and mapped.  After two dot blots of individual clones were 
performed using either the PmeI or Not I  probe, the following clones were selected for 
restriction digestion and run on an agarose gel: BamHI clones 297, 369, 370, 374, 378, 
379, 381, 383, 384, 387, 388, 390 and 394, XbaI clones 2320, 2322, 2323, 2325, 2328,  
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NotI Probe PmeI Probe
Figure 27.  Dot Blot Screening of Pooled BaCMV Clones.  Blot on the left was screened with I 
probe and blot on the right with I probe.  Only the strongest positives are visible here.  Clones 
3058, 3063, 589, and 639 were weakly positive so are obscure in this figure.  The pBlueScript negative 




Pool # RE used Clones in pool Total number Omitted 
S5 BamHI 130 – 139  9 131 
S19 BamHI 296 – 305 7 296, 301, 305 
S26 BamHI 366 – 375 8 372, 368 
S27 BamHI 376 – 385  10 None  
S28 BamHI 386 – 395  3 389 – 395  
S71 Xho I 2320 – 2329  10 None 
S72 Xho I 2330 – 2338  9 None 
S81 Not I /SmaI 3051 – 3060  10 3058 
S84 Not I /SmaI 3081 – 3090  10 None 
S85 Not I /SmaI 3091 – 3101  10 None 
Table 7.  Individual Clones Selected from Pooled Clone Groups   
Restriction enzymes (RE) used to generate the clones are listed, the total number included in the dot blot 
pools, and clones that were omitted are listed. 
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2329, 2330, 2331, 2333, 2334 and 2335; SmaI/Not I  clone 3052.  Based on these gel 
analyses, some clones were eliminated as duplicates and others were culled due to poor 
DNA quality.  The following clones were selected for sequencing: 297, 370, 378, 381, 
384, 387, 388, 2322, 2330, 3052, 3094 and 3095.  Clones 297, 370, 381, 384, 387, 388, 
2322, 3052 and 3095 were all duplicates of previously-sequenced clones.  Clone 378 
gave poor sequence and 2330 was all vector DNA.  However, QN3094 was successful at 
adding approximately 4.3 kbp of new sequence to the 3’ terminus.  When this clone was 
eventually sequenced, we found it included the BaCMV gene homologous to the terminal 
RhCMV gene.  Due to the repetitive nature of the remaining QN3094 DNA sequence, 
this clone is believed to represent the most terminal region of the genome at the 3’ end 
and to include some of the terminal repeats.   
The H639 and B165 probes were generated from the endmost clones that had 
been identified at the time.  These clones were chosen since H639 and B165 both 
appeared to be closest to the UL terminus.  Dot blots using the H639 probe did not 
identify any clones near the UL terminus.  The pooled clones that were screened using 
this probe showed a number of positives, but these later mapped to internal regions.  
While positive and negative controls yielded the expected results, the color was faint for 
the positive control.  Ninety clones had been selected for individual screening from 
pooled clones.  Some of the individual clones that showed a strong positive reaction, 
especially B424, were actually from the center of the genome map.  Therefore, another 
probe, B165, was produced since this clone is more clearly associated with the UL 
terminus.  One clone, E2290 showed positive results and it was reserved for further 
analysis.   
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Dot blot results for pooled clones probed with B165 showed 4 positives, and 30 
clones were selected for individual screening from these 4 pools (Figure 28).  Using the 
B165 probe, E2290 was also seen as a strong positive along with another clone, B359.   
  
Figure 28.  Dot Blots Screened with B165 Probe.  Blot on the left was performed using pooled clones 
while blot  on the right was performed on individual clones.  Numbers in grid  represent clone pool
number while image below is the actual blot.  Positive and negative controls are located in the two 
right columns.  Positive controls were H639 (right terminus) and QN3063 (left terminus) while neg-
ative controls included H589 and QN3058 (both in US region) and  pBlueScript. 
 
Both clones were analyzed further and showed vector and insert bands after restriction.  
However, little DNA was present in the B359 digest so new DNA preps were made using 
the Qiagen method.  The new plasmid DNA did not resemble the original clone for either 
B359 or E2290.  The original B359 clone DNA prep had a single dark insert band on an 
agarose gel.  Therefore the remaining original B359 DNA was sent for sequencing.  Good 
sequence data was obtained and aligned with B165 near the UL terminus but only the KS 
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(reverse) primer seemed to work; the forward primer yielded no useful sequence.  This 
suggests that the region in the vector MCS where the forward primer binds was probably 
damaged, missing, or has features that make it difficult to sequence.  While these dot 
blots showed some true positives that yielded good sequence data, they did not provide 
sequence data from the 5’ terminus.  Clones believed to be near the termini of the 
genome were used to produce probes.  It is now known that these were not terminal 
clones.  Potential terminal clones described in sections A and B above were also 
screened.  Clones representing the UL and US termini were in the libraries being 
screened.  The US terminus was eventually identified in clone QN3094 while N3851 was 
shown to be located near the UL terminus.   
2. Evaluating Clone pBS E2290 
Clone E2290 was positive when screened with both H639 and B165 probes, and 
therefore was expected to be located near the left terminus of the BaCMV genome.  Also, 
after digestion with EcoRI and electrophoresis, clone E2290 appeared to have 3 bands.  
These band sizes were approximately 14 kb, 3 kb and 1.3 kb, and were likely the result of 
two unique EcoRI fragments ligating together to form a chimeric clone (the 3kb band 
being vector DNA).  To subclone each EcoRI fragment, the E2290 plasmid clone DNA 
was digested with EcoRI and religated to see if clones with the individual EcoRI 
fragments could be obtained and used for sequencing.  It was expected that clones 
containing the vector band and either the 1.3 kb or 14 kb insert bands would be 
recovered.  The original clone with the two insert bands could also be recovered.  Clones 
containing some combination of the desired sizes were obtained (Figure 29).  Re-cloning 
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the large insert is a low efficiency event and did not occur.  Clone 3185, which appeared 
to contain the small EcoRI insert was sent for sequencing. 
Figure 29.  Restriction Enzyme Digests of E2290 Subclones 3185 - 3195.  The f irst lane 
is the 1 Kb size marker.  Lanes 2 and 3 are Lambda DNA used to determine concentration. 



































When the E3185 subclone data was analyzed, the DNA sequence aligned at 
positions near the UL terminus where the probes were expected to bind.  BLAST 
searches of this DNA sequence showed significant homology with the HCMV UL19 
gene.  Therefore data that was generated from this screening was useful, but was located 
about 25 kbp into the genome.  DNA sequence from the other end of the clone DNA 
(representing the 14 kbp EcoRI fragment) did not align with any BaCMV sequences and 
a BLAST search for this sequence showed significant homology with human DNA.  
These results show that E2290 is a chimeric clone made up of BaCMV and human DNA 
EcoRI fragments ligated together.  The human DNA is likely from the MRC-5 cells used 
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to grow the virus.  This indicates that the viral DNA preparation is not completely pure 
and contains some cellular DNA.  Eventually, BaCMV BAC clones were produced and 
sequence from the UL terminus was generated. 
3. Screening Pooled Clones for Sequence in Gap Regions Using Southern Blot 
All gels containing clones used for Southern blots were loaded in the same 
sequence as shown in Figure 30 so only the gel probed with the H596 probe is shown 
below.  Some Southern blots did not show many positives or showed only weak 
1Kb  347   349    350    351   386    419    420   422   585  1709 2246 2247 2262 2263 2270  2273 2293 2352  2303 2311            pBS H596 1Kb
Figure 30.  Gel Electrophoresis of Clones Used for Southern Blotting.  This blot was 
screened with the H596 probe.  The negative control is pBlueScript DNA, the positive 










positives as seen in Figure 31.  Weak positives probably result from spurious binding of 
probes to partially-matched sequence.  Positive controls for the H596 and B315 probes 
did not develop on the respective membranes even though the probes had been tested 
prior to performing the Southern blots.  The B110 positive control was positive and a few 
clones were positive as well.  One of these, clone B422, is seen in the lower left-hand 
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quadrant of Figure 31.  This clone was sent for sequencing and was found to be a 
duplicate of clone B127.  Clone B127 had already been mapped to the beginning of the 




Figure 31.  Southern Blots Using H659, B315 and B110 Probes.   
Rulers on either side of each gel show orientation of digests.  
Positives are only visible on the B110 gel.  
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4. Screening BAC Clones for Sequence in Gap Regions Using Southern Blot 
The EtBr-stained gel prepared for screening BAC clones is shown in Figure 32.   
Figure 32.  Digests of BAC ( I Clones) 3826, 3828, 3854 and 3870.  The probes 
used for screening are listed above each group of digests.  DNA standards are 































































Results for the Southern blot showed that positive and negative controls worked for blots 
probed with B110, B315 and H596.  The H659 probe did not work at all.  For each of the 
probes that worked, bands were visible for BAC clones 3870 and 3854 (Figure 33).  The 
ends of both of these clones were sequenced.  The BAC 3870 sequence aligned with the 
left end sequence of clone H596 and the right end sequence of clone B97.  This filled in a 
large gap near the US terminus.  The B315 probe showed positive because 3870 is quite  
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Figure 33. BAC Clones - Southern Blot Screening.  Clone numbers on the
horizontal axis indicate probe used for the blot.  Clone numbers on the vert-
ical axis  indicate clone DNA being probed.  Clones N3870 and N3854 were
positive using probes  B110, B315 and H596.  Bands are indicated with 
brackets. 
 
large (approximately 14 kbp) and the B315 clone lies within 3870.  The BAC 3870 clone 
provided a considerable amount of new sequence data and overlapped with a number of 
clones (in the US region) that had not been accurately mapped (Figure 34).  The 3854 
BAC sequence duplicated an existing Not I  clone, 1645, which is adjacent to the left end 
of 3870.  It is not understood why these two clones showed positive results for the B110 
probe since this clone was from a distant location on the BaCMV genome.  However, 
there are blocks of repetitive DNA scattered throughout most herpesvirus genomes, and 
the B110 area could be repetitive as well.  This could explain the homology of B110 
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which comes from an area of the genome with repetitive DNA sequences to other regions 
of the BaCMV genome. 
B145
B314 B315










Figure 34.  Alignment of BAC Clone I 3870 in US Region.  Top figure shows 
a generalized representation of the Internal Repetitive, Unique Short and Terminal 
Repetitive Short Regions of the BaCMV Genome.  H = III clones, B = 
HI clones, N = I clones, red boxes are PCR product and the grey box 
represents BAC clone N3870 and all are drawn to scale.  Question marks 





D. Generating BaCMV Clones or PCR Products for Sequencing 
1. Genome Sequencing by Transposon Priming 
At least 800 trace files from 21 different clones were generated through 
transposon mutagenesis.  Of those shown in Figure 11, GPS clone 4428 (from B150) 
provided 1440 bp and GPS clone 4434 (from H602) produced 1420 bp of new sequence.  
While this represented only partial sequence for these two clones, for many of the other 
clones in the BaCMV library the internal DNA sequence was produced entirely using 
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transposon priming.  Sequencing of GPS-1 clones yielded almost 102,000 base pairs 
which represents about one-half of the total genome. 
2. Cloning of the UL1 Region Using HCMV Primers SP216 and SP217 
Dot blot and Southern blot screening had not provided any sequence from the UL 
terminus, so PCR was used to amplify BaCMV DNA using HCMV primers at the UL1 
region.  The UL1 region is the coding region in HCMV adjacent to the UL terminus, so 
amplification of this sequence would likely provide sequence near the BaCMV UL 
terminus.  After PCR, both the HCMV and BaCMV products showed a single band at 
approximately 600 bp as expected (Figure 12).  However, the results of TOPO cloning of 
the BaCMV product were poor.  The number of colonies on the plates was much greater 
than is normal for TOPO reactions, and many of the clones had multiple, unexpected 
bands.  A second PCR amplification and TOPO cloning showed better results.  Fewer 
colonies were observed on the two plates as is typical of TOPO cloning reactions.  The 
size of the DNA inserts was the expected 600 bp, so clone 3599 was sent for sequencing.  
Although both primers yielded sequence, only one DNA trace would assemble into the 
existing contiguous DNA sequence because the other trace was all vector DNA.  The 
trace that was BaCMV PCR product did not assemble into the UL1 region where it was 
expected to, but instead assembled near the US terminus overlapping N1690.  This was 
probably because the HCMV primers were degenerate (similar, but not identical to, other 
sites in the genome) and bound at a location other than the desired UL1 region in 
BaCMV. 
E. Generating DNA Across the B110/H659 Gap Using PCR 
PCR amplification was used to span the gap between clones B110 and H659 at 
the 3’ end of the UL region using various primer pairs.  The approximately 1 kb product 
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Figure 35.  Gel Electrophoresis of  SP467 and S 469 PCR Product and RI 
Digests of TOPO Clones 7316 - 7323.  (A) Left lane is size marker,  two center 
lanes are PCR product and right lane is lambda DNA for determining concentra-









generated with the primer pair SP467 and SP469 is shown in Figure 35 (A) and was 
TOPO cloned.  Eight colonies were selected for miniprep purification and assigned clone 
numbers 7316 – 7323 (Figure 35 B).   
 
As expected, five of the TOPO clones had a 3.9 kb vector band and a 1 kb insert 
that could be the PCR product.  Clone 7321 was sent for sequencing and yielded 
approximately 800 bp of useful sequence.  This did not span the gap between the clones, 
but did add new sequence data overlapping the 3’ end of the B110 clone.  The 
amplification product was generated by primer SP469 binding where it was designed to 
(in the B110 clone area) and binding at another site within the gap.  The SP467 primer 
did not work so the PCR product did not span the gap.  
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Figure 36.  Gel Electrophoresis of SP469
and S  PCR Product.  Left lane is  the 
size marker in bp and right lane is the 
PCR product. This reaction yielded a 






Since no PCR product was generated 
by the other primer to span the gap, another 
primer (SP266) was used with the SP467 
primer.  The PCR product of primer pair 
SP469 and SP266 was about 1.2 kb and is 
shown in Figure 36.  Twelve colonies from 
TOPO clones were selected for miniprep 
purification and assigned clone numbers 7336 
– 7347 (Figure 37).  Two clones, 7338 and 
7342, were sent for sequencing and yielded 
good data from the ends of each clone.  Both 
clones contained a 1234 bp insert which 
overlapped clone 7321 and added 351 
additional bps to the 3’ end of the gap.   
While this sequence extended further outward from the B110 clone, it did not join 
with the H659 clone sequence to cover the gap as expected.  This outcome was surprising 
since the lower primer, SP266, was complementary to sequence from clone H659.  One 
explan-ation for the smaller PCR product could be that SP266 binds to a region closer to 
the B110 end of the gap.  In fact, a good portion of the sequence from the 1,234 bp insert 
appears to be highly repetitive.  The repetitive nature of this region could also account for 




Figure 37. Gel Electrophoresis and RI Digests of TOPO Clones 7336 - 7347.  Left lane 
is the size marker, numbered  lanes are TOPO clone DNA as indicated.  All clones have a 









F. Generating DNA Across the Internal N3851 Gap Using PCR 
PCR was also used to amplify DNA for sequencing from the BAC clone N3851.  
Primer walking is difficult with BACs, and although we had some success, primer 
walking with BAC N3851 we did not generate useful sequence data for this area.  New 
PCR primers (SP378 and SP471) were designed from sequence on either side of the gap 
for PCR.  The 5.5 kb PCR product generated using these primers was used to create 
TOPO clones 7272 – 7278 (Figure 38).  Three of these clones, 7272, 7274 and 7275, 
were sent for sequencing using the SP378 and SP471 primers but yielded no useful data.  
Most of the data files had either multiple traces or ambiguous DNA sequence.  Though 
TOPO cloning was not successful, the PCR primers were used to sequence the ends of 
the 5.5 kbp product.  Sequences generated from the SP471 and SP378 primers aligned 
within the BAC N3851 clone.  The SP471 sequence aligned near the left end of the gap 
while the SP378 primer sequence aligned near the right end of the gap.  These two 
sequences provided an additional ~1,300 bp of the original 5.5 kbp PCR product. 
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Figure 38.  Gel Electrophoresis PCR Product and TOPO Clones 7272-7278.  
(A) Left lane is the DNA size standard and right lane is PCR product.  The middle band is 
approximately 1.6 kb and is not prominent in this image.  (B) Left lane is the DNA size standard 
and other lanes are TOPO clones of PCR product as indicated by number.
of SP378 and S 471 P
(A)                                              (B)
 
G. Generating Sequence Data Through Primer Walking 
Because TOPO cloning of the PCR product from primers SP378 and SP471 was 
not successful, primer walking was used to generate new sequence from either the PCR 
product itself or from pBAC N3851 DNA.  Primers 474, 486, 491, 492 and 497 were 
used for primer walking from the left end of the gap and yielded about 1,700 additional 
bp.  Primers 475, 485, and 490 were used at the right end of the gap and yielded 
approximately 1,240 new bp.  Sequence generated by PCR is not as reliable as sequence 
from clone DNA as PCR amplification is error prone.  Therefore, the sequence produced 
by primer walking of PCR product was not as accurate as that of sequence generated 
from clone N3851.  The sequence remaining to be determined within BAC clone N3851 
is about 2,900 bp. 
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H. Mapping Existing and New Genomic Clones 
BaCMV clones were initially mapped based on their homology to the HCMV 
AD169 genomic sequence.  During the course of this project, the BLAST algorithm was 
improved and other alignment algorithms became available.  Also, DNA sequences from 
rhesus and African Green monkey CMVs, began to appear in Genbank.  This allowed 
many existing clones whose ends were sequenced to be mapped.  Some of the genomic 
clones produced in attempts to clone the termini (such as N3870) were found to contain 
previously-uncloned sections of BaCMV DNA.  Finally, this led to the discovery of clone 
N1670 which contained the 5’ terminus of BaCMV.  This was a large Not I  clone 
(produced early in this project) which initially showed no significant homology to 
anything in Genbank. 
I. Final Clone Homology Map 
The preliminary clone map consisted of 46 individual clones.  The final clone 
map consists of 83 individual clones and all but one of these was completely sequenced 
(see thick black bar in Figure 39).  In the final version, the mapped clones are assembled 
to form 3 contiguous sequences representing about 217,000 bp of DNA.  Within the BAC 
clone N3851 there is a gap of missing sequence which is approximately 2,900 bp in 
length.  The projected amount of unsequenced DNA in this region is based on the known 
size of the BAC clone (as observed on an agarose gel) excluding the amount of DNA that 
has already been sequenced.  Another gap near the UL terminus, between clones B110 
and H659, is less-well defined.  This is because there is no identified clone that spans this 
gap.  Therefore the estimated range for this gap is between 4,000 and 9,000 bp based on 
comparison with closely-related primate CMV genomes.
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III. DATA ANALYSIS 
In the areas of the BaCMV genome that are sequenced, the overall GC content is 
48.5%.  This is very similar to the GC content for RhCMV which is 49%.  In the RhCMV 
genome, there is a region (genes Rh20 – Rh27) that has a lower GC content (between 20 
– 40%) and this sequence corresponds to the HCMV RL11 gene family.  The sequenced 
BaCMV genes include homologues for Rh20 through Rh25, and also show a reduced GC 
content at about 40%.  BaCMV sequence containing potential homologues to Rh26 – 
Rh28 has yet to be produced as this is the location of one of the remaining gaps.  Putative 




















































































Figure 39. The upper bar represents the sequenced human CMV (AD169) 
genome.The gB and pp65 genes are shown as arrowheads.  The thin black bar represents the BaCMV (OCO M4-37) genome. The 
thick black bar represents the sequenced portions of the BaCMV genome.The  boxes represent cloned BaCMV DNA fragments 
and have been placed on the map based on their similarity with HCMV. B =  HI clone, H =  a III 
clone, QB = a HI-blunt clone, QN = a I-blunt clone, T = Topo-cloned PCR fragment, X = a I clone and red is 
uncloned PCR fragments. 
Bam Hind 
Bam Not Xba 
BaCMV (OCOM4-37) Final Clone Homology Map. 













Table 8: Properties of the BaCMV (OCOM4-37) Genome 










Homologue  % Identity   Homologue   % Identity
BaUL01 166 18.7 TRL1 33.7 Rh01 50.6   
BaUL02 105 11.5       
BaUL03 121 13.2       
BaUL04 220 23.9       
BaUL05 251 28.0 UL153  Rh05 41.8 RL11  Membrane protein 
BaUL06 222 25.6       
BaUL07 217 24.7   rh07 23.8   
BaUL08 176 20.0   rh06 17.9   
BaUL09 173 20.5   rh07 26.0   
BaUL10 231 26.0   rh08 24.6   
BaUL11 173 20.5   rh07 21.4   
BaUL12 182 20.6   rh08 17.5   
BaUL13 185 21.0   rh08 18.1   
BaUL14 
Ex1 
135 14.2   rh10 
Ex6 
63.0  Cyclooxygenase-2 
BaUL14 
Ex2 
89 10.1   rh10 
Ex5 
60.0  Cyclooxygenase-2 
BaUL14 
Ex3 
113 13.4   rh10 
Ex4 
76.0  Cyclooxygenase-2 
BaUL14 
Ex4 
47 5.5   rh10 
Ex3 
40.0  Cyclooxygenase-2 
BaUL14 
Ex5 
115 12.2   rh10 
Ex2 
74.0  Cyclooxygenase-2 
BaUL14 
Ex6 
65 7.4   rh10 
Ex1 
43.0  Cyclooxygenase-2 
BaUL15 190 22.3   rh10 40.0   
BaUL16 200 22.6   rh12 18.5   
BaUL17 141 15.8   rh13.1 54   
BaUL18 186 20.3   rh14 47.9   
BaUL19 119 13.1   rh16    
BaUL20 296 33.6 UL04 19.1 Rh19 33.8 RL11  
BaUL21 184 20.5 UL06 17.4 Rh20 39.7 RL11  
BaUL22 236 27.1   Rh21 26.2 RL11  
BaUL23 236 27.1 UL11  Rh22 29.4 RL11  Membrane protein  
BaUL24 242 27.6 UL11  Rh23 46.3 RL11 Membrane protein 
BaUL25 152 17.1 UL09  Rh25 48 RL11 Membrane protein 
BaUL28 217 23.9 UL11  Rh29  RL11 Membrane protein 
BaUL29 193 21.5 UL11  Rh29  RL11 Membrane protein 
BaUL30 164 18.0   rh30 55.1   
BaUL31 360 41.3 UL13 16.7 Rh31 44.4   
BaUL32 307 35.5 UL14 28.7 Rh33 57.4   
BaUL33 109 12.6 UL17 21.2 Rh35 33.6   
BaUL34 98 10.9 UL19 38.8     
BaUL35 465 52.1 UL20 23.8 Rh36 42.4   
BaUL36 145 16.4 UL21A  rh37 59.5   
BaUL37 312 35.8 UL23 34.9 Rh40 57.1 US22  
BaUL38 206 230 UL24 46.5 Rh42 63.1 US22  
BaUL39 584 67.4 UL25 41.3 Rh43 56.8 US25  
BaUL40 238 27.0 UL26 44.1 Rh44 72.3   
BaUL41 577 65.6 UL27 54.8 Rh46 71.4   
BaUL42 337 38.7 UL28 66.5 Rh47 82.2 US22  
BaUL43 336 38.7 UL29 60.7 Rh50 76.8 US22 Immediate early protein 
BaUL44 542 61.2 UL31 55.4 Rh54 77.2   
BaUL45 777 85.9 UL32 28.2 Rh55 48.1  pp150 
BaUL46 318 35.9 UL33 56.9 Rh56 76.7 7TM G-protein-coupled 
receptor 
BaUL47 286 32.7 UL34 58.7 Rh57 79.3   
BaUL48 597 68.7 UL35 44.2 Rh59 61.4 UL25  
Continued on next page:  
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Table 8:  Properties of the BaCMV (OCOM4-37) Genome (continued) 
 










Homologue  % Identity Homologue   % Identity
BaUL49 450 51.8 UL36 33.5 Rh60 49.8 US22  
BaUL50 69 7.9 UL36 53.7 Rh61 62.3 US22  
BaUL51   UL37 37.0 Rh62 51.0   
BaUL52 306 34.8 UL38 47.1 Rh64 76.3   
BaUL53 101 11.7 UL37  Rh66   Nuclear egress lamina 
protein 
BaUL54 139 15.3   rh67 35.3   
BaUL55 143 16.0 UL42 32.5 Rh68 53.5  Glycoprotein 
BaUL56 340 39.2 UL43 42.4 Rh69 56.5 US22 Tegument protein  
BaUL57 388 43.6 UL44 68.1 Rh70 90.3  DNA polymerase 
processivity factor 
BaUL58 833 94.8 UL45 57.6 Rh72 70.0  Ribonucleotide reductase-1 
BaUL59 290 33.1 UL46 71.0 Rh75 84.1  Minor capsid binding 
protein 
BaUL60 960 110.7 UL47 43.0 Rh76 73.7  Capsid assembly protein 
BaUL61 793 89.3 UL48 51.0 Rh78 73.0  Large tegument protein 
BaUL62 470 53.5 UL49 74.0 Rh80 83.6   
BaUL63 303 33.6 UL50 52.8 Rh81 66.0   
BaUL64 104 11.7 UL51 82.0 Rh82 92.0   
BaUL65 556 63.3 UL52 60.4 Rh83 79.3  Virion protein 
BaUL66 288 33.0 UL53 72.2 Rh85 86.5  Virion protein 
BaUL67 1039 116.5 UL54 72.0 Rh87 81.4  DNA polymerase 
BaUL68 877 99.9 UL55 56.9 Rh89 73.6  Glycoprotein B 
BaUL69 773 88.8 UL56 79.3 Rh91 91.4  Transport capsid assembly 
protein 
BaUL70 1043 116.5 UL57 71.1 Rh92 92.5  Major DNA binding 
protein 
BaUL71 42 4.5   rh93 69.0   
BaUL72 293 31.1   rh96 62.3   
BaUL73 746 43.4 UL69 43.4 Rh97 58.5   
BaUL74 207 22.6   rh99 35.7   
BaUL75 972 111.9 UL70 68.0 Rh100 81.3  DNA helicase-primase 
component 
BaUL76 234 26.3 UL71 55.6  0.0  Tegument protein 
BaUL77 348 39.9 UL72 49.1 Rh101 67.1   
BaUL78 76 8.4 UL73 26.3 Rh102 52.6  Glycoprotein N  
BaUL79 427 49.4 UL74 35.0 Rh103 59.5  Glycoprotein O 
BaUL80 719 81.2 UL75 48.9 Rh104 64.7  Glycoprotein H 
BaUL81 293 32.6 UL76 53.2 Rh105 76.8   
BaUL82 592 67.0 UL77 68.6 Rh106 83.8  Pyruvoyl decarboxylase 
BaUL83 363 42.2 UL78 25.2 Rh107 41.4 7TM  GCR homologue 
BaUL84 265 30.5 UL79 77.4 Rh108 90.6   
BaUL85 652 70.0 UL80 44.4 Rh109 71.0  Capsid assembly protein 
BaUL86 532 60.0 UL82 37.2 Rh110 59.6 UL82 Major late antigen; pp71 
BaUL87 553 63.0 UL83 32.7 Rh111 47.9 UL82 Phosphorylated matrix 
protein (pp65)  
BaUL88 525 59.8 UL83 38.9 Rh112 51.2 UL82 Phosphorylated matrix 
protein (pp65) 
BaUL89 467 52.7 UL84 53.7 Rh114 76.4  Early nonstructural protein  
BaUL90 120 66.4   rh115 71.0   
BaUL91 302 34.2 UL85 75.2 Rh117 84.2  Minor capsid protein; mCP 
BaUL92 1343 151.3 UL86 77.2 Rh118 87.8  Major capsid protein; MCP 
BaUL93 104 11.8   rh119 84.6   
BaUL94 846 96.0 UL87 69.9 Rh122 85.9  Virion protein 
BaUL95 385 46.8 UL88 56.5 Rh123 71.5  Virion protein 
BaUL96 423 48.1 UL89 78.4 Rh124 87.8   
BaUL97 114 12.1 UL91 55.0 Rh126 73.0   
BaUL98 252 28.5 UL92 88.6 Rh127 81.1  Virion protein 
BaUL99 409 47.0 UL93 52.8 Rh128 72.1  Virion protein 
Continued on next page:  
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 Homologue  % Identity  Homologue  % Identity
BaUL100 345 37.9 UL94 55.1 Rh129 78.8  Virion protein 
BaUL101 431 47.6 UL95 68.2 Rh130 80.3  Virion protein 
BaUL102 127 14.5 UL96 53.9 Rh131 72.4  Virion protein 
BaUL103 503 57.4 UL97 57.1 Rh132 65.4  Phosphotransferase; 
phosphorylates ganciclovir 
BaUL104 559 63.2 UL98 69.2 Rh134 83.1  DNase; exonuclease 
BaUL105 112 65.0   rh135 75.0   
BaUL106 131 14.6 UL99 29.0 Rh136/137 57.3  Phosphoprotein (pp28)  
BaUL107 359 41.4 UL100 54.9 Rh138 70.8  Glycoprotein M 
BaUL108 737 80.9 UL102 62.4 Rh139 79.4  Helicase-primase;  
BaUL109 187 21.4 UL103 47.1 Rh140 55.1   
BaUL110 655 77.5 UL104 72.4 Rh141 86.1  Structural protein; DNA 
packaging/ cleavage 
protein  
BaUL111 877 99.0 UL105 77.1 Rh142 92.2  DNA helicase 
BaUL112 139 15.7 UL111  Rh143 42.4  IL-10-like protein;  
BaUL113a 274 29.0 UL112 38.1 Rh144 53.4   
BaUL113b 271 28.1 UL113 39.9 Rh145 58.3   
BaUL114 248 28.4 UL114 67.7 Rh146 80.6  Uracil-N glycosylase 
BaUL115 257 29.4 UL115 42.9 Rh147 75.0  Glycoprotein L 
BaUL116 340 36.2 UL116 25.9 Rh148 43.2   
BaUL117 388 43.2 UL117 49.5 Rh150 69.6   
BaUL118 200 23.6 UL118 32.5 Rh151 55.3  Large splice transcript 
BaUL119 216 21.8 UL119 23.2 Rh152 44.4   
BaUL120 204 23.3 UL120 33.3 Rh154 64.1   
BaUL121 183 21.2 UL121 26.3 Rh155 52.0  Serine/alanine-rich 
glycoprotein 
BaUL122 320 35.1 UL122/3 53.4 Rh156 70.3  Immediate early protein 2 
(MIE2) 
BaUL123     rh157    
BaUL124 144 16.8 UL147 28.0 Rh158 42.9   
BaUL125   UL148  Rh159    
BaUL126   UL132  Rh160   BaCMV UL seq 
incomplete 
BaUL127 136 15.6 UL146 30.7 RhUL146 56.1   
BaUL128 99 11.1 UL145 49.5 Rh162 85.9  HCMV Toledo 
BaUL129 177 22.9 UL144 27.3 Rh163 62.0  HCMV Toledo; TNF 
receptor 
BaUL130 443 50.3 UL141 30.6 Rh164 52.8  HCMV Toledo 
BaUL131 193 21.7   rh165 30.8   
BaUL132 193 21.7 UL133  Rh166 39.1   
BaUL133 221 24.0   rh167 38.0   
BaUL134 208 23.0   rh168 26.0   
BaUL135 187 20.7   rh169 40.0   
BaUL136 149 17.1   rh170 34.0   
BaUL137 319 34.6 UL133  Rh171 42.9  Cercopithecine HV5 
SPLF5 glycoprotein; Cys-
rich 
BaUL138 176 20.0   rh172 57.6  Cercopithecine HV5 
SPLF4 glycoprotein; Cys-
rich 
BaUL139 397 42.0   rh173 44.8 RL12 Cercopithecine HV5 
SPLF3 glycoprotein 
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Table 8:  Properties of the BaCMV (OCOM4-37) Genome (continued) 
 










Homologue  % Identity   Homologue   % Identity
 
BaUL141 339 38.4   rh174 32.7  Cercopithecine HV5 
SPLF1 glycoprotein  
BaUL142 185 20.8   rh176 31.4   
BaUL143 204 22.5   rh178 31.9   
BaUS1 699 77.1 TRS1 36.0 Rh230 59.8 US22 Transcriptional 
transactivator; tegument 
protein (AGM SPLF5) 
BaUS2 189 22.3 US32 39.3 Rh226 79.7 US1 (AGM SPLF4) 
BaUS3 171 19.5 US31 32.0 Rh225 50.3 US1 Site-specific DNA 
methylase (AGM SPLF3) 
BaUS4 205    Rh224 51.0  (AGM SPLF2) 
BaUS5 296 33.6 US30 26.8 Rh223 46.9  (AGM SPLF1) 
BaUS6 337 37.9 US29 37.8 Rh221 54.1   
BaUS7 494 55.0 US28.5 42.5 Rh220 66.7 7TM GCR homologue 
BaUS8 359 41.0 US28.1 27.5 Rh218 42.2 7TM GCR homologue 
BaUS9 330 38.1 US28.2  Rh216 63.6 7TM GCR homologue  
BaUS10 330 38.1 US28.3 23.7 Rh215 34.3 7TM GCR homologue 
BaUS11 326 36.1 US28.4 25.5 Rh214 67.8 7TM GCR homologue 
BaUS12 483 55.9 US26 52.0 rh211 71.5 US22 Early nuclear protein; 
tegument protein 
BaUS13 484 56.9 US24 64.5 rh209 80.9 US22  
BaUS14 599 69.8 US23 58.7 Rh204 76.8 US22  
BaUS15 368 42.2 US22 55.4 Rh203 73.9 US22 ICP22 
BaUS16 170 19.3 US21 49.7 Rh202 69.6 US12 Uncharacterized protein 
family, UPF0005 
BaUS17 274 31.4 US20 45.0 Rh201 62.1 US12 Probable transmembrane 
protein 
BaUS18 261 29.5 US19 26.8 Rh200 44.1 US12  
BaUS19 264 29.7 US18 29.8 Rh199 54.9 US12  
BaUS20 264 29.5 US17 34.5 Rh198 68.3 US12  
BaUS21 227 25.9 US14  Rh197 34.6 US12  
BaUS22 270 30.6 US14 29.8 Rh196 56.5 US12  
BaUS23 242 26.9 US14  Rh195 34.3 US12  
BaUS24 277 31.5 US14  Rh194 38.0 US12  
BaUS25 251 28.6 US13 21.5 Rh192 51.8 US12  
BaUS26 248 28.3 US12 34.7 Rh190 70.7 US12  
BaUS27 260 30.3 US11 33.5 Rh189 41.8 US6  
BaUS28 187 20.8 US8 29.5 Rh187 36.4 US6  
BaUS29 209 25.4 N/A  rh186 23.7 US6  
BaUS30 166 18.3 US6 28.3 Rh185 46.5 US6 Functional homologue of 
US6 
BaUS31 190 21.4 US3 21.2 Rh184 35.4 US3 Immediately-early 
glycoprotein 
BaUS32 354 40.8 US2 31.4 Rh182 31.2 US6  
BaUS33 158 18.3 US1 57.0 Rh181 69.5 US1  
BaUS34 129 14.2   rh179 51.2   
Table 8.  Properties of the BaCMV (OCOM4-37) Genome 
 
Most ORFs are numbered based on homology with HCMV genes.  SPLF genes, however, are numbered based on homology with 
AGMCMV.  Shaded areas represent different contiguous sequences.   
Match with UL146 was produced with undesignated Rhesus CMV, accession #AAO40076.   
NS, not significant; aa, amino acids; MW, molecular weight; SPLF, SalI-P fragment near L/S segment junction; GCR, G-protein-
coupled receptor; 7TM, seven-transmembrane; ICP, infected cell protein. 
% Identity is based on amino acid sequence homology. 
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Typically, the genes in herpesviruses are collinear with respect to related 
herpesviruses genomes.  Co-linearity of genomes becomes more prominent within 
herpesvirus subfamilies.  HCMV is in the beta-herpesvirus subfamily, and four different 
genomic isomers form as the DNA replicates.  However, the animal CMVs, which are 
also in the beta-herpesvirus subfamily do not form such isomers and are found in a single 
UL/US conformation.  An unusual feature of the BaCMV OCOM4-37 genome is that the 
US region is inverted relative to the genomes of CCMV and RhCMV.  There are three 
individual BaCMV clones (B127, H589 and N1670) that separately contain the UL/US 
junction (Figure 40).  These clones were individually obtained at different times with 
different REs using genomic BaCMV OCOM4-37 DNA.  The BamHI and Hind III 
clones were made using DNA prepared in 1997, immediately after the virus was isolated.  
The Not I  clone was made using DNA prepared from virus grown in 1998.  Having three 
independent clones that contain the same sequence suggests that this is the correct 
orientation of the viral genome and is unlikely to be an artifact of cloning.  It is possible 
that other isomers also exist in BaCMV, but we have never obtained a clone supportive of 
that. 
Figure 40.  Map of Clones III 589, 1655 and HI 127.  Clone H589 is 8,340 bp, clone 
N1655 is 6,918 bp and clone B127 is 2,997 bp.  Numbers at ends indicate location in unique short 
alignment of the genome.  Rectangular box shows region where the three clones overlap at UL/US 
junction.
Hind  Bam  NotI 
  
DNA prepared 1998 
DNA prepared 1997 
DNA prepared 1997 
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While the BaCMV ORFs are co-linear with the US region of CCMV and 
RhCMV, the entire US is inverted with respect to CCMV and RhCMV (Figure 41).  In  
Figure 41.  Comparison of Four Cytomegalovirus Genomes.  (A) Shows four different isomers that exist 
for HCMV.  Letters A and B designate ends of the UL segment and letters a and b designate ends of US 
segments.  (B) Shows orientation of the chimpanzee (CCMV) and rhesus (RhCMV) genomes. (C) Shows 
orientation of the BaCMV OCOM4-37 genome.  Direction of arrows shows orientation of UL and US
regions.  CCMV, RhCMV and BaCMV genomes are aligned horizontally with respect to the corres-
ponding HCMV isomer.

















(A) HMCV Isomers                                        (B) CCMV and RhCMV Genome Orientation     (C) BaCMV Genome Orientation
UL                     US
A B a b
A B ab
UL                     US
 
the HCMV genome, the sequence where inversion of the UL and US segments occurs is 
the UL/US joint region and is characterized by highly repetitive DNA containing direct 
and inverted repeats.  This is also characteristic of the BaCMV inversion site (Table 9).   
Though similar in this respect, the BaCMV repetitive region is considerable smaller 
(1,354 bp) than it’s counterpart in HCMV (10,277 bp). 









Table 9.  Example of Repetitive Elements in the BaCMV UL/US Region 
A. Individual ORFs: Functional proteins 
1. DNA replication proteins. 
There are six essential replication proteins in HCMV, CCMV and RhCMV that 
are also found in BaCMV, and these are the most conserved genes in all herpesviruses.  
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In HCMV, these proteins are the DNA polymerase (UL54); accessory protein UL44, also 
referred to as the DNA polymerase processivity factor; DNA helicase (UL105); single-
stranded binding protein (UL57); and the helicase-primase components (UL70 and 
UL102) (Appleton et al. 2004).  In HSVI, there is a seventh required protein, the origin 
binding protein, which has not been found in any cytomegalovirus. 
HCMV DNA polymerase enzyme is in the type B polymerase family which 
functions in base excision repair and replication.  The sequence for this gene homologue 
in BaCMV (BaUL67) shares identity with other primate DNA polymerases as follows: 
81.4% with RhCMV, 71.7% with CCMV and 72% with HCMV.   
The gene for the HCMV accessory protein is also found in BaCMV (BaUL57) 
and shares identity with homologous genes of RhCMV (89.5%), CCMV (72.8%) and 
HCMV (73.5%).  In clinical strains of HCMV, the N-terminal 309 aa of this protein are 
essential for binding DNA polymerase (Weiland et al. 1994) and this is where greatest 









Figure 42.  Conservation of the CMV Accessory Protein.  Figure shows the first 110 amino acids 
of the alignment.  Shaded gray areas s how sequence having 100%  identity.  Sequences were
aligned with MegAlign (DNA Star) using ClustalW algorithm.
 
Six conserved motifs are required for proper function of DNA helicase and these 
have been identified in HSV, HCMV & RhCMV; these motifs exist in BaCMV as well 
(Figure 43).  Within cells, DNA helicase is involved in unwinding the DNA double helix 
during replication.  In herpesviruses, DNA helicase (HCMV UL105) interacts with the 
helicase- primase components (HCMV UL70 and UL102) to form a heteromeric complex 
that is required for viral DNA synthesis. 
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Figure 43.  Conservation of the Helicase Protein.  Alignment for the DNA Helicase sequence
of 5 herpesviruses.  AAs enclosed in gray box correspond to motif V.  Note 100% conservation in 
these 19 aas for all cytomegaloviruses represented here and approximately 75% conservation with 
HSV1.  
Additional trans-activating factors seen in HCMV and RhCMV are also found in 
BaCMV.  In HCMV, these proteins include UL36-UL38 (BaUL49, BaUL50, BaUL51, 
BaUL52, BaUL53), TRS1 (BaUS1), IE1 (BaCMV homologue only partially sequenced), 
IE2 (BaUL122), UL84 (BaUL89) and UL112/113 (BaUL113a, BaUL113b) all of which 
are required for transient complementation of ori-Lyt-dependent DNA replication (Pari 
and Anders 1993).  In BaCMV, there are two homologues for each of the HCMV UL36 
and UL37 genes (see Table 8).  HCMV ORFs UL36-UL38, TRS1, IE1 and IE2 are all 
recognized as regulatory proteins.  HCMV UL84 encodes a protein that initiates DNA 
replication from the origin of replication (Sarisky and Hayward 1996) and the major 
protein of UL112/113 (pp43) interacts with IE2 as a co-transcriptional activator of the 
UL54 (DNA polymerase) promoter (Li et al. 1999).  HCMV UL36 and UL37 have been 
characterized as anti-apoptotic proteins which inhibit cell death and thereby promote viral 
replication (Andoniou and Degli-Esposti, 2006).  An origin of lytic replication (ori-lyt) in 
BaCMV has been identified between homologues of the HCMV UL57 and UL69 genes.  
In the large UL contig (Figure 16), this would be located between nucleotides 67,068 to 
69,382.  One feature of the ori-lyt sequence is the Y-block which consists of an 
oligopyrimidine stretch of 31 nucleotides in HCMV AD169 (Huang et al. 1996).  A 
similar stretch of 33 nucleotides is present in BaCMV OCOM4-37.  Additionally, the 
HCMV ori-lyt resides in a complex repetitive region of the genome (Masse et al. 1992) 
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which is also true for the BaCMV ori-lyt site.  As a point of interest, this region of the 
genome has been particularly difficult to sequence in all herpesviruses.  Sequencing the 
ori-lyt region in BaCMV required subcloning fragments as small as 400 bp since 
sequencing attempts on larger fragments often stopped at the ori-lyt site. 
Sequence motifs designated pac1 and pac2 are conserved in herpesviruses.  These 
motifs are typically located about 30-35 bp from each terminus of the genome and are 
believed to function in cleavage of concantemeric viral DNA prior to packaging.  The 
pac1 DNA sequence motif is characterized by an A-rich region flanked by poly-C runs, 
and pac2 is characterized by an A-rich region which is often near a CGCGGCG 
sequence.  For murine cytomegalovirus (MCMV), the pac1 poly-C run was found to be 
critical for cleavage site function while the A-rich region was not; for pac2, the A-rich 
region and a distal CGCGGCG motif were both required (McVoy et al. 1998).   
In BaCMV OCOM4-37, a motif that matches the pac1 site is located between 
196,182 and 196,207 and compares with the HCMV sequence as seen in Figure 44. 
CGGGGGGGTGTTTccgcgGGGGGG (BaCMV)
CGGGGGGGTGTTTttagcGGGGGG (HCMV) 
Figure 44.  Comparison of BaCMV OCOM4-37 and HCMV Sequences.  The A-rich 




This location is not 30-35 bp from the terminus as is seen in HSV-1.  In HCMV Towne, 
both the pac1 and pac2 motifs are in the USc region (see Figure 1 for location).  However 
in HSV-1, pac1 is in the ULb region and pac2 in the USc region  (Kemble and Mocarski 
1989).  This places the pac1 site for the Towne strain between 30912-30935 bp and the 
pac2 site between 226792-226821 bp.  Therefore the proposed site of pac1 in BaCMV is 
comparable to pac1 in RhCMV. 
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The pac2 motif in HCMV is not well-defined since sequences that match the 
criteria for pac2 are not found in the expected orientation to pac1 (McVoy et al. 2000).  
Essentially this means that pac2 elements have not been found on the ends of HCMV 
genomes.  Similarly, a good candidate for a BaCMV pac2 site has not been identified. 
2. Additional Genes Functioning in DNA Replication and Nucleotide Metabolism 
In HCMV, uracil-DNA glycosylase (UL114) is involved in excision repair of 
inappropriate uracil nucleotides.  The homologous gene in BaCMV shares 7l% identity 
with HCMV and 79.8% with RhCMV.  Another HCMV enzyme, dUTPase (UL72) plays 
a role in preventing misincorporation of uracil into DNA during replication (Chen et al. 
2002) and this BaCMV homologue shares 49.1% identity with HCMV and 67.1% with 
RhCMV. 
The HCMV UL45 gene codes for a tegument protein which corresponds to the 
large subunit of ribonucleotide reductase.  Normally, ribonucleotide reductase helps 
regulate dNTP concentrations within the cell, but UL45 lacks a number of catalytic 
residues, so its role is not entirely understood.  Nevertheless, it has been shown to affect 
virus growth at low m.o.i. (Patrone et al. 2003).  The BaCMV homologue to UL45 is 
conserved, having 47.9% identity with HCMV and 73.3% with RhCMV. 
In HCMV, the phosphotransferase gene (UL97) has been shown to function as a 
protein kinase (Chou and Meichsner, 2000; Rawlinson et al. 1997).  The UL97 gene 
product functions in phosphorylation of ganciclovir (one of the few drugs available to 
treat HCMV infections) which is necessary for efficacy of the drug (Michel et al. 1998; 
Sullivan et al. 1992).  HCMV strains that are resistant to ganciclovir contain mutations 
between codons 591-607 of the UL97 gene which impairs phosphorylation and hence 
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sensitivity to the drug (Chou et al. 2002).  The BaCMV gene shares 50.2% identity with 
HCMV and 72.9% with RhCMV.  For the 17-base-pair sequence between codons 591-
607, BaCMV shares 82.4% identity with HCMV AD169.  None of the aa changes in 
HCMV leading to ganciclovir resistance were present in the collinear region in BaCMV.  
This would follow since drug resistance is usually seen in strains of virus exposed to the 
drug, and administration of ganciclovir would be more common in human than in baboon 
CMV infections. 
Finally, the HCMV pyruvoyl decarboxylase (UL77) has a putative role in 
polyamine biosynthesis (Yoakum 1993) and the BaCMV homologue shares 70.3% 
identity with HCMV and 80.4% with RhCMV. 
B. ORFs That Encode Regulatory Genes. 
HCMV ORFs that regulate viral gene expression include the major immediate-
early exon UL122-UL123 (BaUL122), UL36-UL38 (BaUL49-BaUL53), TRS1 (BaUS1), 
UL69 (BaUL73) and US3 (BaUS31).  BaCMV homologues exist for each of these genes.  
In HCMV, the TRS1 transcript works in conjunction with the IRS1 transcript to 
transactivate UL44 and other genes (Stasiak and Mocarski 1992) and also plays a role in 
evasion of antiviral host cell responses (Child et al. 2004). 
C. ORFs That Encode Structural Proteins. 
Betaherpesvirus genomes code for a variety of capsid and tegument proteins and 
also viral glycoproteins.  When compared with the HCMV AD169 prototype genome, the 
BaCMV genome possesses homologues for the majority of these genes.   
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Capsid gene homologues include the major capsid protein, UL86 (BaUL92), 
minor capsid binding protein UL46 (BaUL59) (Gibson et al. 1996) and minor capsid 
protein, UL85 (BaUL91).   
There are also a number of HCMV tegument protein homologs that have been 








UL31 BaUL44  Nuclear egress (Davison et al. 
2003b) 




 Maintains structural integrity (Zhou et al. 1999) 
UL37 BaUL53  Interacts with UL36 and likely comprises 
second layer of the integument 
(Klupp et al. 2002) 
UL47 BaUL60  Unpackaging and transport of capsids to 
nuclear pore 
(Hyun et al. 1999) 
UL48 BaUL61 pp212 Complexed with tegument protein UL37; 
ubiquitin-specific protease (N-terminal 
region); involved in capsid transport    
(Ogawa-Goto et al. 
2002) 
UL65      ---  Protein kinase (Chee et al. 1990) 
UL80 BaUL85  Capsid assembly protein (Nguyen et al. 2008) 
UL82 BaUL86 pp71 Upper matrix protein; IE gene transactivator (Ruger et al. 1987) 
UL83 BaUL87 pp65 Lower matrix protein; protein kinase (Nowak et al. 1984a)  
UL99 BaUL106 pp28 Required for trafficking  (Jones and Lee, 
2004) 
Table 10. HCMV Cytomegalovirus Tegument Proteins and BaCMV Homologues 
important for intracellular transport of virions (Ogawa-Goto et al. 2002).  Second, the 
UL80 capsid assembly protein (BaUL85) transports the major capsid protein into the 
nucleus (Nguyen et al. 2008).  Third, UL82 (BaUL86) the upper matrix protein pp71 
functions as a transcriptional activator (Liu and Stinski 1992).  Fourth, UL83 (BaUL87) 
is the lower matrix protein pp65 and a transactivator of IE gene expression (Preston and 
Nicholl, 2005) and disruption of the MHC class I antigen presentation pathway 
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(Trgovcich et al. 2006).  Fifth, UL32 (BaUL45) the large phosphoprotein pp150 that is 
critical for virion egress, possibly at the stage of final envelopment (AuCoin et al. 2006).  
Sixth, UL99 (BaUL106) the small phosphoprotein pp28 that plays a role in the assembly 
(Sanchez et al. 2000) and cytoplasmic envelopment (Seo and Britt 2007) of the virion.  
And finally, UL56 (BaUL69) is a transport protein which is likely involved in cleavage 
and packaging of the capsid (Bogner et al. 1998).  Clearly, there are a number of HCMV 
tegument genes for which homologs exist in the BaCMV genome.  See Table 8 for 
conservation information between BaCMV and HCMV. 
There are genes for various glycoproteins in all primate CMVs that are also 
present in the BaCMV genome.  GenBank searches identified the following HCMV 
glycoproteins that are also found in both RhCMV and BaCMV (Table 11).  
Glycoprotein HCMV BaCMV RhCMV BaCMV Conservation 
--- UL37 BaUL53 Rh66 57.1% with RhCMV 
--- UL42 BaUL55 Rh68 53.5% with RhCMV 
gB UL55 BaUL68 Rh89 53.5% with RhCMV 
gN UL73 BaUL78 Rh102 41.4% with RhCMV 
gO UL74 BaUL79 Rh103 59.5% with RhCMV 
gH UL75/ BaUL80 Rh104 81.3% with RhCMV 
gM UL100 BaUL107 Rh138 70.8% with RhCMV 
gL UL115 BaUL115 Rh147 75.0% with RhCMV 
--- UL116 BaUL116 Rh148 43.2% with RhCMV 
--- UL121 BaUL121 Rh155 52.0% with RhCMV 
--- US02 BaUS32 Rh182 31.4% with HCMV 
IE US03 BaUS31 Rh184 35.4% with RhCMV 
--- US11 BaUS27 Rh189 41.8% with RhCMV 
Table 11.  Homology of HCMV, RhCMV and BaCMV Glycoproteins   
Comparison of predicted aa identity in ORFs from these three primates shows BaCMV glycoproteins 
usually share strongest conservation with RhCMV glycoproteins. 
Not surprisingly, the HCMV glycoproteins lacking homologs in RhCMV (gpUL04, 
gpUL16 and gpUS10) are absent in BaCMV as well.  
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Glycoprotein B is an important envelope glycoprotein in that it acts as both a 
ligand and fusion protein, and it is critical for viral entry and cell-to-cell spread (Singh 
and Compton 2000).  Furin protease cleaves proteins at a specific recognition motif, 
RXK/RR (Hosaka et al. 1991).  Typically, gB homologs contain this motif since the gB 
protein undergoes proteolytic processing possibly using cellular furin protease or a 
similar enzyme.  This recognition cleavage site is found in a number of alpha-
herpesviruses and virtually all known beta-herpesviruses.  The furin protease cleavage 
site is located between aa 451-454 in the BaCMV UL55 protein (Figure 45).  This aa 
sequence is RTKR which aligns directly with the HCMV RTRR cleavage site.  The K to 
R aa alteration is a conservative change since both aa are basic and share similar 
properties.  Overall homology of BaCMV gB with HCMV is 56.8% and 73.5% with 
RhCMV. 
Figure 45.  Alignment of Glycoprotein B.  Black bar shows furin protease cleavage site 
for human, rhesus and baboon cytomegalovirus genes.  This corresponds (in this align- 
ment) to amino acids 456-459 for HCMV, 456-459 for CCMV, 370-373 for RhCMV and 
451-454 for BaCMV.  
Three glycoproteins, gH/gL/gO, form a tripartate complex linked to membrane 
fusion, cell-to-cell spread and virion maturation in HCMV (Huber and Compton 1998; 
Theiler and Compton 2001).  For the BaCMV glycoprotein H homologue, identity is 
shared at 48.9% with HCMV (UL75) and 64.7% with RhCMV.  The BaCMV homologue 
for HCMV glycoprotein L (UL115) has two presumed N-glycosylation sites (NXS/T 
with X being any residue) between aa 21-24 and 57-60 (Figure 46). 
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Figure 46.  Alignment Showing Homology of Glycoprotein L.  This figures shows the align- 
ment of HCMV, CCMV, RhCMV and BaCMV sequences for glycoprotein L (UL115).  The 
gray shading shows the two N-glycosylation (NXS/T) sites found in both RhCMV and BaCMV.
 
RhCMV gL also has two glycosylation sites, so it shares greater homology with 
the BaCMV glycoprotein than that of HCMV which only has one.  This BaCMV aa 
sequence shares 47.1% identity with HCMV and 67.7% with RhCMV.  In the low-
passaged HCMV clinical strain TR, gO has been shown to act as a chaperone protein that 
promotes incorporation of gH/gL into virions without being present therein itself 
(Ryckman et al. 2009).   
In HCMV, glycoproteins gM and gN are joined by a disulfide bond to form a 
complex which is transported to the viral assembly compartment (Mach et al. 2005).  The 
cytoplasmic portion of glycoprotein gM contains trafficking signals (which certainly play 
a role in transport) needed for viral assembly and replication.  One of the trafficking 
motifs consist of a tyrosine-based motif (YXXL) and the other is a cluster of 12 acidic aa 
(EEEDDDDDEDFED) (Krzyzaniak et al. 2007).  The tyrosine motif is found in both 
RhCMV and BaCMV, but the acidic aa clusters are very different from that of HCMV.  
The BaCMV gM only contains only 5 acidic aa residues and the RhCMV genome only 
contains 3.  The significance of this difference is uncertain.  The BaCMV counterpart of 
gM shares 54.9% identity with HCMV gM and 70.8 % with RhCMV gM.  For 
glycoprotein gN, modification of the C-terminus by palmitic acid is required for the 
protein to function in secondary envelopment and replication of HCMV (Mach et al. 
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2007).  The BaCMV homologue of glycoprotein gN is 27 aa shorter than HCMV and 
RhCMV but still shares 26.3% identity with HCMV and 52.6% with RhCMV. 
Glycoprotein gO (UL74) homologs are found in beta-herpesviruses but not other 
herpesviruses (Huber and Compton 1998).  Comparison of glycoprotein gO homologs 
show they each contain a single hydrophobic domain that functions as a cleavable signal 
peptide as in HCMV UL74 (Theiler and Compton 2001).  This domain is located at the 
N-terminus and spans aa 14-34 in HCMV, 5-20 in RhCMV and 6-19 in BaCMV (Figure 
47A).  Also, as seen in other CMVs, the BaCMV gO sequence has a number of N- and 
O-linked glycosylation sites as would be expected in an envelope glycoprotein.  Also, the 
BaCMV UL74 gene product contains a bipartite NLS, RKQKPERSA-QKTKKR (Figure 
47B), 
Figure 47.  Alignment Showing Homology of Glycoprotein O.  A. Locations of 
hydrophobic cleavable signal peptide sequences are shown in gray boxes.  B. Shows 
a  bi-partite nuclear localization signal.
 
located between aa 252 and 267.  BaCMV shares 35.6 % aa sequence identity with 
HCMV and 59.5% with RhCMV. 
D. Immunomodulatory Proteins. 
There are 13 reported immunomodulatory proteins found in HCMV that are also 
present in BaCMV OCOM4-37.  Of the 13, several share considerable identity with 
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HCMV homologs including BaUL112 (UL111), BaUL129 (UL144), BaUS32 (US2), 
BaUS31, (US3) and BaUS27 (US11).  Functions of HCMV UL111 and UL144 are well 
characterized and discussed below.   
Immunomodulatory proteins that show high identity with RhCMV homologs, but 
somewhat lower identity with HCMV, include UL36, UL37 and the UL118/119 spliced 
transcript.  The HCMV UL36 gene acts as a cell death suppressor, designated vICA 
(Skaletskaya et al. 2001).  Cell death suppression is probably an anti-apoptotic event 
necessary to avoid immune clearance of virally-infected cells by cytotoxic T or natural 
killer cells.  There are two homologs in BaCMV (BaUL49 and BaUL50) for the HCMV 
UL36 gene.  These two homologs may actually require formation of a spliced transcript 
to be functional.  The product of the HCMV gene UL37 plays a similar role during 
infection as it encodes an inhibitor of apoptosis, denoted vMIA, which operates by a 
different mode of action than vICA (Goldmacher et al. 1999).   
For the HCMV UL37 gene, there are also two homologs in BaCMV; BaUL51 and 
BaUL53.  Duplicate transcripts for the HCMV UL37 gene are seen in RhCMV as well 
(Rh62 and Rh66).  The HCMV large spliced transcript, UL118/119 shares good identity 
with BaUL118 and BaUL119.  In HCMV, these spliced transcripts are known to encode a 
Fcγ receptor homolog, vFcγR (Atalay et al. 2002).  Other viruses that have similar Fc-
binding capacity are able to block antiviral activities such as complement activation or 
ADCC, both of which are mediated by the Fc domain of IgG (Dubin et al. 1991),  
BaUS29 shows identity with the HCMV US6 family of genes; however, no HCMV 
homologue has been identified.  BLAST analysis also identified BaUL112 as an 
interleukin-10 (IL-10) homologue that shares good identity with the RhCMV Rh143 
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counterpart, but identity with the HCMV UL111 IL-10 sequence is much lower.  In 
RhCMV, the IL-10 gene has been expressed in tissue culture and also in RhCMV-
infected rhesus macaques.  Based on conservation of this gene in primates, it is 
hypothesized to play a role in primate CMV persistence and pathogenesis  (Lockridge et 
al. 2000).  The BaUL129 gene is homologous with the HCMV Toledo strain tumor 
necrosis factor receptor (TNFR) gene, UL144.  This gene product may be involved in 
preventing apoptosis of virally-infected cells.  HCMV UL144 activates NF-κB (nuclear 
factor kappa B) at early times of infection and induces expression of CCL22.  NF-κB 
exhibits anti-apoptotic activity (De Smaele et al. 2001) and CCL22 (chemokine ligand 
22) is a TH2 chemo-attractant which inhibits the TH1 immune response (Nakayama et al. 
2004).  Four HCMV genes that function in downregulation of major histocompatibility 
complex class 1 (MHC1) molecules are US2, US3, US8 and US11.  The BaCMV 
homologues of these genes are BaUS32, BaUS31, BaUS30, and BaUS27 respectively. 
An additional immunomodulatory protein sequence found in BaCMV (gene 
BaUL14) is a homologue of the primate COX-2 protein.  In RhCMV, there are six exons 
designated for the COX-2 gene and it is proposed these are spliced transcripts.  Analysis 
of the BaCMV genome revealed all six exons for the COX-2 gene and showed that each 
of these were collinear with the RhCMV sequence.  However, the primate COX-2 
sequence that is most identical to that of the BaCMV sequence was from the 
Cercopithecine herpesvirus strain Colburn (Figure 48).  The BaCMV vCOX-2 gene 
shows good identity with the human COX-2 aa sequence (about 55%) and with the 
RhCMV aa sequence (about 66%).  
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Identities = 20/33 (60%), Positives = 23/33 (69%), Gaps = 0/33 (0%) 
Frame = +1/-2 
 
BaUL14  211   AFSNLSYYTITPFLVPRDRLNPFGVKGE*TSLA  309 
              AFSNLSYYT T   VPRD   P GVKG+ + +A 
COX-2  10552  AFSNLSYYTRTLPPVPRDCPTPLGVKGDSSPIA  10454 
 
Identities = 13/20 (65%), Positives = 14/20 (70%), Gaps = 0/20 (0%) 
Frame = +3/-1 
 
BaUL14  363   YQVRRYCLIRHRLWKKLFLG  422 
              +QVRR C IRHRLW K   G 
COX-2  10397  HQVRRVCPIRHRLWTKFLFG  10338
 
Identities = 94/118 (79%), Positives = 104/118 (88%), Gaps = 0/118 (0%) 
Frame = +2/-1 
 
BaUL14  482   LSVLPLHHQVVLGHIYGETLEKQHQLRLFKDGKMKYQIIDGEVYPPTVKEAQVHMVYEPS  661 
              LS + +  QV L HIYGETLEKQH+LRLFKDGKMKYQ+IDGE+YPPTVKE QVHM+Y P  
COX-2  10160  LSTVFVLSQVDLSHIYGETLEKQHKLRLFKDGKMKYQVIDGEMYPPTVKETQVHMLYAPE  9981 
 
BaUL14  662   VPEKLRFALGNEMFGLVPGLMVYAIIWLREHNRVCDVLKQEHPEWNDEQLFQITRLII  835 
              VP+ LRFA+GNE+FGLVPGLM+YA IWLREHNRVCDVLK EHPEW DEQLFQ TRLII  9807 
 
Identities = 36/63 (57%), Positives = 43/63 (68%), Gaps = 0/63 (0%) 
Frame = +2/-1 
 
BaUL14 929   SRGKRIPPALKDTSREASEQAPKKRYRSLNEYKKRFGFKSHKLLNELTGNTVLQFSYHFT  1108 
             S G+ IPPAL+   RE  E   K RY+SLNEY+KRF  K ++   ELTGNT   FSY+FT 
COX-2  9512  SGGRNIPPALRRVFREGIEHGRKMRYQSLNEYRKRFRLKPYESFEELTGNTTFGFSYNFT  9333 
 
BaUL14 1109  HFF  1117 
             HFF 
COX-2  9332  HFF  9324 
 
Identities = 76/111 (68%), Positives = 87/111 (78%), Gaps = 0/111 (0%) 
Frame = +3/-1 
 
BaUL14  1185  KEIAVELEAFYGDIEAVELYAGFLAEKPCPDAILDEGVLEPGAPFSLRGLAANVICSPGY  1364 
             KEIA  LEA YGD+EAVELY GF+ EKP P AI  E ++E GAPFSL+GL ANVICSP Y 
COX-2  9248  KEIAAGLEALYGDVEAVELYTGFIVEKPRPGAIFGESIMELGAPFSLKGLMANVICSPAY  9069 
 
BaUL14 1365  WKRNTVGSSAGFNIVRSATIQSLICSNVKGCPLAAFRAPNKELMTALNGSS  1517 
             WK +T G   G +IV++ATIQSLIC+NVKGCPLAAFR  N EL+ A NGSS 
COX-2  9068  WKPSTFGGDVGLDIVKTATIQSLICANVKGCPLAAFRVSNAELLKAFNGSS  8916 
 
Identities = 23/56 (41%), Positives = 37/56 (66%), Gaps = 0/56 (0%) 
Frame = +2/-3 
 
BaUL14 1649  TLHIAIQGHGVYVRQPLERTAAVIIAEFMINT*VQEIQQYG*DNHSGREGRSDNKQ  1816 
             +L + +  +GV+V Q LE TAAVIIA+F++   V E+Q YG +N + R    ++K+ 
COX-2  8829  SLGLNVNRYGVFVGQSLEGTAAVIIAKFLVRVQVYEVQCYGQNNTNSR*HCGEDKE  8662 
Figure 48.  Six Exons for the BaCMV Homologues of SCMV Coburn COX-2 Gene  
Identities are percent identical match between aa, positives include conserved changes 
and gaps are missing aa.  Frame indicates which reading frame the sequence is located 
within.  Data acquired from BLASTX (Basic Local Alignment Search Tool), at NCBI 
(National Center for Biotechnology Information) website. 
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E. Gene Families Found in BaCMV. 
Gene families are groups of genes sharing sequence homology and usually cluster 
together.  The proteins encoded by these genes may also have similar biochemical 
functions.  Gene families are often conserved across different species.  There are eight 
different gene families in HCMV that are also present in BaCMV, as shown in Table 12. 
BaCMV gene family members Characteristics of family* HCMV family  References  
BaUL5, BaUL20 - BaUL29 Genome location, structure, 
glycosylation sites 
RL11 (Chee et al. 1990) 
BaUL39 and BaUL48 Genome location, structure UL25 (Rawlinson et al. 
1996) 
BaUL46, BaUL83, BaUS7 – 
BaUS11 
GPCR motif; 7TM domains, S-
T-rich carboxy terminus 
7TM (Vischer et al. 
2006) 
BaUL86 – BaUL88 Genome location, structure, 
phosphoprotein 
UL82  
BaUS2, BaUS3, BaUS33 Genome location, structure US1  
BaUS27 – US 32 Genome location, structure, 
function 
US6 (Jones and 
Muzithras 1991) 
BaUS16 – BaUS26 Genome location, structure, 
7TM domains 
US12 (Lesniewski et al. 
2006) 
BaUL37, BaUL38, BaUL42, 
BaUL43, BaUL49, BaUL50, 
BaUL56, BaUS1, BaUS13 – 
BaUS15 
Two stretches of hydrophobicity, 
C-terminal acidic residues 
US22 (Chee et al. 1990) 
Table 12.  BaCMV Gene Family Members and Homologous HCMV Gene Families 
*GPCR, G-protein coupled receptor; 7TM, seven-transmembrane. 
 
1. RL11 family. 
The HCMV RL11 family consists of 9 genes (UL1, and UL4 - UL11) and they 
are most likely involved in producing membrane glycoproteins (Davison et al. 2003a).  
BaCMV homologs have been identified for some of these HCMV genes including 
BaUL5 (UL153), BaUL20 (UL4), BaUL21 (UL6), BaUL25 (UL9), BaUL23, BaUL24, 
BaUL28 and BaUL29 (four homologues of UL11) and BaUL22 (matches Rh21).  None 
 136
of these genes are required for growth in cell culture (Mocarski and Kemble 1996) and 
yet portions of these genes are fairly well-conserved in beta-herpesviruses (Hansen et al. 
2003). 
2. UL25 Family. 
The HCMV UL25 gene encodes a tegument phosphoprotein (Battista et al. 1999) 
and UL35 encodes two proteins, one of which localizes to the nucleus while the other is 
packaged in the viral particle (Liu and Biegalke 2002).  There are only two BaCMV 
genes that belong to the UL25 family.  These are genes BaUL39 (UL25) and BaUL48 
(UL 35), both of which share significant identity with the HCMV and RhCMV 
homologs. 
3. Seven–Transmembrane Family. 
Proteins in this family are so-named because they contain seven membrane-
spanning domains.  In HCMV, there are four of these: US27, US28, UL33 and UL78.  
The best characterized, US28, has been shown to act as a G-protein coupled receptor 
(GPCR) in arterial smooth muscle cells (Streblow et al. 2003).  BaCMV shares identity 
with the same HCMV 7-TM genes that RhCMV does, namely, UL33, UL78, and US28 
(Penfold et al. 2003).  In BaCMV, the homologs of the four RhCMV 7TM genes are 
BaUS10, BaUS9, BaUS8, and BaUS6 (which correspond to Rh214, Rh215, Rh216 and 
Rh220 respectively).  As is seen in RhCMV, BaCMV has no counterpart to the HCMV 
US27 7-TM protein. 
4. UL82 Family. 
This family of HCMV proteins includes the upper matrix protein, [pp71 (UL82)], 
the lower matrix protein [pp65 (UL83)], and UL84.  There is a single homologue for 
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UL82 in BaCMV (BaUL88) and two copies of the UL83 homologue (BaUL89 and 
BaUL90).  This is analogous with the RhCMV genome which also has two copies of a 
UL83 homologue (Rh111 and Rh112; Figure 49).  These genes probably arose by tandem 
duplication and encode a 71,000 mw tegument phosphoprotein (pp71) and a 65,000 mw 
tegument phosphoprotein (pp65) respectively.  In HCMV, UL82 (pp71) has been shown 
 
BaCMV OCOM4-37
Figure 49.  UL82 Gene Family from three 
indicated by wide arrows.  The size of the encoded protein is shown below each orf.  Based on 
the HCMV AD169 (X17403), and the RhCMV 68-1 (AF411695)  genomic sequences. 
RhCMV and BaCMV orfs are shown in brackets.
Primate CMVs. The orfs are drawn to scale and 
532 aa
HCMV AD169
UL82 (pp71) UL83 (pp65) UL84
559 aa 561 aa 586 aa
553 aa 525 aa 467 aa
RhCMV 68-1
530 aa 472 aa 542 aa 512 aa
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to localize to the nucleus immediately PI (Shen et al. 2008), disrupt the MHCI antigen 
presentation pathway (Trgovcich et al. 2006), and accelerate the progression of cells 
through the G1 phase of the cell cycle (Kalejta et al. 2003).  Furthermore, this gene has 
been observed to interact with the cellular protein, hDaxx, to regulate IE gene expression 
and viral replication (Cantrell and Bresnahan, 2005; 2006).  The HCMV UL83 protein 
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product (pp65) is also transported to the nucleus early after infection, correlates with 
virus associated protein kinase activity, is dispensable for growth in cell culture and is 
required for incorporation of other viral proteins into the viral particle (Chevillotte et al. 
2009; Gallina et al. 1996; 1999; Schmolke et al. 1995a; Schmolke et al. 1995b; Yao et al. 
2001).  NLSs are a necessary component of HCMV tegument proteins (like pp65) that 
are translocated into the nucleus following penetration.  Figure 50 shows three sites 
where NLSs in HCMV align with homologous protein sequences in RhCMV and 
BaCMV.  In addition to some of the previously described characteristics, pp65 has been 
observed to elicit a humoral immune response in lupus patients and autoimmune-prone 
mice (Chang et al. 2006) and to inhibit antiviral gene expression in virally-infected 
human fibroblast cells (Browne and Shenk, 2003). 
When the predicted aa sequence of the UL82 family genes are examined, BaCMV 
is more closely related to RhCMV.  The BaCMV UL82 orf shares 37.2% aa sequence 
identity with HCMV UL82 and 59.6% with Rh110.  BaCMV UL83a and UL83b share 
32.7% and 38.9% identity, respectively, with the HCMV counterpart and 39.2% with 
each other.  Identity with BaCMV UL83a and Rh111 is 47.9% and with BaCMV UL83b 
and Rh112 is 51.2%. 
5. US01 Family. 
HCMV has three members in this family (US1, US31 and US32) and BaCMV has 
homologs for each of these (BaUS33, BaUS3 and BaUS2).  The BaCMV genes are 
colinear with the homologous genes of both HCMV and RhCMV (Rh181, Rh225 and and 
Rh226) and share significant identity with them. 
 139
 
HCMV AD169     ELVTTERKTPRVTGGGAMAGASTSAGR RKSASSATACT
HCMV Towne     ELVTTERKTPRVTGGGAMAGASTSAGR RKSASSATACT
BaCMV OCOM4-37 EAEYSR-----PSRSGRRRP--PP---KRR--------T
RhCMV 68-1     EVFRHP-----PSGSSARRPSQPPASSSRKPSSSAASST
K
K
HCMV AD169     MLNIPSINVHHYPSAAERKHRHLPVADAV
HCMV Towne     MLNIPSINVHHYPSAAERKHRHLPVADAV
BaCMV OCOM4-37 PVSIPQLVLQRG----ENRKHRLPVADAV
RhCMV 68-1     PVTPPELILRQG----ESHKRRTTVADAV
HCMV AD169      PAAQPKRRRHRQ------DALPGPCIASTPKKHRG
HCMV Towne      PAAQPKRRRHRQ------DALPGPCIASTPKKHRG
BaCMV OCOM4-37  PYQSQRRRRHTRSESAAAAPSQAPYIGSVSKKHRS





A     Site 1   (120-148)
B     Site 2   (409-447)
C     Site 3   (533-561)
Figure 50. HCMV Nuclear Localization Signals in UL83 (pp65). The 
UL83, B83b and R83b of   
aligned using CLUSTALW and relevant regions extracted. The location of each site in the 
HCMV AD169 UL83 protein sequence is indicated in parentheses. Charged residues important 
in HCMV UL83 (pp65) are boxed. The boldface lysine residue in part B is amino acid 436, 
essential for protein kinase activity of HCMV UL83 (pp65). 
sequences from HCMV, BaCMV and RhCMV respectively were
predicted protein 
 
6. US06 Family. 
Most of the HCMV US06 family members (US2, US3 and US6 – US11) encode 
glycoproteins which are structurally and functionally analogous.  Five ORFs in BaCMV 
belong to the US06 family: BaUS2, BaUS3, BaUS6, BaUS8 and BaUS11.  In HCMV, 
US6 has been shown to elicit downregulation of MHC class I molecules through 
inhibition of the cellular transporter associated with antigen processing (Dugan and 
Hewitt 2008; Jun et al. 2000).  Another HCMV US06 family protein (US2) facilitates 
degradation of MHC class I heavy chains through utilization of chaperone proteins 
(Oresic and Tortorella 2008).  HCMV US3 and US8 have both been shown to transiently 
bind MHCI molecules (Gruhler et al. 2000; Tirabassi and Ploegh 2002).  HCMV US11 
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reportedly diverts MHCI molecules in mouse embryonic fibroblasts from the ER to the 
cytosol where MHCI degradation ensues (Tirosh et al. 2005).  Although it is customary to 
include the HCMV genes US2 and US3 in the US02 gene family, the homologous 
BaCMV genes are more similar to those of the HCMV US06 family so they are included 
here. 
7. US12 Family. 
The HCMV US12 family consists of 10 tandemly-arranged genes spanning the 
range from US12 to US21.  All proteins in the HCMV US12 family are putative seven-
transmembrane domain proteins that are related to G-coupled receptors (Lesniewski et al. 
2006) and some are proposed to play a role in virion maturation and egress based on their 
association with the viral assembly compartment (Das and Pellett, 2007).  Analysis of the 
BaCMV US region revealed the same 11 genes that are found in RhCMV for this family.  
Four of these are duplicates of the HCMV US14 ORF.  The remaining seven share 
homology with the following HCMV genes: US12 (BaUS26), US13 (BaUS25), US17 
(BaUS20), US18 (BaUS19), US19 (BaUS18), US20 (BaUS17) and US21 (BaUS16).   
8. US22 Family. 
Proteins of the HCMV US22 family have two stretches of hydrophobic and 
charged residues and as many as four conserved motifs that are common to                
beta-herpesviruses.  The functions of most members of this gene family are unknown, but 
two MCMV homologs of the HCMV US22 family (m140 and m141) have been shown to 
affect MCMV replication in macrophages (Hanson et al. 2009; Menard et al. 2003).  In 
HCMV, there are at least two proteins in the UL22 family for which functions have been 
established in vitro.  These include the HCMV UL23 protein product which acts as a 
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temperance (or repressing) factor for HCMV replication in HFF cells (Dunn et al. 2003).  
The other is theTRS1 protein which is able to counteract host cell antiviral responses 
(Child et al. 2004).  In BaCMV there are 10 ORFs that share homology with both HCMV 
and RhCMV genes.  These include BaUL37, BaUL38, BaUL42, BaUL43, BaUL49, 
BaUL50, BaUL56, BaUS1, BaUS14 and BaUS15.  They are expected to share similar 
function, whatever that function may be. 
F. Phylogenetic Review. 
Analysis of the phylogenetic relationship between BaCMV and other 
herpesviruses is presented in Figures 51 and 52.  Alignments of the predicted aa 
sequences from six ORFs that are conserved in herpesviruses were performed using 
CLUSTALW and then used to construct phylogenetic trees (Figures 51 and 52).  These 
ORFs were BaUL67 (DNA polymerase), BaUL68 (glycoprotein B), BaUL75 (helicase), 
BaUL91 (major capsid protein), BaUL70 (single-stranded binding protein), and 
BaUL114 (uracil N-glycosylase) gene sequences.  Herpesviruses included in these 
analyses were HCMV, RhCMV, CCMV, RatCMV, MCMV, KSHV and HSV-1.  Using 
these eight strains provided comparison between alpha-, beta- and gamma-herpesvirus 
families.  These strains were chosen for comparison because they have completely-
sequenced genomes.  Trees were rooted at the mid-point between the two most divergent 
operational taxonomic units (i.e. alpha-herpesvirus HSV-1 and gamma-herpesvirus 
KSHV).  All of these trees indicate that the most closely-related virus to BaCMV is 
RhCMV.  The next closest relation is CCMV, followed by HCMV, MCMV, RCMV, 
KSHV and HSV-1 respectively.  The drill monkey CMV (DrCMV) is actually more-
closely related to BaCMV than any of the eight strains used for comparison (Blewett et 
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al. 2003).  Unfortunately very little sequence data exists for DrCMV so it was not 
included in the trees.  However, when the aa sequences that are available for DrCMV 
were compared with three primate herpesviruses (RhCMV, BaCMV and HCMV) then 








Figure 51.  Phylogenetic Relationships for DNA Polymerase, Glycoprotein B and Helicase Proteins.  The 
evolutionary history was inferred using the Neighbor-Joining method (Saitou and Nei 1987).  The optimal 
tree is shown.  The percentage of replicate trees in which the associated taxa clustered together in the 
bootstrap test (500 replicates) are shown next to the branches (Felsenstein 1985).  The tree is drawn to 
scale, with branch lengths in the same units as those of the evolutionary distances used to infer the 
phylogenetic tree.  The evolutionary distances were computed using the Poisson correction method 
(Zuckerkandl 1965) and are in the units of the number of amino acid substitutions per site.  All positions 
containing gaps and missing data were eliminated from the dataset.  Phylogenetic analyses were conducted 
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Figure 52.  Phylogenetic Relationships for the Major Capsid Protein, Single-Stranded Binding Protein and 
Uracil-N Glycosylase.  The evolutionary history was inferred using the Neighbor-Joining method (Saitou 
and Nei 1987).  The optimal tree is shown.  The percentage of replicate trees in which the associated taxa 
clustered together in the bootstrap test (500 replicates) are shown next to the branches (Felsenstein 1985).  
The tree is drawn to scale, with branch lengths in the same units as those of the evolutionary distances used 
to infer the phylogenetic tree.  The evolutionary distances were computed using the Poisson correction 
method (Zuckerkandl 1965) and are in the units of the number of amino acid substitutions per site.  All 
positions containing gaps and missing data were eliminated from the dataset.  Phylogenetic analyses were 









Over 217,000 bp of the BaCMV OCOM4-37 genome were sequenced.  The 
genome is projected to contain between 221,000 and 229,000 bp and to potentially 
encode over 170 proteins.  Homologues of genes found in other herpesviruses have been 
identified in BaCMV within the UL and US sequences.  There is considerable homology 
between the BaCMV ORFs and those of other animal CMVs.  In most respects, the 
BaCMV genome is more similar to RhCMV than to either HCMV or CCMV.  Some 
general similarities between the RhCMV and BaCMV genomes are (1) a lack of 
extensive repeats between the UL and US regions, (2) genes that are homologous to those 
found in clinical strains of HCMV but not the prototype strain AD169, and (3) 
duplications of the UL83 gene.  One difference between the BaCMV genome and those 
of other sequenced animal CMVs is that the entire US region is inverted. 
BLAST searches were conducted using BaCMV ORFs, and those matching 
published CMV genes were considered authentic.  Highest matches were with either 
RhCMV or, in a few instances, African green monkey CMV genes.  The next highest 
matches were with genes from CCMV and then HCMV.  The overall G+C content for 
HCMV is 57% as compared to 49% for RhCMV.  For the part of the BaCMV genome 





G+C content is 48%.  As expected, this number is more similar to the RhCMV G+C ratio 
than HCMV. 
Sequence analysis of the BaCMV genome showed that partially-sequenced 
homologues of HCMV IE genes are present in BaCMV.  These include IE2, UL36 – 
UL38, US3, TRS1, and a portion of IE1.  The BaCMV IE1 gene sequence is incomplete 
because it has not been completely sequenced.  In HCMV, the IE proteins are produced 
very early in the infection cycle and function as regulatory proteins, and so are likely to 
do so in BaCMV as well (Colberg-Poley, 1996; Colberg-Poley et al. 1992).  A common 
feature seen both in BaCMV and RhCMV is duplication of the HCMV UL37 gene 
homologue.   
There are additional BaCMV genes that show identity with HCMV gene 
sequences and may function as regulatory proteins.  One of these is BaUL121 which 
shares 26% identity with HCMV UL121 and 52 % identity with Rh155.  In BaCMV, this 
sequence contains a highly-charged region at the C-terminus between aa 167 - 184.  This 
charged terminus is characteristic of some trans-acting transcriptional activators, and 
may indicate a regulatory role for this gene.  Another HCMV transactivator (UL69) 
shares 43% identity with BaUL73 homologue while the Rh97 gene shares 58% identity 
with BaUL73.  The UL69 gene in HCMV is homologous to the HSV IE ICP27 gene 
which is essential for transition from E to L gene expression (Winkler et al. 1994).  In 
summary, all HCMV regulatory and transactivator proteins found in BaCMV are well-
conserved when compared with both HCMV and RhCMV genes.   
Genes that code for enzymes in HCMV are also found in BaCMV.  The gene 





to GenBank (accession #AAK71288).  The BaUL105 ORF is the homologue of HCMV 
UL97, which exhibits protein kinase activity.  UL97 mediates phosphorylation events 
during DNA replication, capsid maturation, nuclear egress, and cytoplasmic assembly 
(Azzeh et al. 2006; Krosky et al. 2003).  Additionally, the UL97 protein phosphorylates, 
and thereby activates, the antiviral drug ganciclovir (Littler et al. 1992).  In many 
herpesviruses, prodrug phosphorylation is accomplished by the enzyme thymidine kinase.  
However in HCMV and other CMVs (including BaCMV) a thymidine kinase gene has 
not been identified.  Other important ORFs found in BaCMV are homologs for HCMV 
DNA helicase-primase (UL70) and two DNA repair enzymes, dUTPase (UL72) and 
DNase (UL98).  Each of these genes is well-conserved among HCMV, RhCMV and 
BaCMV sequences (see Table 6).  The HCMV UL77 gene codes for the pyruvoyl 
decarboxylase enzyme which is involved in cellular polyamine synthesis (Yoakum 1993); 
a critical process in HCMV replication.  This essential gene (Kalejta 2008) is unique to 
beta-herpesviruses and has also been identified in MCMV (Rawlinson et al. 1996), and 
Rat CMV (Vink et al. 2000) in addition to the primate CMVs.   
Structural proteins are also highly conserved between HCMV and BaCMV.  
These include the major and minor capsid proteins (BaUL91 and BaUL92, respectively) 
and the capsid assembly protein (BaUL85).  Tegument proteins are other structural 
proteins that are well-conserved, and BaCMV has homologs of most HCMV tegument 
genes.  Some of the tegument proteins in HCMV are UL32 (pp150), UL48 (the large 
tegument protein), UL82 (pp71), UL83 (pp65) and UL99 (pp28).  As previously 
mentioned, both BaCMV and RhCMV have duplicate copies of the HCMV AD169 UL83 





the UL83b gene shows the greatest homology with HCMV UL83 (38.9%).  In RhCMV, 
these two genes are designated Rh111 (BaUL87) and Rh112 (BaUL88).  As seen in 
BaCMV, the RhCMV Rh112 gene shares highest identity with the HCMV gene.  
Immunological analysis of Rh112 has demonstrated that this protein shares antigenic 
sites, or epitopes, with HCMV pp65 (Yue et al. 2006).  The BaCMV (BaUL88) protein 
shares 51.2% aa identity with Rh112, so it is likely that immunological analysis of the 
BaCMV protein would produce a similar outcome.  Support for this was seen when 
pooled baboon sera from BaCMV-positive baboons were used to screen a lambda 
BaCMV genomic expression library.  Though many positive clones were obtained, >75% 
of these clones were the UL83b gene.  No clones expressing UL83a were recovered, 
suggesting that the UL83b gene is a much more important target of the baboon humoral 
immune response in natural infections.   
HCMV strain AD169 lacks numerous genes when compared to clinical HCMV 
strains such as Towne and Toledo (Cha et al. 1996).  To determine whether duplicates of 
UL83 exist in these clinical strains, PCR amplification of the UL82 – UL84 region was 
performed.  PCR analysis showed that neither HCMV strains Towne or Toledo contained 
this extra gene (Blewett, unpublished observations).  Duplication of the UL83 gene may 
have developed during evolution of the virus or the genes may have different functions 
(Hansen et al. 2003). 
The HCMV genome contains a number of gene families consisting of members 
having functional or structural similarity.  Nine families have been identified in HCMV 
and representatives for each of these gene families are present in BaCMV.  Eight of these 





members have similar structure and function as downregulators of MHCI expression on 
cell surfaces (Pande et al. 2005).  Due to these similarities, the BaCMV US2 homologs 
have been included in the US6 family. 
There are at least 22 genes in a 13 kb region of sequence (designated the UL/b’ 
region) that are found in certain clinical strains of HCMV like Toledo or Towne, but not 
in HCMV AD169 (Prichard et al. 2001).  These genes include UL133 – UL154 and many 
of these are hypothesized to be transmembrane glycoproteins or to function as 
chemokines (Rigoutsos et al. 2003).  In BaCMV, homologues of seven of these genes 
(BaUL05, BaUL126, BaUL129, BaUL130, BaUL131, BaUL132, and BaUL134) have 
been identified and all show high homology (see Table 10) with either RhCMV or 
clinical HCMV strains.  RhCMV has an additional gene in this region related to the 
HCMV UL148 gene.  Consequently, an eighth BaCMV gene related to HCMV UL148 
may exist since this region is in one of the sequence gaps adjacent to BaUL126. 
For CMV to survive and proliferate within a host cell, the viral genome must code 
for a number of immunomodulatory proteins.  The proteins encoded by these genes 
usually function in evasion of host cell defenses.  There are a number of genes in 
BaCMV that share identity with HCMV immunomodulatory genes and probably function 
in that capacity.  One of these genes is an IL-10 homologue which shows good aa 
sequence identity with the RhCMV (Rh143) homologue but no significant sequence 
homology with the HCMV (UL111A) gene homolog.  The exact function of the RhCMV 
Rh143 gene product has not been determined, but in HCMV there is evidence that the 
vIL-10 protein inhibits dendritic cell maturation and function (Chang et al. 2004).  There 





(UL144) suppresses apoptotic progression in virally-infected cells, this would be a likely 
function for the BaUL131 encoded protein if it is actually expressed and functions as a 
TNF receptor. 
Virally-infected cells often undergo apoptosis as a result of the infection.  
Therefore, to survive, viruses must inhibit processes leading to apoptosis.  HCMV 
encodes two apoptosis inhibitors vICA (UL36) and vMIA (UL37).  vICA acts to inhibit 
apoptosis by suppressing caspase-8 activation.  Caspase-8 protease is necessary for 
inducing apoptosis and also controlling differentiation of monocytes to macrophages 
(Droin et al. 2008; Lamkanfi et al. 2006; Rebe et al. 2007).  Mutation analysis of the 
HCMV UL36 gene has shown that vICA also controls a caspase-independent cell death 
pathway at late stages of macrophage differentiation; caspase-dependent cell death 
responses occurred in early stage of macrophage differentiation  (McCormick et al. 
2010).  In BaCMV, there are two putative genes (BaUL49 & BaUL50) that code for an 
HCMV UL36 homologue.  The first gene (BaUL49) is considerably larger than the 
second (BaUL50) and shows lower identity with HCMV homlogs.  This distinction exists 
for RhCMV as well.  It is uncertain whether these genes are spliced transcripts or 
function separately.  The HCMV UL37 product (vMIA) is another immunomodulatory 
protein that is targeted to mitochondria where it is capable of inhibiting the proapoptotic 
Bcl-2 family members Bax and Bak (Norris and Youle 2008).  As seen with UL36, there 
are two homologs (BaUL51 and BaUL53) for HCMV UL37 in BaCMV, but their 
functions are unknown.  While the functions of BaCMV homologs for the UL36 and 





identified in MCMV (Cam et al. 2010; Manzur et al. 2008) and it would follow that all 
CMVs must express these proteins to complete the infection cycle. 
A viral cyclooxygenase-2 (vCOX-2) homologue has been identified in RhCMV 
and is probably also important in immunomodulation.  A homologue for this gene, 
however, has not been identified in HCMV.  This may explain why in HCMV, cellular 
COX-2 inhibitors compromise viral replication in vitro (Tanaka et al. 1988; Zhu et al. 
2002).  Also, COX-2 inhibitors also block cell-to-cell spread in HCMV which makes 
them possible candidates for control of HCMV infection (Schrőer and Shenk 2008).  
Cellular COX-2 is an enzyme that is important in the eicosanoid synthesis pathway.  
Eicosnaoids are a group of cytokines that regulate various immune responses.  Many 
viruses upregulate the eicosanoid pathway early in infection and this increases COX-2 
which is required for accumulation of the transcriptional regulator IE2.  In RhCMV, 
studies have shown that when viral COX-2 is expressed during infection, cellular COX-2 
is not, and that COX-2 deletion mutants do not replicate normally in endothelial cells 
(Rue et al. 2004)  The function of this protein has not been established in BaCMV 
however the degree of identity it shares with the human COX-2 gene would suggest a 
similar function. 
G protein-coupled receptors (GPCR), also known as seven-transmembrane 
receptors (7TM), are a large family of proteins found in cell plasma membranes.  When 
these receptors are bound by a ligand, they function in signal transduction leading to 
regulation of intracellular activities (Bourne et al. 1990).  There are three genes (UL33, 
US27 and US28) in HCMV that are homologous with cellular GPCR (Welch et al. 1991).  





and independent signaling in infected cells via the C-terminal tail of the protein (Stropes 
et al. 2009).  In BaCMV, two homologs exist for the HCMV genes UL33 and US28.  For 
the HCMV US28 gene, there are actually five tandem BaCMV sequences that show 
identity (average of 30%) with this homolog.  These five US28 homologs exist in the 
RhCMV genome as well, although they are divergent from one another.  Character- 
ization of these five genes has shown that one of them (RhUS28.5) shows a ligand- 
binding profile similar to that of HCMV US28, and analysis of northern blots showed 
that paired genes RhUS28.1/RhUS28.2 and RhUS28.3/RhUS28.4 are each expressed as a 
single transcriptional unit (Penfold et al. 2003).  No functional capacity has yet been 
designated for the RhUS28.1-RhUS28.4 genes.  The BaCMV homologue of RhUS28.5 
(BaUS07) shows greatest aa sequence identity (66.7%) of all the RhUS28 homologs 
found in BaCMV. 
Phylogenetic analysis using eight herpesviruses showed that BaCMV groups with 
other beta-herpesviruses and is most closely related to those CMVs that infect primates.  
Based on the limited amount of drill CMV DNA sequence available (fragments of the 
glycoprotein B and DNA polymerase genes), drill CMV is the herpesvirus most closely 
related to BaCMV.  Of the viruses examined in detail, BaCMV is most similar to 
RhCMV, and then to CCMV and HCMV.  More distantly-related CMVs (such as 
MCMV and RatCMV) group separately from the primate CMVs.  A significant amount 
of research has been conducted on the structure and function of the HCMV genome and, 
to a lesser extent, the RhCMV genome.  These studies have revealed the location and 
function of structural genes, the temporal expression of IE, E, and L proteins and 





high homology and colinearity between these two primate virus genomes and that of 
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